id	sid	tid	token	lemma	pos
dpc-4315	1	1	dermatology	dermatology	NOUN
dpc-4315	1	2	:	:	PUNCT
dpc-4315	1	3	practical	practical	ADJ
dpc-4315	1	4	and	and	CCONJ
dpc-4315	1	5	conceptual	conceptual	ADJ
dpc-4315	1	6	review	review	NOUN
dpc-4315	1	7	|	|	ADV
dpc-4315	1	8	dermatol	dermatol	ADJ
dpc-4315	1	9	pract	pract	NOUN
dpc-4315	1	10	concept	concept	NOUN
dpc-4315	1	11	.	.	PUNCT
dpc-4315	2	1	2024;14(3):e2024204	2024;14(3):e2024204	NUM
dpc-4315	2	2	1	1	NUM
dpc-4315	2	3	interleukin-13	interleukin-13	NUM
dpc-4315	2	4	inhibitors	inhibitor	NOUN
dpc-4315	2	5	in	in	ADP
dpc-4315	2	6	the	the	DET
dpc-4315	2	7	treatment	treatment	NOUN
dpc-4315	2	8	of	of	ADP
dpc-4315	2	9	atopic	atopic	NOUN
dpc-4315	2	10	dermatitis	dermatitis	NOUN
dpc-4315	2	11	:	:	PUNCT
dpc-4315	2	12	the	the	DET
dpc-4315	2	13	role	role	NOUN
dpc-4315	2	14	of	of	ADP
dpc-4315	2	15	tralokinumab	tralokinumab	NOUN
dpc-4315	2	16	annunziata	annunziata	VERB
dpc-4315	2	17	dattola1	dattola1	PROPN
dpc-4315	2	18	,	,	PUNCT
dpc-4315	2	19	martina	martina	PROPN
dpc-4315	2	20	tolone2	tolone2	PROPN
dpc-4315	2	21	,	,	PUNCT
dpc-4315	2	22	emanuele	emanuele	PROPN
dpc-4315	2	23	amore1	amore1	PROPN
dpc-4315	2	24	,	,	PUNCT
dpc-4315	2	25	luigi	luigi	PROPN
dpc-4315	2	26	bennardo2	bennardo2	PROPN
dpc-4315	2	27	,	,	PUNCT
dpc-4315	2	28	federica	federica	PROPN
dpc-4315	2	29	trovato1	trovato1	PROPN
dpc-4315	2	30	,	,	PUNCT
dpc-4315	2	31	simone	simone	PROPN
dpc-4315	2	32	amato1	amato1	PROPN
dpc-4315	2	33	,	,	PUNCT
dpc-4315	2	34	teresa	teresa	PROPN
dpc-4315	2	35	grieco1	grieco1	PROPN
dpc-4315	2	36	,	,	PUNCT
dpc-4315	2	37	antonio	antonio	PROPN
dpc-4315	2	38	giovanni	giovanni	PROPN
dpc-4315	2	39	richetta1	richetta1	PROPN
dpc-4315	2	40	,	,	PUNCT
dpc-4315	2	41	giovanni	giovanni	PROPN
dpc-4315	2	42	pellacani1	pellacani1	NOUN
dpc-4315	2	43	,	,	PUNCT
dpc-4315	2	44	nevena	nevena	PROPN
dpc-4315	2	45	skroza3	skroza3	NOUN
dpc-4315	2	46	,	,	PUNCT
dpc-4315	2	47	steven	steven	PROPN
dpc-4315	2	48	paul	paul	PROPN
dpc-4315	2	49	nisticò1,2	nisticò1,2	PROPN
dpc-4315	2	50	1	1	NUM
dpc-4315	2	51	department	department	NOUN
dpc-4315	2	52	of	of	ADP
dpc-4315	2	53	dermatology	dermatology	NOUN
dpc-4315	2	54	university	university	PROPN
dpc-4315	2	55	of	of	ADP
dpc-4315	2	56	rome	rome	PROPN
dpc-4315	2	57	“	"	PUNCT
dpc-4315	2	58	la	la	X
dpc-4315	2	59	sapienza	sapienza	PROPN
dpc-4315	2	60	”	"	PUNCT
dpc-4315	2	61	,	,	PUNCT
dpc-4315	2	62	rome	rome	PROPN
dpc-4315	2	63	,	,	PUNCT
dpc-4315	2	64	italy	italy	PROPN
dpc-4315	2	65	2	2	NUM
dpc-4315	2	66	department	department	PROPN
dpc-4315	2	67	of	of	ADP
dpc-4315	2	68	health	health	NOUN
dpc-4315	2	69	sciencesunit	sciencesunit	PROPN
dpc-4315	2	70	of	of	ADP
dpc-4315	2	71	dermatology	dermatology	NOUN
dpc-4315	2	72	,	,	PUNCT
dpc-4315	2	73	magna	magna	PROPN
dpc-4315	2	74	graecia	graecia	PROPN
dpc-4315	2	75	university	university	PROPN
dpc-4315	2	76	,	,	PUNCT
dpc-4315	2	77	catanzaro	catanzaro	PROPN
dpc-4315	2	78	,	,	PUNCT
dpc-4315	2	79	italy	italy	PROPN
dpc-4315	2	80	3	3	NUM
dpc-4315	2	81	dermatology	dermatology	NOUN
dpc-4315	2	82	unit	unit	NOUN
dpc-4315	2	83	‘	'	PUNCT
dpc-4315	2	84	daniele	daniele	PROPN
dpc-4315	2	85	innocenzi	innocenzi	NOUN
dpc-4315	2	86	’	'	PUNCT
dpc-4315	2	87	,	,	PUNCT
dpc-4315	2	88	department	department	NOUN
dpc-4315	2	89	of	of	ADP
dpc-4315	2	90	medical	medical	ADJ
dpc-4315	2	91	-	-	PUNCT
dpc-4315	2	92	surgical	surgical	ADJ
dpc-4315	2	93	sciences	science	NOUN
dpc-4315	2	94	and	and	CCONJ
dpc-4315	2	95	biotechnologies	biotechnology	NOUN
dpc-4315	2	96	,	,	PUNCT
dpc-4315	2	97	sapienza	sapienza	PROPN
dpc-4315	2	98	university	university	PROPN
dpc-4315	2	99	of	of	ADP
dpc-4315	2	100	rome	rome	PROPN
dpc-4315	2	101	polo	polo	PROPN
dpc-4315	2	102	pontino	pontino	PROPN
dpc-4315	2	103	,	,	PUNCT
dpc-4315	2	104	latina	latina	PROPN
dpc-4315	2	105	,	,	PUNCT
dpc-4315	2	106	italy	italy	PROPN
dpc-4315	2	107	key	key	ADJ
dpc-4315	2	108	words	word	NOUN
dpc-4315	2	109	:	:	PUNCT
dpc-4315	2	110	atopic	atopic	NOUN
dpc-4315	2	111	dermatitis	dermatitis	NOUN
dpc-4315	2	112	,	,	PUNCT
dpc-4315	2	113	anti	anti	X
dpc-4315	2	114	il13	il13	PROPN
dpc-4315	2	115	,	,	PUNCT
dpc-4315	2	116	tralokinumab	tralokinumab	NOUN
dpc-4315	2	117	,	,	PUNCT
dpc-4315	2	118	biologic	biologic	NOUN
dpc-4315	2	119	therapy	therapy	NOUN
dpc-4315	2	120	citation	citation	NOUN
dpc-4315	2	121	:	:	PUNCT
dpc-4315	2	122	dattola	dattola	PROPN
dpc-4315	2	123	a	a	PRON
dpc-4315	2	124	,	,	PUNCT
dpc-4315	2	125	tolone	tolone	NOUN
dpc-4315	2	126	m	m	NOUN
dpc-4315	2	127	,	,	PUNCT
dpc-4315	2	128	amore	amore	PROPN
dpc-4315	2	129	e	e	PROPN
dpc-4315	2	130	,	,	PUNCT
dpc-4315	2	131	et	et	PROPN
dpc-4315	2	132	al	al	PROPN
dpc-4315	2	133	.	.	PUNCT
dpc-4315	3	1	interleukin-13	interleukin-13	PRON
dpc-4315	3	2	inhibitors	inhibitor	NOUN
dpc-4315	3	3	in	in	ADP
dpc-4315	3	4	the	the	DET
dpc-4315	3	5	treatment	treatment	NOUN
dpc-4315	3	6	of	of	ADP
dpc-4315	3	7	atopic	atopic	NOUN
dpc-4315	3	8	dermatitis	dermatitis	NOUN
dpc-4315	3	9	:	:	PUNCT
dpc-4315	3	10	the	the	DET
dpc-4315	3	11	role	role	NOUN
dpc-4315	3	12	of	of	ADP
dpc-4315	3	13	tralokinumab	tralokinumab	NOUN
dpc-4315	3	14	.	.	PUNCT
dpc-4315	4	1	dermatol	dermatol	NOUN
dpc-4315	4	2	pract	pract	PROPN
dpc-4315	4	3	concept	concept	NOUN
dpc-4315	4	4	.	.	PUNCT
dpc-4315	5	1	2024;14(3):e2024204	2024;14(3):e2024204	X
dpc-4315	5	2	.	.	X
dpc-4315	5	3	doi	doi	NOUN
dpc-4315	5	4	:	:	PUNCT
dpc-4315	5	5	https://doi.org/10.5826/dpc.1403a204	https://doi.org/10.5826/dpc.1403a204	NOUN
dpc-4315	5	6	accepted	accept	VERB
dpc-4315	5	7	:	:	PUNCT
dpc-4315	5	8	april	april	PROPN
dpc-4315	5	9	24	24	NUM
dpc-4315	5	10	,	,	PUNCT
dpc-4315	5	11	2024	2024	NUM
dpc-4315	5	12	;	;	PUNCT
dpc-4315	5	13	published	publish	VERB
dpc-4315	5	14	:	:	PUNCT
dpc-4315	5	15	july	july	PROPN
dpc-4315	5	16	2024	2024	NUM
dpc-4315	5	17	copyright	copyright	NOUN
dpc-4315	5	18	:	:	PUNCT
dpc-4315	5	19	©	©	PROPN
dpc-4315	5	20	2024	2024	NUM
dpc-4315	5	21	dattola	dattola	PROPN
dpc-4315	5	22	et	et	PROPN
dpc-4315	5	23	al	al	PROPN
dpc-4315	5	24	.	.	PUNCT
dpc-4315	6	1	this	this	PRON
dpc-4315	6	2	is	be	AUX
dpc-4315	6	3	an	an	DET
dpc-4315	6	4	open	open	ADJ
dpc-4315	6	5	-	-	PUNCT
dpc-4315	6	6	access	access	NOUN
dpc-4315	6	7	article	article	NOUN
dpc-4315	6	8	distributed	distribute	VERB
dpc-4315	6	9	under	under	ADP
dpc-4315	6	10	the	the	DET
dpc-4315	6	11	terms	term	NOUN
dpc-4315	6	12	of	of	ADP
dpc-4315	6	13	the	the	DET
dpc-4315	6	14	creative	creative	ADJ
dpc-4315	6	15	commons	common	NOUN
dpc-4315	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4315	6	17	license	license	NOUN
dpc-4315	6	18	(	(	PUNCT
dpc-4315	6	19	by	by	ADP
dpc-4315	6	20	-	-	PUNCT
dpc-4315	6	21	nc-4.0	nc-4.0	NOUN
dpc-4315	6	22	)	)	PUNCT
dpc-4315	6	23	,	,	PUNCT
dpc-4315	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4315	6	25	,	,	PUNCT
dpc-4315	6	26	which	which	PRON
dpc-4315	6	27	permits	permit	VERB
dpc-4315	6	28	unrestricted	unrestricted	ADJ
dpc-4315	6	29	noncommercial	noncommercial	ADJ
dpc-4315	6	30	use	use	NOUN
dpc-4315	6	31	,	,	PUNCT
dpc-4315	6	32	distribution	distribution	NOUN
dpc-4315	6	33	,	,	PUNCT
dpc-4315	6	34	and	and	CCONJ
dpc-4315	6	35	reproduction	reproduction	NOUN
dpc-4315	6	36	in	in	ADP
dpc-4315	6	37	any	any	DET
dpc-4315	6	38	medium	medium	NOUN
dpc-4315	6	39	,	,	PUNCT
dpc-4315	6	40	provided	provide	VERB
dpc-4315	6	41	the	the	DET
dpc-4315	6	42	original	original	ADJ
dpc-4315	6	43	authors	author	NOUN
dpc-4315	6	44	and	and	CCONJ
dpc-4315	6	45	source	source	NOUN
dpc-4315	6	46	are	be	AUX
dpc-4315	6	47	credited	credit	VERB
dpc-4315	6	48	.	.	PUNCT
dpc-4315	7	1	funding	funding	NOUN
dpc-4315	7	2	:	:	PUNCT
dpc-4315	7	3	none	none	NOUN
dpc-4315	7	4	.	.	PUNCT
dpc-4315	8	1	competing	compete	VERB
dpc-4315	8	2	interests	interest	NOUN
dpc-4315	8	3	:	:	PUNCT
dpc-4315	8	4	none	none	NOUN
dpc-4315	8	5	.	.	PUNCT
dpc-4315	9	1	authorship	authorship	NOUN
dpc-4315	9	2	:	:	PUNCT
dpc-4315	9	3	all	all	DET
dpc-4315	9	4	authors	author	NOUN
dpc-4315	9	5	have	have	AUX
dpc-4315	9	6	contributed	contribute	VERB
dpc-4315	9	7	significantly	significantly	ADV
dpc-4315	9	8	to	to	ADP
dpc-4315	9	9	this	this	DET
dpc-4315	9	10	publication	publication	NOUN
dpc-4315	9	11	.	.	PUNCT
dpc-4315	10	1	corresponding	correspond	VERB
dpc-4315	10	2	author	author	NOUN
dpc-4315	10	3	:	:	PUNCT
dpc-4315	10	4	dr	dr	PROPN
dpc-4315	10	5	.	.	PROPN
dpc-4315	10	6	dattola	dattola	PROPN
dpc-4315	10	7	annunziata	annunziata	PROPN
dpc-4315	10	8	phd	phd	PROPN
dpc-4315	10	9	,	,	PUNCT
dpc-4315	10	10	department	department	NOUN
dpc-4315	10	11	of	of	ADP
dpc-4315	10	12	dermatology	dermatology	NOUN
dpc-4315	10	13	,	,	PUNCT
dpc-4315	10	14	la	la	X
dpc-4315	10	15	sapienza	sapienza	NOUN
dpc-4315	10	16	of	of	ADP
dpc-4315	10	17	rome	rome	PROPN
dpc-4315	10	18	.	.	PUNCT
dpc-4315	11	1	phone	phone	NOUN
dpc-4315	11	2	no	no	PRON
dpc-4315	11	3	:	:	PUNCT
dpc-4315	11	4	+393208419714	+393208419714	PROPN
dpc-4315	11	5	.	.	PUNCT
dpc-4315	12	1	email	email	NOUN
dpc-4315	12	2	:	:	PUNCT
dpc-4315	13	1	nancydattola@gmail.com	nancydattola@gmail.com	X
dpc-4315	13	2	introduction	introduction	NOUN
dpc-4315	13	3	:	:	PUNCT
dpc-4315	13	4	the	the	DET
dpc-4315	13	5	advent	advent	NOUN
dpc-4315	13	6	of	of	ADP
dpc-4315	13	7	biotechnological	biotechnological	ADJ
dpc-4315	13	8	drugs	drug	NOUN
dpc-4315	13	9	has	have	AUX
dpc-4315	13	10	significantly	significantly	ADV
dpc-4315	13	11	changed	change	VERB
dpc-4315	13	12	the	the	DET
dpc-4315	13	13	management	management	NOUN
dpc-4315	13	14	of	of	ADP
dpc-4315	13	15	atopic	atopic	NOUN
dpc-4315	13	16	dermatitis	dermatitis	NOUN
dpc-4315	13	17	(	(	PUNCT
dpc-4315	13	18	ad	ad	NOUN
dpc-4315	13	19	)	)	PUNCT
dpc-4315	13	20	and	and	CCONJ
dpc-4315	13	21	the	the	DET
dpc-4315	13	22	approach	approach	NOUN
dpc-4315	13	23	to	to	ADP
dpc-4315	13	24	the	the	DET
dpc-4315	13	25	moderate	moderate	ADJ
dpc-4315	13	26	-	-	PUNCT
dpc-4315	13	27	to	to	ADP
dpc-4315	13	28	-	-	PUNCT
dpc-4315	13	29	severe	severe	ADJ
dpc-4315	13	30	form	form	NOUN
dpc-4315	13	31	of	of	ADP
dpc-4315	13	32	this	this	DET
dpc-4315	13	33	chronic	chronic	ADJ
dpc-4315	13	34	relapsing	relapse	VERB
dpc-4315	13	35	disease	disease	NOUN
dpc-4315	13	36	.	.	PUNCT
dpc-4315	14	1	objectives	objective	NOUN
dpc-4315	14	2	:	:	PUNCT
dpc-4315	14	3	the	the	DET
dpc-4315	14	4	aim	aim	NOUN
dpc-4315	14	5	of	of	ADP
dpc-4315	14	6	our	our	PRON
dpc-4315	14	7	review	review	NOUN
dpc-4315	14	8	is	be	AUX
dpc-4315	14	9	to	to	PART
dpc-4315	14	10	summarize	summarize	VERB
dpc-4315	14	11	the	the	DET
dpc-4315	14	12	current	current	ADJ
dpc-4315	14	13	literature	literature	NOUN
dpc-4315	14	14	on	on	ADP
dpc-4315	14	15	anti	anti	ADJ
dpc-4315	14	16	-	-	ADJ
dpc-4315	14	17	interleukin	interleukin	ADJ
dpc-4315	14	18	(	(	PUNCT
dpc-4315	14	19	il)-13	il)-13	NOUN
dpc-4315	14	20	in	in	ADP
dpc-4315	14	21	atopic	atopic	NOUN
dpc-4315	14	22	dermatitis	dermatitis	NOUN
dpc-4315	14	23	.	.	PUNCT
dpc-4315	15	1	methods	method	NOUN
dpc-4315	15	2	:	:	PUNCT
dpc-4315	15	3	a	a	DET
dpc-4315	15	4	literature	literature	NOUN
dpc-4315	15	5	search	search	NOUN
dpc-4315	15	6	was	be	AUX
dpc-4315	15	7	organized	organize	VERB
dpc-4315	15	8	and	and	CCONJ
dpc-4315	15	9	a	a	DET
dpc-4315	15	10	systematic	systematic	ADJ
dpc-4315	15	11	review	review	NOUN
dpc-4315	15	12	was	be	AUX
dpc-4315	15	13	performed	perform	VERB
dpc-4315	15	14	to	to	PART
dpc-4315	15	15	summarize	summarize	VERB
dpc-4315	15	16	the	the	DET
dpc-4315	15	17	most	most	ADV
dpc-4315	15	18	recent	recent	ADJ
dpc-4315	15	19	evidence	evidence	NOUN
dpc-4315	15	20	supporting	support	VERB
dpc-4315	15	21	the	the	DET
dpc-4315	15	22	efficacy	efficacy	NOUN
dpc-4315	15	23	and	and	CCONJ
dpc-4315	15	24	safety	safety	NOUN
dpc-4315	15	25	of	of	ADP
dpc-4315	15	26	tralokinumab	tralokinumab	NOUN
dpc-4315	15	27	.	.	PUNCT
dpc-4315	16	1	results	result	NOUN
dpc-4315	16	2	:	:	PUNCT
dpc-4315	16	3	tralokinumab	tralokinumab	NOUN
dpc-4315	16	4	(	(	PUNCT
dpc-4315	16	5	anti	anti	NOUN
dpc-4315	16	6	-	-	ADJ
dpc-4315	16	7	il-13	il-13	NUM
dpc-4315	16	8	)	)	PUNCT
dpc-4315	16	9	300	300	NUM
dpc-4315	16	10	mg	mg	NOUN
dpc-4315	16	11	every	every	DET
dpc-4315	16	12	2	2	NUM
dpc-4315	16	13	weeks	week	NOUN
dpc-4315	16	14	subcutaneously	subcutaneously	ADV
dpc-4315	16	15	has	have	AUX
dpc-4315	16	16	proven	prove	VERB
dpc-4315	16	17	effective	effective	ADJ
dpc-4315	16	18	in	in	ADP
dpc-4315	16	19	several	several	ADJ
dpc-4315	16	20	clinical	clinical	ADJ
dpc-4315	16	21	trials	trial	NOUN
dpc-4315	16	22	in	in	ADP
dpc-4315	16	23	adults	adult	NOUN
dpc-4315	16	24	and	and	CCONJ
dpc-4315	16	25	adolescents	adolescent	NOUN
dpc-4315	16	26	with	with	ADP
dpc-4315	16	27	moderate	moderate	ADJ
dpc-4315	16	28	to	to	ADP
dpc-4315	16	29	severe	severe	ADJ
dpc-4315	16	30	atopic	atopic	NOUN
dpc-4315	16	31	dermatitis	dermatitis	NOUN
dpc-4315	16	32	inadequately	inadequately	ADV
dpc-4315	16	33	controlled	control	VERB
dpc-4315	16	34	with	with	ADP
dpc-4315	16	35	other	other	ADJ
dpc-4315	16	36	topical	topical	ADJ
dpc-4315	16	37	or	or	CCONJ
dpc-4315	16	38	systemic	systemic	ADJ
dpc-4315	16	39	therapies	therapy	NOUN
dpc-4315	16	40	.	.	PUNCT
dpc-4315	17	1	tralokinumab	tralokinumab	NOUN
dpc-4315	17	2	was	be	AUX
dpc-4315	17	3	found	find	VERB
dpc-4315	17	4	to	to	PART
dpc-4315	17	5	be	be	AUX
dpc-4315	17	6	significantly	significantly	ADV
dpc-4315	17	7	superior	superior	ADJ
dpc-4315	17	8	in	in	ADP
dpc-4315	17	9	terms	term	NOUN
dpc-4315	17	10	of	of	ADP
dpc-4315	17	11	efficacy	efficacy	NOUN
dpc-4315	17	12	in	in	ADP
dpc-4315	17	13	reducing	reduce	VERB
dpc-4315	17	14	investigator	investigator	NOUN
dpc-4315	17	15	’s	’s	PART
dpc-4315	17	16	global	global	ADJ
dpc-4315	17	17	assessment	assessment	NOUN
dpc-4315	17	18	(	(	PUNCT
dpc-4315	17	19	iga	iga	PROPN
dpc-4315	17	20	)	)	PUNCT
dpc-4315	17	21	,	,	PUNCT
dpc-4315	17	22	eczema	eczema	NOUN
dpc-4315	17	23	area	area	NOUN
dpc-4315	17	24	and	and	CCONJ
dpc-4315	17	25	severity	severity	NOUN
dpc-4315	17	26	index	index	NOUN
dpc-4315	17	27	(	(	PUNCT
dpc-4315	17	28	easi	easi	NOUN
dpc-4315	17	29	)	)	PUNCT
dpc-4315	17	30	-75	-75	NUM
dpc-4315	17	31	,	,	PUNCT
dpc-4315	17	32	numeric	numeric	ADJ
dpc-4315	17	33	pain	pain	NOUN
dpc-4315	17	34	rating	rating	NOUN
dpc-4315	17	35	scale	scale	NOUN
dpc-4315	17	36	(	(	PUNCT
dpc-4315	17	37	nrs	nrs	PROPN
dpc-4315	17	38	)	)	PUNCT
dpc-4315	17	39	pruritus	pruritus	NOUN
dpc-4315	17	40	,	,	PUNCT
dpc-4315	17	41	and	and	CCONJ
dpc-4315	17	42	dermatology	dermatology	NOUN
dpc-4315	17	43	life	life	NOUN
dpc-4315	17	44	quality	quality	NOUN
dpc-4315	17	45	index	index	NOUN
dpc-4315	17	46	(	(	PUNCT
dpc-4315	17	47	dlqi	dlqi	ADJ
dpc-4315	17	48	)	)	PUNCT
dpc-4315	17	49	scale	scale	NOUN
dpc-4315	17	50	numbers	number	NOUN
dpc-4315	17	51	.	.	PUNCT
dpc-4315	18	1	during	during	ADP
dpc-4315	18	2	follow	follow	NOUN
dpc-4315	18	3	-	-	PUNCT
dpc-4315	18	4	up	up	NOUN
dpc-4315	18	5	,	,	PUNCT
dpc-4315	18	6	tralokinumab	tralokinumab	NOUN
dpc-4315	18	7	was	be	AUX
dpc-4315	18	8	well	well	ADV
dpc-4315	18	9	tolerated	tolerate	VERB
dpc-4315	18	10	with	with	ADP
dpc-4315	18	11	limited	limited	ADJ
dpc-4315	18	12	severity	severity	NOUN
dpc-4315	18	13	of	of	ADP
dpc-4315	18	14	adverse	adverse	ADJ
dpc-4315	18	15	events	event	NOUN
dpc-4315	18	16	.	.	PUNCT
dpc-4315	19	1	conclusions	conclusion	NOUN
dpc-4315	19	2	:	:	PUNCT
dpc-4315	19	3	tralokinumab	tralokinumab	NOUN
dpc-4315	19	4	leads	lead	VERB
dpc-4315	19	5	to	to	ADP
dpc-4315	19	6	statistically	statistically	ADV
dpc-4315	19	7	significant	significant	ADJ
dpc-4315	19	8	improvements	improvement	NOUN
dpc-4315	19	9	in	in	ADP
dpc-4315	19	10	disease	disease	NOUN
dpc-4315	19	11	severity	severity	NOUN
dpc-4315	19	12	and	and	CCONJ
dpc-4315	19	13	outcome	outcome	NOUN
dpc-4315	19	14	scores	score	NOUN
dpc-4315	19	15	.	.	PUNCT
dpc-4315	20	1	it	it	PRON
dpc-4315	20	2	represents	represent	VERB
dpc-4315	20	3	an	an	DET
dpc-4315	20	4	effective	effective	ADJ
dpc-4315	20	5	treatment	treatment	NOUN
dpc-4315	20	6	option	option	NOUN
dpc-4315	20	7	for	for	ADP
dpc-4315	20	8	adults	adult	NOUN
dpc-4315	20	9	with	with	ADP
dpc-4315	20	10	moderate	moderate	ADJ
dpc-4315	20	11	to	to	ADP
dpc-4315	20	12	severe	severe	ADJ
dpc-4315	20	13	ad	ad	NOUN
dpc-4315	20	14	,	,	PUNCT
dpc-4315	20	15	but	but	CCONJ
dpc-4315	20	16	further	far	ADV
dpc-4315	20	17	large	large	ADJ
dpc-4315	20	18	-	-	PUNCT
dpc-4315	20	19	scale	scale	NOUN
dpc-4315	20	20	studies	study	NOUN
dpc-4315	20	21	are	be	AUX
dpc-4315	20	22	needed	need	VERB
dpc-4315	20	23	to	to	PART
dpc-4315	20	24	verify	verify	VERB
dpc-4315	20	25	long	long	ADJ
dpc-4315	20	26	-	-	PUNCT
dpc-4315	20	27	term	term	NOUN
dpc-4315	20	28	superiority	superiority	NOUN
dpc-4315	20	29	over	over	ADP
dpc-4315	20	30	other	other	ADJ
dpc-4315	20	31	treatments	treatment	NOUN
dpc-4315	20	32	.	.	PUNCT
dpc-4315	21	1	abstract	abstract	ADJ
dpc-4315	21	2	2	2	NUM
dpc-4315	21	3	review	review	NOUN
dpc-4315	21	4	|	|	ADV
dpc-4315	21	5	dermatol	dermatol	ADJ
dpc-4315	21	6	pract	pract	NOUN
dpc-4315	21	7	concept	concept	NOUN
dpc-4315	21	8	.	.	PUNCT
dpc-4315	22	1	2024;14(3):e2024204	2024;14(3):e2024204	NUM
dpc-4315	22	2	introduction	introduction	NOUN
dpc-4315	22	3	atopic	atopic	NOUN
dpc-4315	22	4	dermatitis	dermatitis	NOUN
dpc-4315	22	5	(	(	PUNCT
dpc-4315	22	6	ad	ad	NOUN
dpc-4315	22	7	)	)	PUNCT
dpc-4315	22	8	,	,	PUNCT
dpc-4315	22	9	also	also	ADV
dpc-4315	22	10	known	know	VERB
dpc-4315	22	11	as	as	ADP
dpc-4315	22	12	atopic	atopic	NOUN
dpc-4315	22	13	eczema	eczema	NOUN
dpc-4315	22	14	,	,	PUNCT
dpc-4315	22	15	is	be	AUX
dpc-4315	22	16	a	a	DET
dpc-4315	22	17	chronic	chronic	ADJ
dpc-4315	22	18	and	and	CCONJ
dpc-4315	22	19	relapsing	relapse	VERB
dpc-4315	22	20	inflammatory	inflammatory	ADJ
dpc-4315	22	21	disease	disease	NOUN
dpc-4315	22	22	of	of	ADP
dpc-4315	22	23	the	the	DET
dpc-4315	22	24	skin	skin	NOUN
dpc-4315	22	25	with	with	ADP
dpc-4315	22	26	a	a	DET
dpc-4315	22	27	significant	significant	ADJ
dpc-4315	22	28	economic	economic	ADJ
dpc-4315	22	29	and	and	CCONJ
dpc-4315	22	30	social	social	ADJ
dpc-4315	22	31	impact	impact	NOUN
dpc-4315	22	32	.	.	PUNCT
dpc-4315	23	1	ad	ad	NOUN
dpc-4315	23	2	prevalence	prevalence	NOUN
dpc-4315	23	3	is	be	AUX
dpc-4315	23	4	the	the	DET
dpc-4315	23	5	highest	high	ADJ
dpc-4315	23	6	among	among	ADP
dpc-4315	23	7	inflammatory	inflammatory	ADJ
dpc-4315	23	8	diseases	disease	NOUN
dpc-4315	23	9	,	,	PUNCT
dpc-4315	23	10	affecting	affect	VERB
dpc-4315	23	11	adults	adult	NOUN
dpc-4315	23	12	and	and	CCONJ
dpc-4315	23	13	children	child	NOUN
dpc-4315	23	14	[	[	X
dpc-4315	23	15	1	1	NUM
dpc-4315	23	16	]	]	PUNCT
dpc-4315	23	17	.	.	PUNCT
dpc-4315	24	1	the	the	DET
dpc-4315	24	2	onset	onset	NOUN
dpc-4315	24	3	of	of	ADP
dpc-4315	24	4	ad	ad	NOUN
dpc-4315	24	5	may	may	AUX
dpc-4315	24	6	occur	occur	VERB
dpc-4315	24	7	in	in	ADP
dpc-4315	24	8	early	early	ADJ
dpc-4315	24	9	childhood	childhood	NOUN
dpc-4315	24	10	,	,	PUNCT
dpc-4315	24	11	in	in	ADP
dpc-4315	24	12	the	the	DET
dpc-4315	24	13	context	context	NOUN
dpc-4315	24	14	of	of	ADP
dpc-4315	24	15	the	the	DET
dpc-4315	24	16	atopic	atopic	NOUN
dpc-4315	24	17	(	(	PUNCT
dpc-4315	24	18	allergic	allergic	ADJ
dpc-4315	24	19	)	)	PUNCT
dpc-4315	24	20	march	march	PROPN
dpc-4315	24	21	,	,	PUNCT
dpc-4315	24	22	which	which	PRON
dpc-4315	24	23	starts	start	VERB
dpc-4315	24	24	with	with	ADP
dpc-4315	24	25	ad	ad	NOUN
dpc-4315	24	26	and	and	CCONJ
dpc-4315	24	27	food	food	NOUN
dpc-4315	24	28	allergy	allergy	NOUN
dpc-4315	24	29	in	in	ADP
dpc-4315	24	30	infants	infant	NOUN
dpc-4315	24	31	,	,	PUNCT
dpc-4315	24	32	sometimes	sometimes	ADV
dpc-4315	24	33	associated	associate	VERB
dpc-4315	24	34	with	with	ADP
dpc-4315	24	35	asthma	asthma	NOUN
dpc-4315	24	36	in	in	ADP
dpc-4315	24	37	older	old	ADJ
dpc-4315	24	38	children	child	NOUN
dpc-4315	24	39	,	,	PUNCT
dpc-4315	24	40	and	and	CCONJ
dpc-4315	24	41	rhino	rhino	NOUN
dpc-4315	24	42	-	-	NOUN
dpc-4315	24	43	conjunctivitis	conjunctivitis	NOUN
dpc-4315	24	44	in	in	ADP
dpc-4315	24	45	adolescents	adolescent	NOUN
dpc-4315	24	46	.	.	PUNCT
dpc-4315	25	1	it	it	PRON
dpc-4315	25	2	often	often	ADV
dpc-4315	25	3	persists	persist	VERB
dpc-4315	25	4	into	into	ADP
dpc-4315	25	5	adulthood	adulthood	NOUN
dpc-4315	25	6	[	[	X
dpc-4315	25	7	2	2	NUM
dpc-4315	25	8	]	]	PUNCT
dpc-4315	25	9	.	.	PUNCT
dpc-4315	26	1	a	a	DET
dpc-4315	26	2	senile	senile	ADJ
dpc-4315	26	3	type	type	NOUN
dpc-4315	26	4	of	of	ADP
dpc-4315	26	5	ad	ad	NOUN
dpc-4315	26	6	,	,	PUNCT
dpc-4315	26	7	with	with	ADP
dpc-4315	26	8	onset	onset	NOUN
dpc-4315	26	9	after	after	ADP
dpc-4315	26	10	age	age	NOUN
dpc-4315	26	11	60	60	NUM
dpc-4315	26	12	,	,	PUNCT
dpc-4315	26	13	was	be	AUX
dpc-4315	26	14	recently	recently	ADV
dpc-4315	26	15	added	add	VERB
dpc-4315	26	16	to	to	ADP
dpc-4315	26	17	the	the	DET
dpc-4315	26	18	classification	classification	NOUN
dpc-4315	26	19	.	.	PUNCT
dpc-4315	27	1	[	[	X
dpc-4315	27	2	3	3	NUM
dpc-4315	27	3	]	]	PUNCT
dpc-4315	27	4	.	.	PUNCT
dpc-4315	28	1	therefore	therefore	ADV
dpc-4315	28	2	,	,	PUNCT
dpc-4315	28	3	ad	ad	NOUN
dpc-4315	28	4	is	be	AUX
dpc-4315	28	5	considered	consider	VERB
dpc-4315	28	6	eczema	eczema	NOUN
dpc-4315	28	7	of	of	ADP
dpc-4315	28	8	all	all	DET
dpc-4315	28	9	age	age	NOUN
dpc-4315	28	10	groups	group	NOUN
dpc-4315	28	11	.	.	PUNCT
dpc-4315	29	1	ad	ad	NOUN
dpc-4315	29	2	often	often	ADV
dpc-4315	29	3	manifests	manifest	VERB
dpc-4315	29	4	as	as	ADP
dpc-4315	29	5	a	a	DET
dpc-4315	29	6	series	series	NOUN
dpc-4315	29	7	of	of	ADP
dpc-4315	29	8	acute	acute	ADJ
dpc-4315	29	9	foci	focus	NOUN
dpc-4315	29	10	of	of	ADP
dpc-4315	29	11	intensely	intensely	ADV
dpc-4315	29	12	pruritic	pruritic	ADJ
dpc-4315	29	13	eczematous	eczematous	ADJ
dpc-4315	29	14	lesions	lesion	NOUN
dpc-4315	29	15	,	,	PUNCT
dpc-4315	29	16	localized	localize	VERB
dpc-4315	29	17	to	to	ADP
dpc-4315	29	18	typical	typical	ADJ
dpc-4315	29	19	areas	area	NOUN
dpc-4315	29	20	such	such	ADJ
dpc-4315	29	21	as	as	ADP
dpc-4315	29	22	the	the	DET
dpc-4315	29	23	flexor	flexor	ADJ
dpc-4315	29	24	compartments	compartment	NOUN
dpc-4315	29	25	of	of	ADP
dpc-4315	29	26	the	the	DET
dpc-4315	29	27	extremities	extremity	NOUN
dpc-4315	29	28	,	,	PUNCT
dpc-4315	29	29	but	but	CCONJ
dpc-4315	29	30	it	it	PRON
dpc-4315	29	31	can	can	AUX
dpc-4315	29	32	have	have	VERB
dpc-4315	29	33	a	a	DET
dpc-4315	29	34	generalized	generalized	ADJ
dpc-4315	29	35	distribution	distribution	NOUN
dpc-4315	29	36	[	[	X
dpc-4315	29	37	4	4	NUM
dpc-4315	29	38	]	]	PUNCT
dpc-4315	29	39	or	or	CCONJ
dpc-4315	29	40	sometimes	sometimes	ADV
dpc-4315	29	41	affect	affect	VERB
dpc-4315	29	42	only	only	ADV
dpc-4315	29	43	the	the	DET
dpc-4315	29	44	hands	hand	NOUN
dpc-4315	29	45	.	.	PUNCT
dpc-4315	30	1	the	the	DET
dpc-4315	30	2	crucial	crucial	ADJ
dpc-4315	30	3	components	component	NOUN
dpc-4315	30	4	in	in	ADP
dpc-4315	30	5	the	the	DET
dpc-4315	30	6	pathophysiology	pathophysiology	NOUN
dpc-4315	30	7	of	of	ADP
dpc-4315	30	8	ad	ad	NOUN
dpc-4315	30	9	are	be	AUX
dpc-4315	30	10	t	t	PROPN
dpc-4315	30	11	helper	helper	NOUN
dpc-4315	30	12	type	type	NOUN
dpc-4315	30	13	2	2	NUM
dpc-4315	30	14	(	(	PUNCT
dpc-4315	30	15	th2	th2	PROPN
dpc-4315	30	16	)	)	PUNCT
dpc-4315	30	17	inflammation	inflammation	NOUN
dpc-4315	30	18	and	and	CCONJ
dpc-4315	30	19	disruption	disruption	NOUN
dpc-4315	30	20	of	of	ADP
dpc-4315	30	21	the	the	DET
dpc-4315	30	22	skin	skin	NOUN
dpc-4315	30	23	barrier	barrier	NOUN
dpc-4315	30	24	.	.	PUNCT
dpc-4315	31	1	local	local	ADJ
dpc-4315	31	2	inflammation	inflammation	NOUN
dpc-4315	31	3	is	be	AUX
dpc-4315	31	4	associated	associate	VERB
dpc-4315	31	5	with	with	ADP
dpc-4315	31	6	defects	defect	NOUN
dpc-4315	31	7	in	in	ADP
dpc-4315	31	8	epidermal	epidermal	ADJ
dpc-4315	31	9	barrier	barrier	NOUN
dpc-4315	31	10	proteins	protein	NOUN
dpc-4315	31	11	,	,	PUNCT
dpc-4315	31	12	including	include	VERB
dpc-4315	31	13	the	the	DET
dpc-4315	31	14	best	well	ADV
dpc-4315	31	15	-	-	PUNCT
dpc-4315	31	16	known	know	VERB
dpc-4315	31	17	filaggrin	filaggrin	NOUN
dpc-4315	31	18	mutations	mutation	NOUN
dpc-4315	31	19	,	,	PUNCT
dpc-4315	31	20	which	which	PRON
dpc-4315	31	21	promote	promote	VERB
dpc-4315	31	22	the	the	DET
dpc-4315	31	23	interaction	interaction	NOUN
dpc-4315	31	24	between	between	ADP
dpc-4315	31	25	skin	skin	NOUN
dpc-4315	31	26	-	-	PUNCT
dpc-4315	31	27	resident	resident	ADJ
dpc-4315	31	28	immune	immune	ADJ
dpc-4315	31	29	cells	cell	NOUN
dpc-4315	31	30	and	and	CCONJ
dpc-4315	31	31	environmental	environmental	ADJ
dpc-4315	31	32	antigens	antigen	NOUN
dpc-4315	31	33	[	[	X
dpc-4315	31	34	5	5	NUM
dpc-4315	31	35	]	]	PUNCT
dpc-4315	31	36	.	.	PUNCT
dpc-4315	32	1	the	the	DET
dpc-4315	32	2	reduction	reduction	NOUN
dpc-4315	32	3	of	of	ADP
dpc-4315	32	4	lympho	lympho	NOUN
dpc-4315	32	5	-	-	PUNCT
dpc-4315	32	6	epithelial	epithelial	ADJ
dpc-4315	32	7	kazal	kazal	NOUN
dpc-4315	32	8	-	-	PUNCT
dpc-4315	32	9	type	type	NOUN
dpc-4315	32	10	-	-	PUNCT
dpc-4315	32	11	related	relate	VERB
dpc-4315	32	12	inhibitor	inhibitor	NOUN
dpc-4315	32	13	(	(	PUNCT
dpc-4315	32	14	lekt1	lekt1	NOUN
dpc-4315	32	15	)	)	PUNCT
dpc-4315	32	16	may	may	AUX
dpc-4315	32	17	lead	lead	VERB
dpc-4315	32	18	to	to	ADP
dpc-4315	32	19	a	a	DET
dpc-4315	32	20	rapid	rapid	ADJ
dpc-4315	32	21	degradation	degradation	NOUN
dpc-4315	32	22	of	of	ADP
dpc-4315	32	23	desmogleins	desmoglein	NOUN
dpc-4315	32	24	,	,	PUNCT
dpc-4315	32	25	reducing	reduce	VERB
dpc-4315	32	26	intracellular	intracellular	ADJ
dpc-4315	32	27	adhesiveness	adhesiveness	NOUN
dpc-4315	32	28	[	[	X
dpc-4315	32	29	6	6	NUM
dpc-4315	32	30	]	]	PUNCT
dpc-4315	32	31	.	.	PUNCT
dpc-4315	33	1	another	another	DET
dpc-4315	33	2	role	role	NOUN
dpc-4315	33	3	has	have	AUX
dpc-4315	33	4	been	be	AUX
dpc-4315	33	5	assigned	assign	VERB
dpc-4315	33	6	to	to	ADP
dpc-4315	33	7	skin	skin	NOUN
dpc-4315	33	8	biofilm	biofilm	NOUN
dpc-4315	33	9	,	,	PUNCT
dpc-4315	33	10	in	in	ADP
dpc-4315	33	11	particular	particular	ADJ
dpc-4315	33	12	to	to	ADP
dpc-4315	33	13	staphylococcus	staphylococcus	NOUN
dpc-4315	33	14	aureus	aureus	NOUN
dpc-4315	33	15	.	.	PUNCT
dpc-4315	34	1	this	this	DET
dpc-4315	34	2	bacterium	bacterium	NOUN
dpc-4315	34	3	increases	increase	VERB
dpc-4315	34	4	skin	skin	NOUN
dpc-4315	34	5	inflammation	inflammation	NOUN
dpc-4315	34	6	in	in	ADP
dpc-4315	34	7	ad	ad	NOUN
dpc-4315	34	8	.	.	PUNCT
dpc-4315	35	1	in	in	ADP
dpc-4315	35	2	moderate	moderate	ADJ
dpc-4315	35	3	to	to	ADP
dpc-4315	35	4	severe	severe	ADJ
dpc-4315	35	5	cases	case	NOUN
dpc-4315	35	6	of	of	ADP
dpc-4315	35	7	ad	ad	NOUN
dpc-4315	35	8	(	(	PUNCT
dpc-4315	35	9	20	20	NUM
dpc-4315	35	10	%	%	NOUN
dpc-4315	35	11	of	of	ADP
dpc-4315	35	12	ad	ad	NOUN
dpc-4315	35	13	patients	patient	NOUN
dpc-4315	35	14	)	)	PUNCT
dpc-4315	35	15	,	,	PUNCT
dpc-4315	35	16	current	current	ADJ
dpc-4315	35	17	therapeutic	therapeutic	ADJ
dpc-4315	35	18	approaches	approach	NOUN
dpc-4315	35	19	may	may	AUX
dpc-4315	35	20	range	range	VERB
dpc-4315	35	21	from	from	ADP
dpc-4315	35	22	the	the	DET
dpc-4315	35	23	use	use	NOUN
dpc-4315	35	24	of	of	ADP
dpc-4315	35	25	:	:	PUNCT
dpc-4315	35	26	phototherapy	phototherapy	NOUN
dpc-4315	35	27	,	,	PUNCT
dpc-4315	35	28	corticosteroids	corticosteroid	NOUN
dpc-4315	35	29	,	,	PUNCT
dpc-4315	35	30	methotrexate	methotrexate	NOUN
dpc-4315	35	31	,	,	PUNCT
dpc-4315	35	32	cyclosporine	cyclosporine	NOUN
dpc-4315	35	33	,	,	PUNCT
dpc-4315	35	34	mycophenolate	mycophenolate	PROPN
dpc-4315	35	35	mofetil	mofetil	NOUN
dpc-4315	35	36	and	and	CCONJ
dpc-4315	35	37	azathioprine	azathioprine	NOUN
dpc-4315	35	38	.	.	PUNCT
dpc-4315	36	1	in	in	ADP
dpc-4315	36	2	addition	addition	NOUN
dpc-4315	36	3	to	to	ADP
dpc-4315	36	4	their	their	PRON
dpc-4315	36	5	limited	limited	ADJ
dpc-4315	36	6	effectiveness	effectiveness	NOUN
dpc-4315	36	7	,	,	PUNCT
dpc-4315	36	8	these	these	DET
dpc-4315	36	9	approaches	approach	NOUN
dpc-4315	36	10	can	can	AUX
dpc-4315	36	11	sometimes	sometimes	ADV
dpc-4315	36	12	cause	cause	VERB
dpc-4315	36	13	serious	serious	ADJ
dpc-4315	36	14	side	side	NOUN
dpc-4315	36	15	effects	effect	NOUN
dpc-4315	36	16	[	[	X
dpc-4315	36	17	7	7	NUM
dpc-4315	36	18	]	]	PUNCT
dpc-4315	36	19	.	.	PUNCT
dpc-4315	37	1	recent	recent	ADJ
dpc-4315	37	2	studies	study	NOUN
dpc-4315	37	3	elucidating	elucidate	VERB
dpc-4315	37	4	the	the	DET
dpc-4315	37	5	pathogenesis	pathogenesis	NOUN
dpc-4315	37	6	of	of	ADP
dpc-4315	37	7	ad	ad	NOUN
dpc-4315	37	8	have	have	AUX
dpc-4315	37	9	identified	identify	VERB
dpc-4315	37	10	cytokines	cytokine	NOUN
dpc-4315	37	11	involved	involve	VERB
dpc-4315	37	12	in	in	ADP
dpc-4315	37	13	the	the	DET
dpc-4315	37	14	underlying	underlie	VERB
dpc-4315	37	15	inflammatory	inflammatory	ADJ
dpc-4315	37	16	cascade	cascade	NOUN
dpc-4315	37	17	,	,	PUNCT
dpc-4315	37	18	including	include	VERB
dpc-4315	37	19	the	the	DET
dpc-4315	37	20	central	central	ADJ
dpc-4315	37	21	role	role	NOUN
dpc-4315	37	22	of	of	ADP
dpc-4315	37	23	interleukin	interleukin	NOUN
dpc-4315	37	24	(	(	PUNCT
dpc-4315	37	25	il-)13	il-)13	VERB
dpc-4315	37	26	in	in	ADP
dpc-4315	37	27	the	the	DET
dpc-4315	37	28	development	development	NOUN
dpc-4315	37	29	and	and	CCONJ
dpc-4315	37	30	maintenance	maintenance	NOUN
dpc-4315	37	31	of	of	ADP
dpc-4315	37	32	ad	ad	NOUN
dpc-4315	37	33	.	.	PUNCT
dpc-4315	38	1	the	the	DET
dpc-4315	38	2	first	first	ADJ
dpc-4315	38	3	monoclonal	monoclonal	ADJ
dpc-4315	38	4	anti	anti	ADJ
dpc-4315	38	5	-	-	ADJ
dpc-4315	38	6	interleukin	interleukin	ADJ
dpc-4315	38	7	(	(	PUNCT
dpc-4315	38	8	il	il	PROPN
dpc-4315	38	9	)	)	PUNCT
dpc-4315	38	10	4	4	NUM
dpc-4315	38	11	-	-	SYM
dpc-4315	38	12	13	13	NUM
dpc-4315	38	13	receptor	receptor	NOUN
dpc-4315	38	14	antibody	antibody	NOUN
dpc-4315	38	15	(	(	PUNCT
dpc-4315	38	16	dupilumab	dupilumab	NOUN
dpc-4315	38	17	)	)	PUNCT
dpc-4315	38	18	,	,	PUNCT
dpc-4315	38	19	approved	approve	VERB
dpc-4315	38	20	by	by	ADP
dpc-4315	38	21	the	the	DET
dpc-4315	38	22	us	us	PROPN
dpc-4315	38	23	food	food	NOUN
dpc-4315	38	24	and	and	CCONJ
dpc-4315	38	25	drug	drug	PROPN
dpc-4315	38	26	administration	administration	PROPN
dpc-4315	38	27	(	(	PUNCT
dpc-4315	38	28	fda	fda	PROPN
dpc-4315	38	29	)	)	PUNCT
dpc-4315	38	30	for	for	ADP
dpc-4315	38	31	the	the	DET
dpc-4315	38	32	treatment	treatment	NOUN
dpc-4315	38	33	of	of	ADP
dpc-4315	38	34	moderate	moderate	ADJ
dpc-4315	38	35	-	-	PUNCT
dpc-4315	38	36	to	to	ADP
dpc-4315	38	37	-	-	PUNCT
dpc-4315	38	38	severe	severe	ADJ
dpc-4315	38	39	ad	ad	NOUN
dpc-4315	38	40	,	,	PUNCT
dpc-4315	38	41	is	be	AUX
dpc-4315	38	42	widely	widely	ADV
dpc-4315	38	43	known	know	VERB
dpc-4315	38	44	for	for	ADP
dpc-4315	38	45	its	its	PRON
dpc-4315	38	46	high	high	ADJ
dpc-4315	38	47	efficacy	efficacy	NOUN
dpc-4315	38	48	and	and	CCONJ
dpc-4315	38	49	low	low	ADJ
dpc-4315	38	50	side	side	NOUN
dpc-4315	38	51	effect	effect	NOUN
dpc-4315	38	52	profile	profile	NOUN
dpc-4315	38	53	.	.	PUNCT
dpc-4315	39	1	it	it	PRON
dpc-4315	39	2	selectively	selectively	ADV
dpc-4315	39	3	binds	bind	VERB
dpc-4315	39	4	to	to	ADP
dpc-4315	39	5	the	the	DET
dpc-4315	39	6	il-4/13	il-4/13	ADJ
dpc-4315	39	7	receptor	receptor	NOUN
dpc-4315	39	8	[	[	X
dpc-4315	39	9	7	7	NUM
dpc-4315	39	10	]	]	PUNCT
dpc-4315	39	11	.	.	PUNCT
dpc-4315	40	1	more	more	ADV
dpc-4315	40	2	recently	recently	ADV
dpc-4315	40	3	,	,	PUNCT
dpc-4315	40	4	lebrikizumab	lebrikizumab	NOUN
dpc-4315	40	5	and	and	CCONJ
dpc-4315	40	6	tralokinumab	tralokinumab	NOUN
dpc-4315	40	7	,	,	PUNCT
dpc-4315	40	8	two	two	NUM
dpc-4315	40	9	selective	selective	ADJ
dpc-4315	40	10	inhhibitors	inhhibitor	NOUN
dpc-4315	40	11	anti	anti	ADJ
dpc-4315	40	12	-	-	ADJ
dpc-4315	40	13	il-13	il-13	PRON
dpc-4315	40	14	,	,	PUNCT
dpc-4315	40	15	has	have	AUX
dpc-4315	40	16	been	be	AUX
dpc-4315	40	17	developed	develop	VERB
dpc-4315	40	18	to	to	PART
dpc-4315	40	19	manage	manage	VERB
dpc-4315	40	20	atopic	atopic	NOUN
dpc-4315	40	21	dermatitis	dermatitis	NOUN
dpc-4315	40	22	[	[	X
dpc-4315	40	23	7,8	7,8	NUM
dpc-4315	40	24	]	]	PUNCT
dpc-4315	40	25	.	.	PUNCT
dpc-4315	41	1	objectives	objective	VERB
dpc-4315	41	2	the	the	DET
dpc-4315	41	3	aim	aim	NOUN
dpc-4315	41	4	of	of	ADP
dpc-4315	41	5	this	this	DET
dpc-4315	41	6	review	review	NOUN
dpc-4315	41	7	was	be	AUX
dpc-4315	41	8	to	to	PART
dpc-4315	41	9	evaluate	evaluate	VERB
dpc-4315	41	10	the	the	DET
dpc-4315	41	11	efficacy	efficacy	NOUN
dpc-4315	41	12	and	and	CCONJ
dpc-4315	41	13	safety	safety	NOUN
dpc-4315	41	14	of	of	ADP
dpc-4315	41	15	tralokinumab	tralokinumab	NOUN
dpc-4315	41	16	,	,	PUNCT
dpc-4315	41	17	a	a	DET
dpc-4315	41	18	fully	fully	ADV
dpc-4315	41	19	monoclonal	monoclonal	ADJ
dpc-4315	41	20	antibody	antibody	NOUN
dpc-4315	41	21	that	that	PRON
dpc-4315	41	22	potently	potently	ADV
dpc-4315	41	23	and	and	CCONJ
dpc-4315	41	24	specifically	specifically	ADV
dpc-4315	41	25	neutralizes	neutralize	VERB
dpc-4315	41	26	il-13	il-13	NUM
dpc-4315	41	27	,	,	PUNCT
dpc-4315	41	28	in	in	ADP
dpc-4315	41	29	the	the	DET
dpc-4315	41	30	treatment	treatment	NOUN
dpc-4315	41	31	  	  	SPACE
dpc-4315	41	32	of	of	ADP
dpc-4315	41	33	moderate	moderate	ADJ
dpc-4315	41	34	-	-	PUNCT
dpc-4315	41	35	to	to	ADP
dpc-4315	41	36	-	-	PUNCT
dpc-4315	41	37	severe	severe	ADJ
dpc-4315	41	38	ad	ad	NOUN
dpc-4315	41	39	,	,	PUNCT
dpc-4315	41	40	giving	give	VERB
dpc-4315	41	41	the	the	DET
dpc-4315	41	42	clinician	clinician	NOUN
dpc-4315	41	43	a	a	DET
dpc-4315	41	44	practical	practical	ADJ
dpc-4315	41	45	 	 	SPACE
dpc-4315	41	46	summary	summary	NOUN
dpc-4315	41	47	.	.	PUNCT
dpc-4315	42	1	methods	method	NOUN
dpc-4315	42	2	our	our	PRON
dpc-4315	42	3	team	team	NOUN
dpc-4315	42	4	performed	perform	VERB
dpc-4315	42	5	a	a	DET
dpc-4315	42	6	literature	literature	NOUN
dpc-4315	42	7	narrative	narrative	NOUN
dpc-4315	42	8	review	review	NOUN
dpc-4315	42	9	of	of	ADP
dpc-4315	42	10	articles	article	NOUN
dpc-4315	42	11	on	on	ADP
dpc-4315	42	12	the	the	DET
dpc-4315	42	13	use	use	NOUN
dpc-4315	42	14	of	of	ADP
dpc-4315	42	15	tralokinumab	tralokinumab	NOUN
dpc-4315	42	16	in	in	ADP
dpc-4315	42	17	ad	ad	NOUN
dpc-4315	42	18	,	,	PUNCT
dpc-4315	42	19	published	publish	VERB
dpc-4315	42	20	in	in	ADP
dpc-4315	42	21	pubmed	pubmed	PROPN
dpc-4315	42	22	,	,	PUNCT
dpc-4315	42	23	google	google	NOUN
dpc-4315	42	24	scholar	scholar	NOUN
dpc-4315	42	25	,	,	PUNCT
dpc-4315	42	26	and	and	CCONJ
dpc-4315	42	27	clinicaltrials.gov	clinicaltrials.gov	PROPN
dpc-4315	42	28	until	until	ADP
dpc-4315	42	29	november	november	PROPN
dpc-4315	42	30	2023	2023	NUM
dpc-4315	42	31	.	.	PUNCT
dpc-4315	43	1	the	the	DET
dpc-4315	43	2	keywords	keyword	NOUN
dpc-4315	43	3	were	be	AUX
dpc-4315	43	4	:	:	PUNCT
dpc-4315	43	5	“	"	PUNCT
dpc-4315	43	6	tralokinumab	tralokinumab	NOUN
dpc-4315	43	7	,	,	PUNCT
dpc-4315	43	8	il-13	il-13	NUM
dpc-4315	43	9	,	,	PUNCT
dpc-4315	43	10	biological	biological	ADJ
dpc-4315	43	11	therapy	therapy	NOUN
dpc-4315	43	12	”	"	PUNCT
dpc-4315	43	13	combined	combine	VERB
dpc-4315	43	14	with	with	ADP
dpc-4315	43	15	“	"	PUNCT
dpc-4315	43	16	atopic	atopic	NOUN
dpc-4315	43	17	dermatitis	dermatitis	NOUN
dpc-4315	43	18	”	"	PUNCT
dpc-4315	43	19	.	.	PUNCT
dpc-4315	44	1	results	result	VERB
dpc-4315	44	2	ad	ad	NOUN
dpc-4315	44	3	is	be	AUX
dpc-4315	44	4	a	a	DET
dpc-4315	44	5	combination	combination	NOUN
dpc-4315	44	6	of	of	ADP
dpc-4315	44	7	skin	skin	NOUN
dpc-4315	44	8	-	-	PUNCT
dpc-4315	44	9	barrier	barrier	NOUN
dpc-4315	44	10	dysfunction	dysfunction	NOUN
dpc-4315	44	11	and	and	CCONJ
dpc-4315	44	12	immune	immune	ADJ
dpc-4315	44	13	dysregulation	dysregulation	NOUN
dpc-4315	45	1	[	[	X
dpc-4315	45	2	9	9	NUM
dpc-4315	45	3	]	]	PUNCT
dpc-4315	45	4	.	.	PUNCT
dpc-4315	46	1	studies	study	NOUN
dpc-4315	46	2	conducted	conduct	VERB
dpc-4315	46	3	in	in	ADP
dpc-4315	46	4	mouse	mouse	NOUN
dpc-4315	46	5	models	model	NOUN
dpc-4315	46	6	and	and	CCONJ
dpc-4315	46	7	in	in	ADP
dpc-4315	46	8	humans	human	NOUN
dpc-4315	46	9	over	over	ADP
dpc-4315	46	10	time	time	NOUN
dpc-4315	46	11	have	have	AUX
dpc-4315	46	12	demonstrated	demonstrate	VERB
dpc-4315	46	13	the	the	DET
dpc-4315	46	14	central	central	ADJ
dpc-4315	46	15	role	role	NOUN
dpc-4315	46	16	of	of	ADP
dpc-4315	46	17	il-4	il-4	NOUN
dpc-4315	46	18	in	in	ADP
dpc-4315	46	19	the	the	DET
dpc-4315	46	20	pathogenesis	pathogenesis	NOUN
dpc-4315	46	21	of	of	ADP
dpc-4315	46	22	ad	ad	NOUN
dpc-4315	46	23	[	[	X
dpc-4315	46	24	10	10	NUM
dpc-4315	46	25	-	-	SYM
dpc-4315	46	26	12	12	NUM
dpc-4315	46	27	]	]	PUNCT
dpc-4315	46	28	.	.	PUNCT
dpc-4315	47	1	however	however	ADV
dpc-4315	47	2	,	,	PUNCT
dpc-4315	47	3	several	several	ADJ
dpc-4315	47	4	studies	study	NOUN
dpc-4315	47	5	showed	show	VERB
dpc-4315	47	6	that	that	SCONJ
dpc-4315	47	7	il-13	il-13	ADP
dpc-4315	47	8	may	may	AUX
dpc-4315	47	9	be	be	AUX
dpc-4315	47	10	of	of	ADP
dpc-4315	47	11	greater	great	ADJ
dpc-4315	47	12	importance	importance	NOUN
dpc-4315	47	13	in	in	ADP
dpc-4315	47	14	the	the	DET
dpc-4315	47	15	pathophysiology	pathophysiology	NOUN
dpc-4315	47	16	of	of	ADP
dpc-4315	47	17	ad	ad	NOUN
dpc-4315	47	18	than	than	ADP
dpc-4315	47	19	il-4	il-4	NOUN
dpc-4315	48	1	[	[	X
dpc-4315	48	2	13	13	NUM
dpc-4315	48	3	]	]	PUNCT
dpc-4315	48	4	.	.	PUNCT
dpc-4315	49	1	mice	mouse	NOUN
dpc-4315	49	2	transgenic	transgenic	NOUN
dpc-4315	49	3	for	for	ADP
dpc-4315	49	4	cutaneous	cutaneous	ADJ
dpc-4315	49	5	il-13	il-13	PRON
dpc-4315	49	6	expression	expression	NOUN
dpc-4315	49	7	developed	develop	VERB
dpc-4315	49	8	an	an	DET
dpc-4315	49	9	ad	ad	NOUN
dpc-4315	49	10	-	-	PUNCT
dpc-4315	49	11	like	like	ADJ
dpc-4315	49	12	phenotype	phenotype	NOUN
dpc-4315	49	13	.	.	PUNCT
dpc-4315	50	1	greater	great	ADJ
dpc-4315	50	2	il-13	il-13	PRON
dpc-4315	50	3	expression	expression	NOUN
dpc-4315	50	4	has	have	AUX
dpc-4315	50	5	been	be	AUX
dpc-4315	50	6	demonstrated	demonstrate	VERB
dpc-4315	50	7	in	in	ADP
dpc-4315	50	8	acute	acute	ADJ
dpc-4315	50	9	and	and	CCONJ
dpc-4315	50	10	chronic	chronic	ADJ
dpc-4315	50	11	skin	skin	NOUN
dpc-4315	50	12	lesions	lesion	NOUN
dpc-4315	50	13	in	in	ADP
dpc-4315	50	14	individuals	individual	NOUN
dpc-4315	50	15	with	with	ADP
dpc-4315	50	16	ad	ad	NOUN
dpc-4315	50	17	[	[	X
dpc-4315	50	18	13–15	13–15	NUM
dpc-4315	50	19	]	]	PUNCT
dpc-4315	50	20	.	.	PUNCT
dpc-4315	51	1	it	it	PRON
dpc-4315	51	2	has	have	AUX
dpc-4315	51	3	also	also	ADV
dpc-4315	51	4	been	be	AUX
dpc-4315	51	5	shown	show	VERB
dpc-4315	51	6	that	that	SCONJ
dpc-4315	51	7	elevated	elevated	ADJ
dpc-4315	51	8	levels	level	NOUN
dpc-4315	51	9	of	of	ADP
dpc-4315	51	10	il-13	il-13	PRON
dpc-4315	51	11	,	,	PUNCT
dpc-4315	51	12	produced	produce	VERB
dpc-4315	51	13	by	by	ADP
dpc-4315	51	14	cd4	cd4	PROPN
dpc-4315	51	15	+	+	CCONJ
dpc-4315	51	16	and	and	CCONJ
dpc-4315	51	17	cd8	cd8	PROPN
dpc-4315	51	18	+	+	PROPN
dpc-4315	51	19	t	t	NOUN
dpc-4315	51	20	cells	cell	NOUN
dpc-4315	51	21	as	as	ADV
dpc-4315	51	22	well	well	ADV
dpc-4315	51	23	as	as	ADP
dpc-4315	51	24	mast	mast	NOUN
dpc-4315	51	25	cells	cell	NOUN
dpc-4315	51	26	,	,	PUNCT
dpc-4315	51	27	basophils	basophil	NOUN
dpc-4315	51	28	,	,	PUNCT
dpc-4315	51	29	and	and	CCONJ
dpc-4315	51	30	eosinophils	eosinophil	VERB
dpc-4315	51	31	[	[	PUNCT
dpc-4315	51	32	16	16	NUM
dpc-4315	51	33	-	-	SYM
dpc-4315	51	34	19	19	NUM
dpc-4315	51	35	]	]	PUNCT
dpc-4315	51	36	are	be	AUX
dpc-4315	51	37	responsible	responsible	ADJ
dpc-4315	51	38	for	for	ADP
dpc-4315	51	39	skin	skin	NOUN
dpc-4315	51	40	inflammation	inflammation	NOUN
dpc-4315	51	41	and	and	CCONJ
dpc-4315	51	42	fibrotic	fibrotic	ADJ
dpc-4315	51	43	remodeling	remodeling	NOUN
dpc-4315	51	44	in	in	ADP
dpc-4315	51	45	ad	ad	NOUN
dpc-4315	51	46	patients	patient	NOUN
dpc-4315	51	47	[	[	X
dpc-4315	51	48	20	20	NUM
dpc-4315	51	49	]	]	PUNCT
dpc-4315	51	50	.	.	PUNCT
dpc-4315	52	1	further	further	PROPN
dpc-4315	52	2	studies	study	NOUN
dpc-4315	52	3	demonstrate	demonstrate	VERB
dpc-4315	52	4	the	the	DET
dpc-4315	52	5	role	role	NOUN
dpc-4315	52	6	of	of	ADP
dpc-4315	52	7	il-13	il-13	PUNCT
dpc-4315	52	8	in	in	ADP
dpc-4315	52	9	the	the	DET
dpc-4315	52	10	dysfunction	dysfunction	NOUN
dpc-4315	52	11	of	of	ADP
dpc-4315	52	12	the	the	DET
dpc-4315	52	13	epidermal	epidermal	ADJ
dpc-4315	52	14	barrier	barrier	NOUN
dpc-4315	52	15	and	and	CCONJ
dpc-4315	52	16	in	in	ADP
dpc-4315	52	17	the	the	DET
dpc-4315	52	18	damage	damage	NOUN
dpc-4315	52	19	of	of	ADP
dpc-4315	52	20	keratinocytes	keratinocyte	NOUN
dpc-4315	52	21	,	,	PUNCT
dpc-4315	52	22	both	both	PRON
dpc-4315	52	23	implicated	implicate	VERB
dpc-4315	52	24	in	in	ADP
dpc-4315	52	25	the	the	DET
dpc-4315	52	26	pathogenesis	pathogenesis	NOUN
dpc-4315	52	27	of	of	ADP
dpc-4315	52	28	ad	ad	NOUN
dpc-4315	52	29	.	.	PUNCT
dpc-4315	53	1	in	in	ADP
dpc-4315	53	2	vitro	vitro	X
dpc-4315	53	3	studies	study	NOUN
dpc-4315	53	4	suggest	suggest	VERB
dpc-4315	53	5	that	that	SCONJ
dpc-4315	53	6	th2	th2	PROPN
dpc-4315	53	7	-	-	PUNCT
dpc-4315	53	8	type	type	NOUN
dpc-4315	53	9	inflammation	inflammation	NOUN
dpc-4315	53	10	may	may	AUX
dpc-4315	53	11	result	result	VERB
dpc-4315	53	12	in	in	ADP
dpc-4315	53	13	an	an	DET
dpc-4315	53	14	acquired	acquire	VERB
dpc-4315	53	15	filaggrin	filaggrin	NOUN
dpc-4315	53	16	deficiency	deficiency	NOUN
dpc-4315	53	17	[	[	X
dpc-4315	53	18	21	21	NUM
dpc-4315	53	19	]	]	PUNCT
dpc-4315	53	20	.	.	PUNCT
dpc-4315	54	1	it	it	PRON
dpc-4315	54	2	has	have	AUX
dpc-4315	54	3	also	also	ADV
dpc-4315	54	4	been	be	AUX
dpc-4315	54	5	shown	show	VERB
dpc-4315	54	6	that	that	SCONJ
dpc-4315	54	7	il-4	il-4	PRON
dpc-4315	55	1	and	and	CCONJ
dpc-4315	55	2	il-13	il-13	CCONJ
dpc-4315	55	3	reduce	reduce	VERB
dpc-4315	55	4	the	the	DET
dpc-4315	55	5	keratinocyte	keratinocyte	NOUN
dpc-4315	55	6	expression	expression	NOUN
dpc-4315	55	7	of	of	ADP
dpc-4315	55	8	loricrin	loricrin	PROPN
dpc-4315	55	9	,	,	PUNCT
dpc-4315	55	10	involucrin	involucrin	NOUN
dpc-4315	55	11	,	,	PUNCT
dpc-4315	55	12	keratin	keratin	NOUN
dpc-4315	55	13	1	1	NUM
dpc-4315	55	14	,	,	PUNCT
dpc-4315	55	15	keratin	keratin	NOUN
dpc-4315	55	16	10	10	NUM
dpc-4315	55	17	,	,	PUNCT
dpc-4315	55	18	hornerin	hornerin	NOUN
dpc-4315	55	19	,	,	PUNCT
dpc-4315	55	20	desmoglein	desmoglein	NOUN
dpc-4315	55	21	,	,	PUNCT
dpc-4315	55	22	and	and	CCONJ
dpc-4315	55	23	desmocollin	desmocollin	PROPN
dpc-4315	55	24	1	1	NUM
dpc-4315	55	25	,	,	PUNCT
dpc-4315	55	26	as	as	ADV
dpc-4315	55	27	well	well	ADV
dpc-4315	55	28	as	as	ADP
dpc-4315	55	29	the	the	DET
dpc-4315	55	30	lipid	lipid	NOUN
dpc-4315	55	31	composition	composition	NOUN
dpc-4315	55	32	,	,	PUNCT
dpc-4315	55	33	important	important	ADJ
dpc-4315	55	34	for	for	ADP
dpc-4315	55	35	the	the	DET
dpc-4315	55	36	constitution	constitution	NOUN
dpc-4315	55	37	and	and	CCONJ
dpc-4315	55	38	integrity	integrity	NOUN
dpc-4315	55	39	of	of	ADP
dpc-4315	55	40	the	the	DET
dpc-4315	55	41	skin	skin	NOUN
dpc-4315	55	42	barrier	barrier	NOUN
dpc-4315	55	43	[	[	X
dpc-4315	55	44	22	22	NUM
dpc-4315	55	45	]	]	PUNCT
dpc-4315	55	46	.	.	PUNCT
dpc-4315	56	1	furthermore	furthermore	ADV
dpc-4315	56	2	,	,	PUNCT
dpc-4315	56	3	il-13	il-13	ADV
dpc-4315	56	4	,	,	PUNCT
dpc-4315	56	5	together	together	ADV
dpc-4315	56	6	with	with	ADP
dpc-4315	56	7	il-4	il-4	NOUN
dpc-4315	56	8	and	and	CCONJ
dpc-4315	56	9	il-31	il-31	PRON
dpc-4315	56	10	,	,	PUNCT
dpc-4315	56	11	appears	appear	VERB
dpc-4315	56	12	to	to	PART
dpc-4315	56	13	stimulate	stimulate	VERB
dpc-4315	56	14	the	the	DET
dpc-4315	56	15	sensory	sensory	ADJ
dpc-4315	56	16	neurons	neuron	NOUN
dpc-4315	56	17	responsible	responsible	ADJ
dpc-4315	56	18	for	for	ADP
dpc-4315	56	19	peripheral	peripheral	ADJ
dpc-4315	56	20	itching	itching	NOUN
dpc-4315	56	21	.	.	PUNCT
dpc-4315	57	1	therefore	therefore	ADV
dpc-4315	57	2	,	,	PUNCT
dpc-4315	57	3	it	it	PRON
dpc-4315	57	4	can	can	AUX
dpc-4315	57	5	be	be	AUX
dpc-4315	57	6	considered	consider	VERB
dpc-4315	57	7	pruritogenic	pruritogenic	ADJ
dpc-4315	57	8	[	[	X
dpc-4315	57	9	23	23	NUM
dpc-4315	57	10	]	]	PUNCT
dpc-4315	57	11	.	.	PUNCT
dpc-4315	58	1	given	give	VERB
dpc-4315	58	2	these	these	DET
dpc-4315	58	3	reasons	reason	NOUN
dpc-4315	58	4	,	,	PUNCT
dpc-4315	58	5	the	the	DET
dpc-4315	58	6	signal	signal	ADJ
dpc-4315	58	7	path	path	NOUN
dpc-4315	58	8	activated	activate	VERB
dpc-4315	58	9	by	by	ADP
dpc-4315	58	10	il-13	il-13	PUNCT
dpc-4315	58	11	is	be	AUX
dpc-4315	58	12	an	an	DET
dpc-4315	58	13	excellent	excellent	ADJ
dpc-4315	58	14	candidate	candidate	NOUN
dpc-4315	58	15	for	for	ADP
dpc-4315	58	16	target	target	NOUN
dpc-4315	58	17	therapy	therapy	NOUN
dpc-4315	58	18	[	[	X
dpc-4315	58	19	24	24	NUM
dpc-4315	58	20	]	]	PUNCT
dpc-4315	58	21	.	.	PUNCT
dpc-4315	59	1	relevant	relevant	ADJ
dpc-4315	59	2	clinical	clinical	ADJ
dpc-4315	59	3	studies	study	NOUN
dpc-4315	59	4	on	on	ADP
dpc-4315	59	5	the	the	DET
dpc-4315	59	6	role	role	NOUN
dpc-4315	59	7	of	of	ADP
dpc-4315	59	8	il-13	il-13	PUNCT
dpc-4315	59	9	in	in	ADP
dpc-4315	59	10	ad	ad	NOUN
dpc-4315	59	11	are	be	AUX
dpc-4315	59	12	summarized	summarize	VERB
dpc-4315	59	13	in	in	ADP
dpc-4315	59	14	table	table	NOUN
dpc-4315	59	15	1	1	NUM
dpc-4315	59	16	.	.	PUNCT
dpc-4315	59	17	tralokinumab	tralokinumab	NOUN
dpc-4315	59	18	(	(	PUNCT
dpc-4315	59	19	cat-354	cat-354	PROPN
dpc-4315	59	20	)	)	PUNCT
dpc-4315	59	21	is	be	AUX
dpc-4315	59	22	an	an	DET
dpc-4315	59	23	igg4	igg4	NOUN
dpc-4315	59	24	monoclonal	monoclonal	NOUN
dpc-4315	59	25	,	,	PUNCT
dpc-4315	59	26	fully	fully	ADV
dpc-4315	59	27	human	human	ADJ
dpc-4315	59	28	,	,	PUNCT
dpc-4315	59	29	il-13	il-13	ADV
dpc-4315	59	30	-	-	PUNCT
dpc-4315	59	31	neutralizing	neutralize	VERB
dpc-4315	59	32	antibody	antibody	NOUN
dpc-4315	59	33	that	that	PRON
dpc-4315	59	34	inhibits	inhibit	VERB
dpc-4315	59	35	its	its	PRON
dpc-4315	59	36	pharmacodynamics	pharmacodynamic	NOUN
dpc-4315	59	37	.	.	PUNCT
dpc-4315	60	1	pre	pre	ADJ
dpc-4315	60	2	-	-	ADJ
dpc-4315	60	3	clinical	clinical	ADJ
dpc-4315	60	4	studies	study	NOUN
dpc-4315	60	5	show	show	VERB
dpc-4315	60	6	that	that	SCONJ
dpc-4315	60	7	binding	bind	VERB
dpc-4315	60	8	of	of	ADP
dpc-4315	60	9	tralokinumab	tralokinumab	NOUN
dpc-4315	60	10	to	to	PART
dpc-4315	60	11	il-13	il-13	PUNCT
dpc-4315	60	12	prevents	prevent	VERB
dpc-4315	60	13	the	the	DET
dpc-4315	60	14	interaction	interaction	NOUN
dpc-4315	60	15	between	between	ADP
dpc-4315	60	16	il-13	il-13	PUNCT
dpc-4315	60	17	and	and	CCONJ
dpc-4315	60	18	both	both	DET
dpc-4315	60	19	il-13rα1	il-13rα1	PROPN
dpc-4315	60	20	and	and	CCONJ
dpc-4315	60	21	il-13rα2	il-13rα2	PROPN
dpc-4315	60	22	in	in	ADP
dpc-4315	60	23	a	a	DET
dpc-4315	60	24	concentration	concentration	NOUN
dpc-4315	60	25	dependent	dependent	ADJ
dpc-4315	60	26	manner	manner	NOUN
dpc-4315	61	1	[	[	X
dpc-4315	61	2	8	8	NUM
dpc-4315	61	3	]	]	PUNCT
dpc-4315	61	4	.	.	PUNCT
dpc-4315	62	1	tollenaere	tollenaere	INTJ
dpc-4315	62	2	et	et	PROPN
dpc-4315	62	3	al	al	PROPN
dpc-4315	62	4	demonstrated	demonstrate	VERB
dpc-4315	62	5	that	that	SCONJ
dpc-4315	62	6	cat-354	cat-354	NOUN
dpc-4315	62	7	is	be	AUX
dpc-4315	62	8	unable	unable	ADJ
dpc-4315	62	9	to	to	PART
dpc-4315	62	10	displace	displace	VERB
dpc-4315	62	11	il13	il13	PROPN
dpc-4315	62	12	from	from	ADP
dpc-4315	62	13	il-13ra2	il-13ra2	PROPN
dpc-4315	62	14	because	because	SCONJ
dpc-4315	62	15	of	of	ADP
dpc-4315	62	16	its	its	PRON
dpc-4315	62	17	high	high	ADJ
dpc-4315	62	18	affinity	affinity	NOUN
dpc-4315	62	19	.	.	PUNCT
dpc-4315	63	1	review	review	VERB
dpc-4315	63	2	|	|	ADV
dpc-4315	63	3	dermatol	dermatol	ADJ
dpc-4315	63	4	pract	pract	NOUN
dpc-4315	63	5	concept	concept	NOUN
dpc-4315	63	6	.	.	PUNCT
dpc-4315	64	1	2024;14(3):e2024204	2024;14(3):e2024204	NUM
dpc-4315	64	2	3	3	NUM
dpc-4315	64	3	tralokinumab	tralokinumab	NOUN
dpc-4315	64	4	is	be	AUX
dpc-4315	64	5	not	not	PART
dpc-4315	64	6	able	able	ADJ
dpc-4315	64	7	to	to	PART
dpc-4315	64	8	regulate	regulate	VERB
dpc-4315	64	9	this	this	DET
dpc-4315	64	10	pathway	pathway	NOUN
dpc-4315	64	11	but	but	CCONJ
dpc-4315	64	12	only	only	ADV
dpc-4315	64	13	il-13	il-13	ADP
dpc-4315	64	14	/	/	SYM
dpc-4315	64	15	il-13ra1	il-13ra1	PROPN
dpc-4315	64	16	and	and	CCONJ
dpc-4315	64	17	il-13ra1	il-13ra1	PROPN
dpc-4315	64	18	/	/	SYM
dpc-4315	64	19	il-13	il-13	NUM
dpc-4315	64	20	/	/	SYM
dpc-4315	64	21	il-4ra	il-4ra	NOUN
dpc-4315	64	22	complex	complex	NOUN
dpc-4315	65	1	[	[	X
dpc-4315	65	2	25	25	NUM
dpc-4315	65	3	]	]	PUNCT
dpc-4315	65	4	.	.	PUNCT
dpc-4315	65	5	published	publish	VERB
dpc-4315	65	6	values	value	NOUN
dpc-4315	65	7	for	for	ADP
dpc-4315	65	8	antibody	antibody	NOUN
dpc-4315	65	9	-	-	PUNCT
dpc-4315	65	10	antigen	antigen	NOUN
dpc-4315	65	11	shape	shape	NOUN
dpc-4315	65	12	complementarity	complementarity	NOUN
dpc-4315	65	13	range	range	NOUN
dpc-4315	65	14	from	from	ADP
dpc-4315	65	15	0.6	0.6	NUM
dpc-4315	65	16	to	to	ADP
dpc-4315	65	17	0.8	0.8	NUM
dpc-4315	65	18	,	,	PUNCT
dpc-4315	65	19	where	where	SCONJ
dpc-4315	65	20	a	a	DET
dpc-4315	65	21	surface	surface	NOUN
dpc-4315	65	22	complementarity	complementarity	NOUN
dpc-4315	65	23	of	of	ADP
dpc-4315	65	24	1.0	1.0	NUM
dpc-4315	65	25	indicates	indicate	VERB
dpc-4315	65	26	interfaces	interface	NOUN
dpc-4315	65	27	with	with	ADP
dpc-4315	65	28	a	a	DET
dpc-4315	65	29	geometrically	geometrically	ADV
dpc-4315	65	30	perfect	perfect	ADJ
dpc-4315	65	31	fit	fit	NOUN
dpc-4315	65	32	.	.	PUNCT
dpc-4315	66	1	this	this	DET
dpc-4315	66	2	similarity	similarity	NOUN
dpc-4315	66	3	demonstrates	demonstrate	VERB
dpc-4315	66	4	the	the	DET
dpc-4315	66	5	high	high	ADJ
dpc-4315	66	6	complementarity	complementarity	NOUN
dpc-4315	66	7	of	of	ADP
dpc-4315	66	8	the	the	DET
dpc-4315	66	9	interface	interface	NOUN
dpc-4315	66	10	between	between	ADP
dpc-4315	66	11	the	the	DET
dpc-4315	66	12	antigen	antigen	NOUN
dpc-4315	66	13	-	-	PUNCT
dpc-4315	66	14	binding	bind	VERB
dpc-4315	66	15	fragment	fragment	NOUN
dpc-4315	66	16	of	of	ADP
dpc-4315	66	17	tralokinumab	tralokinumab	NOUN
dpc-4315	66	18	and	and	CCONJ
dpc-4315	66	19	il-13	il-13	X
dpc-4315	67	1	[	[	X
dpc-4315	67	2	26,27	26,27	NUM
dpc-4315	67	3	]	]	PUNCT
dpc-4315	67	4	.	.	PUNCT
dpc-4315	68	1	ecztra	ecztra	ADJ
dpc-4315	68	2	trials	trial	NOUN
dpc-4315	68	3	1	1	NUM
dpc-4315	68	4	,	,	PUNCT
dpc-4315	68	5	2	2	NUM
dpc-4315	68	6	and	and	CCONJ
dpc-4315	68	7	3	3	NUM
dpc-4315	68	8	provide	provide	VERB
dpc-4315	68	9	evidence	evidence	NOUN
dpc-4315	68	10	to	to	PART
dpc-4315	68	11	support	support	VERB
dpc-4315	68	12	tralokinumab	tralokinumab	NOUN
dpc-4315	68	13	as	as	ADP
dpc-4315	68	14	a	a	DET
dpc-4315	68	15	treatment	treatment	NOUN
dpc-4315	68	16	for	for	ADP
dpc-4315	68	17	moderate	moderate	ADJ
dpc-4315	68	18	to	to	ADP
dpc-4315	68	19	severe	severe	ADJ
dpc-4315	68	20	ad	ad	NOUN
dpc-4315	68	21	[	[	X
dpc-4315	68	22	28	28	NUM
dpc-4315	68	23	-	-	SYM
dpc-4315	68	24	30	30	NUM
dpc-4315	68	25	]	]	PUNCT
dpc-4315	68	26	.	.	PUNCT
dpc-4315	69	1	ecztra	ecztra	PROPN
dpc-4315	69	2	1	1	NUM
dpc-4315	69	3	and	and	CCONJ
dpc-4315	69	4	2	2	NUM
dpc-4315	69	5	were	be	AUX
dpc-4315	69	6	identical	identical	ADJ
dpc-4315	69	7	monotherapy	monotherapy	NOUN
dpc-4315	69	8	trials	trial	NOUN
dpc-4315	69	9	that	that	PRON
dpc-4315	69	10	enrolled	enrol	VERB
dpc-4315	69	11	a	a	DET
dpc-4315	69	12	total	total	ADJ
dpc-4315	69	13	number	number	NOUN
dpc-4315	69	14	of	of	ADP
dpc-4315	69	15	1596	1596	NUM
dpc-4315	69	16	adult	adult	NOUN
dpc-4315	69	17	patients	patient	NOUN
dpc-4315	69	18	with	with	ADP
dpc-4315	69	19	moderate	moderate	ADJ
dpc-4315	69	20	-	-	PUNCT
dpc-4315	69	21	to	to	ADP
dpc-4315	69	22	-	-	PUNCT
dpc-4315	69	23	severe	severe	ADJ
dpc-4315	69	24	ad	ad	NOUN
dpc-4315	69	25	.	.	PUNCT
dpc-4315	70	1	patients	patient	NOUN
dpc-4315	70	2	were	be	AUX
dpc-4315	70	3	randomized	randomize	VERB
dpc-4315	70	4	into	into	ADP
dpc-4315	70	5	three	three	NUM
dpc-4315	70	6	arms	arm	NOUN
dpc-4315	70	7	:	:	PUNCT
dpc-4315	70	8	to	to	ADP
dpc-4315	70	9	either	either	DET
dpc-4315	70	10	tralokinumab	tralokinumab	NOUN
dpc-4315	70	11	600	600	NUM
dpc-4315	70	12	mg	mg	NOUN
dpc-4315	70	13	and	and	CCONJ
dpc-4315	70	14	300	300	NUM
dpc-4315	70	15	mg	mg	NOUN
dpc-4315	70	16	subcutaneously	subcutaneously	ADV
dpc-4315	70	17	(	(	PUNCT
dpc-4315	70	18	sc	sc	NOUN
dpc-4315	70	19	)	)	PUNCT
dpc-4315	70	20	administered	administer	VERB
dpc-4315	70	21	every	every	DET
dpc-4315	70	22	two	two	NUM
dpc-4315	70	23	weeks	week	NOUN
dpc-4315	70	24	(	(	PUNCT
dpc-4315	70	25	q2w	q2w	NOUN
dpc-4315	70	26	)	)	PUNCT
dpc-4315	70	27	or	or	CCONJ
dpc-4315	70	28	to	to	ADP
dpc-4315	70	29	placebo	placebo	NOUN
dpc-4315	70	30	.	.	PUNCT
dpc-4315	71	1	the	the	DET
dpc-4315	71	2	primary	primary	ADJ
dpc-4315	71	3	endpoints	endpoint	NOUN
dpc-4315	71	4	were	be	AUX
dpc-4315	71	5	an	an	DET
dpc-4315	71	6	investigator	investigator	NOUN
dpc-4315	71	7	global	global	ADJ
dpc-4315	71	8	assessment	assessment	NOUN
dpc-4315	71	9	(	(	PUNCT
dpc-4315	71	10	iga	iga	PROPN
dpc-4315	71	11	)	)	PUNCT
dpc-4315	71	12	of	of	ADP
dpc-4315	71	13	0	0	NUM
dpc-4315	71	14	or	or	CCONJ
dpc-4315	71	15	1	1	NUM
dpc-4315	71	16	and	and	CCONJ
dpc-4315	71	17	a	a	DET
dpc-4315	71	18	75	75	NUM
dpc-4315	71	19	%	%	NOUN
dpc-4315	71	20	improvement	improvement	NOUN
dpc-4315	71	21	in	in	ADP
dpc-4315	71	22	the	the	DET
dpc-4315	71	23	eczema	eczema	NOUN
dpc-4315	71	24	area	area	NOUN
dpc-4315	71	25	and	and	CCONJ
dpc-4315	71	26	severity	severity	NOUN
dpc-4315	71	27	index	index	NOUN
dpc-4315	71	28	(	(	PUNCT
dpc-4315	71	29	easi	easi	NOUN
dpc-4315	71	30	75	75	NUM
dpc-4315	71	31	)	)	PUNCT
dpc-4315	71	32	at	at	ADP
dpc-4315	71	33	16	16	NUM
dpc-4315	71	34	weeks	week	NOUN
dpc-4315	72	1	[	[	X
dpc-4315	72	2	28	28	NUM
dpc-4315	72	3	]	]	PUNCT
dpc-4315	72	4	.	.	PUNCT
dpc-4315	73	1	on	on	ADP
dpc-4315	73	2	the	the	DET
dpc-4315	73	3	other	other	ADJ
dpc-4315	73	4	hand	hand	NOUN
dpc-4315	73	5	,	,	PUNCT
dpc-4315	73	6	the	the	DET
dpc-4315	73	7	ecztra	ecztra	ADJ
dpc-4315	73	8	3	3	NUM
dpc-4315	73	9	trial	trial	NOUN
dpc-4315	73	10	enrolled	enrol	VERB
dpc-4315	73	11	369	369	NUM
dpc-4315	73	12	adult	adult	NOUN
dpc-4315	73	13	patients	patient	NOUN
dpc-4315	73	14	randomized	randomize	VERB
dpc-4315	73	15	to	to	AUX
dpc-4315	73	16	tralokinumab	tralokinumab	VERB
dpc-4315	73	17	sc	sc	PROPN
dpc-4315	73	18	300	300	NUM
dpc-4315	73	19	mg	mg	NOUN
dpc-4315	73	20	q2w	q2w	NOUN
dpc-4315	73	21	or	or	CCONJ
dpc-4315	73	22	placebo	placebo	NOUN
dpc-4315	73	23	,	,	PUNCT
dpc-4315	73	24	with	with	ADP
dpc-4315	73	25	the	the	DET
dpc-4315	73	26	main	main	ADJ
dpc-4315	73	27	difference	difference	NOUN
dpc-4315	73	28	from	from	ADP
dpc-4315	73	29	ecztra	ecztra	NOUN
dpc-4315	73	30	1	1	NUM
dpc-4315	73	31	and	and	CCONJ
dpc-4315	73	32	2	2	NUM
dpc-4315	73	33	being	be	AUX
dpc-4315	73	34	that	that	PRON
dpc-4315	73	35	topical	topical	ADJ
dpc-4315	73	36	corticosteroids	corticosteroid	NOUN
dpc-4315	73	37	were	be	AUX
dpc-4315	73	38	allowed	allow	VERB
dpc-4315	73	39	as	as	SCONJ
dpc-4315	73	40	needed	need	VERB
dpc-4315	73	41	.	.	PUNCT
dpc-4315	74	1	these	these	DET
dpc-4315	74	2	results	result	NOUN
dpc-4315	74	3	are	be	AUX
dpc-4315	74	4	more	more	ADV
dpc-4315	74	5	applicable	applicable	ADJ
dpc-4315	74	6	to	to	ADP
dpc-4315	74	7	real	real	ADJ
dpc-4315	74	8	-	-	PUNCT
dpc-4315	74	9	world	world	NOUN
dpc-4315	74	10	use	use	NOUN
dpc-4315	74	11	,	,	PUNCT
dpc-4315	74	12	as	as	SCONJ
dpc-4315	74	13	systemic	systemic	ADJ
dpc-4315	74	14	therapies	therapy	NOUN
dpc-4315	74	15	are	be	AUX
dpc-4315	74	16	used	use	VERB
dpc-4315	74	17	concomitantly	concomitantly	ADV
dpc-4315	74	18	with	with	ADP
dpc-4315	74	19	topical	topical	ADJ
dpc-4315	74	20	medications	medication	NOUN
dpc-4315	74	21	.	.	PUNCT
dpc-4315	75	1	the	the	DET
dpc-4315	75	2	primary	primary	ADJ
dpc-4315	75	3	endpoints	endpoint	NOUN
dpc-4315	75	4	were	be	AUX
dpc-4315	75	5	the	the	DET
dpc-4315	75	6	same	same	ADJ
dpc-4315	75	7	as	as	ADP
dpc-4315	75	8	ecztra	ecztra	NOUN
dpc-4315	75	9	1	1	NUM
dpc-4315	75	10	and	and	CCONJ
dpc-4315	75	11	2	2	NUM
dpc-4315	75	12	.	.	X
dpc-4315	76	1	both	both	DET
dpc-4315	76	2	studies	study	NOUN
dpc-4315	76	3	also	also	ADV
dpc-4315	76	4	assessed	assess	VERB
dpc-4315	76	5	the	the	DET
dpc-4315	76	6	harmonising	harmonise	VERB
dpc-4315	76	7	outcomes	outcome	NOUN
dpc-4315	76	8	measures	measure	NOUN
dpc-4315	76	9	for	for	ADP
dpc-4315	76	10	eczema	eczema	NOUN
dpc-4315	76	11	core	core	NOUN
dpc-4315	76	12	outcomes	outcome	NOUN
dpc-4315	76	13	:	:	PUNCT
dpc-4315	76	14	reduction	reduction	NOUN
dpc-4315	76	15	of	of	ADP
dpc-4315	76	16	easi	easi	NOUN
dpc-4315	76	17	,	,	PUNCT
dpc-4315	76	18	patient	patient	NOUN
dpc-4315	76	19	-	-	PUNCT
dpc-4315	76	20	oriented	orient	VERB
dpc-4315	76	21	eczema	eczema	NOUN
dpc-4315	76	22	measure	measure	NOUN
dpc-4315	76	23	,	,	PUNCT
dpc-4315	76	24	a	a	DET
dpc-4315	76	25	peak	peak	NOUN
dpc-4315	76	26	pruritus	pruritus	PROPN
dpc-4315	76	27	numerical	numerical	ADJ
dpc-4315	76	28	rating	rating	NOUN
dpc-4315	76	29	scale	scale	NOUN
dpc-4315	76	30	,	,	PUNCT
dpc-4315	76	31	and	and	CCONJ
dpc-4315	76	32	the	the	DET
dpc-4315	76	33	dermatology	dermatology	NOUN
dpc-4315	76	34	life	life	NOUN
dpc-4315	76	35	quality	quality	NOUN
dpc-4315	76	36	index	index	NOUN
dpc-4315	76	37	[	[	X
dpc-4315	76	38	28,31	28,31	NUM
dpc-4315	76	39	-	-	SYM
dpc-4315	76	40	33	33	NUM
dpc-4315	76	41	]	]	PUNCT
dpc-4315	76	42	.	.	PUNCT
dpc-4315	77	1	in	in	ADP
dpc-4315	77	2	ecztra	ecztra	PROPN
dpc-4315	77	3	1	1	NUM
dpc-4315	77	4	and	and	CCONJ
dpc-4315	77	5	2	2	NUM
dpc-4315	77	6	,	,	PUNCT
dpc-4315	77	7	a	a	DET
dpc-4315	77	8	significantly	significantly	ADV
dpc-4315	77	9	higher	high	ADJ
dpc-4315	77	10	proportion	proportion	NOUN
dpc-4315	77	11	of	of	ADP
dpc-4315	77	12	patients	patient	NOUN
dpc-4315	77	13	receiving	receive	VERB
dpc-4315	77	14	tralokinumab	tralokinumab	NOUN
dpc-4315	77	15	.	.	PUNCT
dpc-4315	78	1	in	in	ADP
dpc-4315	78	2	both	both	DET
dpc-4315	78	3	studies	study	NOUN
dpc-4315	78	4	,	,	PUNCT
dpc-4315	78	5	tralokinumab	tralokinumab	NOUN
dpc-4315	78	6	led	lead	VERB
dpc-4315	78	7	to	to	ADP
dpc-4315	78	8	improvement	improvement	NOUN
dpc-4315	78	9	of	of	ADP
dpc-4315	78	10	iga	iga	PROPN
dpc-4315	78	11	in	in	ADP
dpc-4315	78	12	approximately	approximately	ADV
dpc-4315	78	13	twice	twice	ADV
dpc-4315	78	14	as	as	ADV
dpc-4315	78	15	many	many	ADJ
dpc-4315	78	16	patients	patient	NOUN
dpc-4315	78	17	as	as	ADP
dpc-4315	78	18	placebo	placebo	NOUN
dpc-4315	78	19	(	(	PUNCT
dpc-4315	78	20	ecztra	ecztra	NOUN
dpc-4315	78	21	1	1	NUM
dpc-4315	78	22	:	:	SYM
dpc-4315	78	23	15.8	15.8	NUM
dpc-4315	78	24	%	%	NOUN
dpc-4315	78	25	versus	versus	ADP
dpc-4315	78	26	7.1	7.1	NUM
dpc-4315	78	27	%	%	NOUN
dpc-4315	78	28	;	;	PUNCT
dpc-4315	78	29	ecztra	ecztra	NOUN
dpc-4315	78	30	2	2	NUM
dpc-4315	78	31	:	:	PUNCT
dpc-4315	78	32	22.2	22.2	NUM
dpc-4315	78	33	%	%	NOUN
dpc-4315	78	34	versus	versus	ADP
dpc-4315	78	35	10.9	10.9	NUM
dpc-4315	78	36	%	%	NOUN
dpc-4315	78	37	)	)	PUNCT
dpc-4315	78	38	.	.	PUNCT
dpc-4315	79	1	easi	easi	NOUN
dpc-4315	79	2	75	75	NUM
dpc-4315	79	3	was	be	AUX
dpc-4315	79	4	more	more	ADV
dpc-4315	79	5	commonly	commonly	ADV
dpc-4315	79	6	observed	observe	VERB
dpc-4315	79	7	with	with	ADP
dpc-4315	79	8	tralokinumab	tralokinumab	NOUN
dpc-4315	79	9	in	in	ADP
dpc-4315	79	10	ecztra	ecztra	NOUN
dpc-4315	79	11	1	1	NUM
dpc-4315	79	12	(	(	PUNCT
dpc-4315	79	13	25.0	25.0	NUM
dpc-4315	79	14	%	%	NOUN
dpc-4315	79	15	versus	versus	ADP
dpc-4315	79	16	12.7	12.7	NUM
dpc-4315	79	17	%	%	NOUN
dpc-4315	79	18	)	)	PUNCT
dpc-4315	79	19	and	and	CCONJ
dpc-4315	79	20	ecztra	ecztra	NOUN
dpc-4315	79	21	2	2	NUM
dpc-4315	79	22	(	(	PUNCT
dpc-4315	79	23	33.2	33.2	NUM
dpc-4315	79	24	%	%	NOUN
dpc-4315	79	25	versus	versus	ADP
dpc-4315	79	26	11.4	11.4	NUM
dpc-4315	79	27	%	%	NOUN
dpc-4315	79	28	)	)	PUNCT
dpc-4315	79	29	.	.	PUNCT
dpc-4315	80	1	in	in	ADP
dpc-4315	80	2	ecztra	ecztra	PROPN
dpc-4315	80	3	3	3	NUM
dpc-4315	80	4	,	,	PUNCT
dpc-4315	80	5	response	response	NOUN
dpc-4315	80	6	rates	rate	NOUN
dpc-4315	80	7	were	be	AUX
dpc-4315	80	8	higher	high	ADJ
dpc-4315	80	9	for	for	ADP
dpc-4315	80	10	both	both	DET
dpc-4315	80	11	tralokinumab	tralokinumab	NOUN
dpc-4315	80	12	and	and	CCONJ
dpc-4315	80	13	placebo	placebo	NOUN
dpc-4315	80	14	(	(	PUNCT
dpc-4315	80	15	iga	iga	PROPN
dpc-4315	80	16	:	:	PUNCT
dpc-4315	80	17	38.9	38.9	NUM
dpc-4315	80	18	%	%	NOUN
dpc-4315	80	19	versus	versus	ADP
dpc-4315	80	20	26.2	26.2	NUM
dpc-4315	80	21	%	%	NOUN
dpc-4315	80	22	;	;	PUNCT
dpc-4315	80	23	easi	easi	NOUN
dpc-4315	80	24	75	75	NUM
dpc-4315	80	25	:	:	PUNCT
dpc-4315	80	26	56.0	56.0	NUM
dpc-4315	80	27	%	%	NOUN
dpc-4315	80	28	versus	versus	ADP
dpc-4315	80	29	35.7	35.7	NUM
dpc-4315	80	30	%	%	NOUN
dpc-4315	80	31	)	)	PUNCT
dpc-4315	80	32	,	,	PUNCT
dpc-4315	80	33	probably	probably	ADV
dpc-4315	80	34	due	due	ADP
dpc-4315	80	35	to	to	ADP
dpc-4315	80	36	the	the	DET
dpc-4315	80	37	use	use	NOUN
dpc-4315	80	38	of	of	ADP
dpc-4315	80	39	topical	topical	ADJ
dpc-4315	80	40	corticosteroids	corticosteroid	NOUN
dpc-4315	80	41	[	[	X
dpc-4315	80	42	28,33	28,33	NUM
dpc-4315	80	43	]	]	PUNCT
dpc-4315	80	44	.	.	PUNCT
dpc-4315	81	1	in	in	ADP
dpc-4315	81	2	the	the	DET
dpc-4315	81	3	initial	initial	ADJ
dpc-4315	81	4	16	16	NUM
dpc-4315	81	5	-	-	PUNCT
dpc-4315	81	6	week	week	NOUN
dpc-4315	81	7	treatment	treatment	NOUN
dpc-4315	81	8	period	period	NOUN
dpc-4315	81	9	,	,	PUNCT
dpc-4315	81	10	the	the	DET
dpc-4315	81	11	frequency	frequency	NOUN
dpc-4315	81	12	of	of	ADP
dpc-4315	81	13	adverse	adverse	ADJ
dpc-4315	81	14	events	event	NOUN
dpc-4315	81	15	was	be	AUX
dpc-4315	81	16	similar	similar	ADJ
dpc-4315	81	17	between	between	ADP
dpc-4315	81	18	tralokinumab	tralokinumab	NOUN
dpc-4315	81	19	and	and	CCONJ
dpc-4315	81	20	placebo	placebo	NOUN
dpc-4315	81	21	for	for	ADP
dpc-4315	81	22	all	all	DET
dpc-4315	81	23	3	3	NUM
dpc-4315	81	24	studies	study	NOUN
dpc-4315	81	25	.	.	PUNCT
dpc-4315	82	1	conjunctivitis	conjunctivitis	NOUN
dpc-4315	82	2	was	be	AUX
dpc-4315	82	3	an	an	DET
dpc-4315	82	4	adverse	adverse	ADJ
dpc-4315	82	5	event	event	NOUN
dpc-4315	82	6	of	of	ADP
dpc-4315	82	7	special	special	ADJ
dpc-4315	82	8	interest	interest	NOUN
dpc-4315	82	9	because	because	SCONJ
dpc-4315	82	10	it	it	PRON
dpc-4315	82	11	frequently	frequently	ADV
dpc-4315	82	12	occurs	occur	VERB
dpc-4315	82	13	with	with	ADP
dpc-4315	82	14	the	the	DET
dpc-4315	82	15	use	use	NOUN
dpc-4315	82	16	of	of	ADP
dpc-4315	82	17	dupilumab	dupilumab	NOUN
dpc-4315	82	18	,	,	PUNCT
dpc-4315	82	19	which	which	PRON
dpc-4315	82	20	also	also	ADV
dpc-4315	82	21	targets	target	VERB
dpc-4315	82	22	the	the	DET
dpc-4315	82	23	il-4	il-4	NOUN
dpc-4315	82	24	/	/	SYM
dpc-4315	82	25	il-13	il-13	NOUN
dpc-4315	82	26	pathway	pathway	NOUN
dpc-4315	82	27	.	.	PUNCT
dpc-4315	83	1	conjunctivitis	conjunctivitis	NOUN
dpc-4315	83	2	occurred	occur	VERB
dpc-4315	83	3	more	more	ADV
dpc-4315	83	4	frequently	frequently	ADV
dpc-4315	83	5	in	in	ADP
dpc-4315	83	6	patients	patient	NOUN
dpc-4315	83	7	receiving	receive	VERB
dpc-4315	83	8	tralokinumab	tralokinumab	NOUN
dpc-4315	83	9	in	in	ADP
dpc-4315	83	10	all	all	DET
dpc-4315	83	11	studies	study	NOUN
dpc-4315	83	12	,	,	PUNCT
dpc-4315	83	13	although	although	SCONJ
dpc-4315	83	14	most	most	ADJ
dpc-4315	83	15	cases	case	NOUN
dpc-4315	83	16	were	be	AUX
dpc-4315	83	17	mild	mild	ADJ
dpc-4315	83	18	or	or	CCONJ
dpc-4315	83	19	moderate	moderate	ADJ
dpc-4315	84	1	[	[	X
dpc-4315	84	2	28,33	28,33	NUM
dpc-4315	84	3	]	]	PUNCT
dpc-4315	84	4	.	.	PUNCT
dpc-4315	85	1	long	long	ADJ
dpc-4315	85	2	-	-	PUNCT
dpc-4315	85	3	term	term	NOUN
dpc-4315	85	4	efficacy	efficacy	NOUN
dpc-4315	85	5	was	be	AUX
dpc-4315	85	6	variable	variable	ADJ
dpc-4315	85	7	in	in	ADP
dpc-4315	85	8	ecztra	ecztra	PROPN
dpc-4315	85	9	1	1	NUM
dpc-4315	85	10	and	and	CCONJ
dpc-4315	85	11	2	2	NUM
dpc-4315	85	12	,	,	PUNCT
dpc-4315	85	13	with	with	ADP
dpc-4315	85	14	approximately	approximately	ADV
dpc-4315	85	15	half	half	NOUN
dpc-4315	85	16	of	of	ADP
dpc-4315	85	17	the	the	DET
dpc-4315	85	18	patients	patient	NOUN
dpc-4315	85	19	experiencing	experience	VERB
dpc-4315	85	20	response	response	NOUN
dpc-4315	85	21	maintenance	maintenance	NOUN
dpc-4315	85	22	at	at	ADP
dpc-4315	85	23	52	52	NUM
dpc-4315	85	24	weeks	week	NOUN
dpc-4315	85	25	.	.	PUNCT
dpc-4315	86	1	comparably	comparably	ADV
dpc-4315	86	2	,	,	PUNCT
dpc-4315	86	3	maintenance	maintenance	NOUN
dpc-4315	86	4	was	be	AUX
dpc-4315	86	5	much	much	ADV
dpc-4315	86	6	higher	high	ADJ
dpc-4315	86	7	in	in	ADP
dpc-4315	86	8	ecztra	ecztra	ADJ
dpc-4315	86	9	3	3	NUM
dpc-4315	86	10	[	[	X
dpc-4315	86	11	28	28	NUM
dpc-4315	86	12	-	-	SYM
dpc-4315	86	13	30	30	NUM
dpc-4315	86	14	]	]	PUNCT
dpc-4315	86	15	.	.	PUNCT
dpc-4315	87	1	independently	independently	ADV
dpc-4315	87	2	of	of	ADP
dpc-4315	87	3	week	week	NOUN
dpc-4315	87	4	16	16	NUM
dpc-4315	87	5	endpoint	endpoint	NOUN
dpc-4315	87	6	,	,	PUNCT
dpc-4315	87	7	ecztra	ecztra	NOUN
dpc-4315	87	8	3	3	NUM
dpc-4315	87	9	post	post	X
dpc-4315	87	10	hoc	hoc	X
dpc-4315	87	11	analysis	analysis	NOUN
dpc-4315	87	12	showed	show	VERB
dpc-4315	87	13	how	how	SCONJ
dpc-4315	87	14	topical	topical	ADJ
dpc-4315	87	15	corticosteroids	corticosteroid	NOUN
dpc-4315	87	16	(	(	PUNCT
dpc-4315	87	17	tcs	tcs	NOUN
dpc-4315	87	18	)	)	PUNCT
dpc-4315	87	19	in	in	ADP
dpc-4315	87	20	combination	combination	NOUN
dpc-4315	87	21	with	with	ADP
dpc-4315	87	22	tralokinumab	tralokinumab	NOUN
dpc-4315	87	23	provided	provide	VERB
dpc-4315	87	24	a	a	DET
dpc-4315	87	25	good	good	ADJ
dpc-4315	87	26	response	response	NOUN
dpc-4315	87	27	over	over	ADP
dpc-4315	87	28	32	32	NUM
dpc-4315	87	29	weeks	week	NOUN
dpc-4315	87	30	in	in	ADP
dpc-4315	87	31	the	the	DET
dpc-4315	87	32	management	management	NOUN
dpc-4315	87	33	of	of	ADP
dpc-4315	87	34	ad	ad	NOUN
dpc-4315	87	35	,	,	PUNCT
dpc-4315	87	36	as	as	SCONJ
dpc-4315	87	37	evidenced	evidence	VERB
dpc-4315	87	38	by	by	ADP
dpc-4315	87	39	easi	easi	NOUN
dpc-4315	87	40	75	75	NUM
dpc-4315	87	41	at	at	ADP
dpc-4315	87	42	week	week	NOUN
dpc-4315	87	43	16	16	NUM
dpc-4315	87	44	and	and	CCONJ
dpc-4315	87	45	week	week	NOUN
dpc-4315	87	46	32	32	NUM
dpc-4315	87	47	(	(	PUNCT
dpc-4315	87	48	56	56	NUM
dpc-4315	87	49	%	%	NOUN
dpc-4315	87	50	versus	versus	ADP
dpc-4315	87	51	70	70	NUM
dpc-4315	87	52	%	%	NOUN
dpc-4315	87	53	)	)	PUNCT
dpc-4315	87	54	,	,	PUNCT
dpc-4315	87	55	respectively	respectively	ADV
dpc-4315	87	56	.	.	PUNCT
dpc-4315	88	1	presumably	presumably	ADV
dpc-4315	88	2	,	,	PUNCT
dpc-4315	88	3	there	there	PRON
dpc-4315	88	4	are	be	VERB
dpc-4315	88	5	some	some	DET
dpc-4315	88	6	patients	patient	NOUN
dpc-4315	88	7	who	who	PRON
dpc-4315	88	8	need	need	VERB
dpc-4315	88	9	more	more	ADJ
dpc-4315	88	10	time	time	NOUN
dpc-4315	88	11	to	to	PART
dpc-4315	88	12	fully	fully	ADV
dpc-4315	88	13	benefit	benefit	VERB
dpc-4315	88	14	from	from	ADP
dpc-4315	88	15	il-13	il-13	ADP
dpc-4315	88	16	treatment	treatment	NOUN
dpc-4315	88	17	.	.	PUNCT
dpc-4315	89	1	furthermore	furthermore	ADV
dpc-4315	89	2	,	,	PUNCT
dpc-4315	89	3	this	this	DET
dpc-4315	89	4	trial	trial	NOUN
dpc-4315	89	5	identified	identify	VERB
dpc-4315	89	6	a	a	DET
dpc-4315	89	7	group	group	NOUN
dpc-4315	89	8	of	of	ADP
dpc-4315	89	9	“	"	PUNCT
dpc-4315	89	10	super	super	NOUN
dpc-4315	89	11	-	-	NOUN
dpc-4315	89	12	responders	responder	NOUN
dpc-4315	89	13	”	"	PUNCT
dpc-4315	89	14	,	,	PUNCT
dpc-4315	89	15	who	who	PRON
dpc-4315	89	16	reached	reach	VERB
dpc-4315	89	17	easi	easi	NOUN
dpc-4315	89	18	75	75	NUM
dpc-4315	89	19	or	or	CCONJ
dpc-4315	89	20	easi	easi	NOUN
dpc-4315	89	21	90	90	NUM
dpc-4315	89	22	after	after	ADP
dpc-4315	89	23	only	only	ADV
dpc-4315	89	24	4	4	NUM
dpc-4315	89	25	weeks	week	NOUN
dpc-4315	89	26	of	of	ADP
dpc-4315	89	27	treatment	treatment	NOUN
dpc-4315	89	28	[	[	X
dpc-4315	89	29	31,32,34,35	31,32,34,35	NUM
dpc-4315	89	30	]	]	PUNCT
dpc-4315	89	31	.	.	PUNCT
dpc-4315	90	1	ecztra	ecztra	PROPN
dpc-4315	90	2	7	7	NUM
dpc-4315	90	3	,	,	PUNCT
dpc-4315	90	4	a	a	PRON
dpc-4315	90	5	randomized	randomized	ADJ
dpc-4315	90	6	,	,	PUNCT
dpc-4315	90	7	placebo	placebo	NOUN
dpc-4315	90	8	controlled	control	VERB
dpc-4315	90	9	,	,	PUNCT
dpc-4315	90	10	phase	phase	NOUN
dpc-4315	90	11	iii	iii	NUM
dpc-4315	90	12	clinical	clinical	ADJ
dpc-4315	90	13	trial	trial	NOUN
dpc-4315	90	14	demonstrated	demonstrate	VERB
dpc-4315	90	15	the	the	DET
dpc-4315	90	16	efficacy	efficacy	NOUN
dpc-4315	90	17	and	and	CCONJ
dpc-4315	90	18	safety	safety	NOUN
dpc-4315	90	19	of	of	ADP
dpc-4315	90	20	tralokinumab	tralokinumab	NOUN
dpc-4315	90	21	plus	plus	CCONJ
dpc-4315	90	22	tcs	tcs	NOUN
dpc-4315	90	23	after	after	ADP
dpc-4315	90	24	16	16	NUM
dpc-4315	90	25	weeks	week	NOUN
dpc-4315	90	26	in	in	ADP
dpc-4315	90	27	patients	patient	NOUN
dpc-4315	90	28	not	not	PART
dpc-4315	90	29	sufficiently	sufficiently	ADV
dpc-4315	90	30	controlled	control	VERB
dpc-4315	90	31	with	with	ADP
dpc-4315	90	32	oral	oral	ADJ
dpc-4315	90	33	cyclosporine	cyclosporine	NOUN
dpc-4315	90	34	or	or	CCONJ
dpc-4315	90	35	with	with	ADP
dpc-4315	90	36	contraindications	contraindication	NOUN
dpc-4315	90	37	to	to	ADP
dpc-4315	90	38	systemic	systemic	ADJ
dpc-4315	90	39	administration	administration	NOUN
dpc-4315	90	40	[	[	X
dpc-4315	90	41	36	36	NUM
dpc-4315	90	42	]	]	PUNCT
dpc-4315	90	43	.	.	PUNCT
dpc-4315	91	1	a	a	DET
dpc-4315	91	2	16	16	NUM
dpc-4315	91	3	-	-	PUNCT
dpc-4315	91	4	week	week	NOUN
dpc-4315	91	5	real	real	ADJ
dpc-4315	91	6	-	-	PUNCT
dpc-4315	91	7	life	life	NOUN
dpc-4315	91	8	experience	experience	NOUN
dpc-4315	91	9	confirmed	confirm	VERB
dpc-4315	91	10	the	the	DET
dpc-4315	91	11	rapid	rapid	ADJ
dpc-4315	91	12	improvement	improvement	NOUN
dpc-4315	91	13	in	in	ADP
dpc-4315	91	14	symptoms	symptom	NOUN
dpc-4315	91	15	and	and	CCONJ
dpc-4315	91	16	quality	quality	NOUN
dpc-4315	91	17	of	of	ADP
dpc-4315	91	18	life	life	NOUN
dpc-4315	91	19	[	[	X
dpc-4315	91	20	1	1	NUM
dpc-4315	91	21	]	]	PUNCT
dpc-4315	91	22	.	.	PUNCT
dpc-4315	92	1	andreas	andreas	PROPN
dpc-4315	92	2	wollenberg	wollenberg	PROPN
dpc-4315	92	3	md	md	PROPN
dpc-4315	92	4	et	et	PROPN
dpc-4315	92	5	al	al	PROPN
dpc-4315	92	6	.	.	PROPN
dpc-4315	92	7	sought	seek	VERB
dpc-4315	92	8	to	to	PART
dpc-4315	92	9	evaluate	evaluate	VERB
dpc-4315	92	10	the	the	DET
dpc-4315	92	11	efficacy	efficacy	NOUN
dpc-4315	92	12	and	and	CCONJ
dpc-4315	92	13	safety	safety	NOUN
dpc-4315	92	14	of	of	ADP
dpc-4315	92	15	tralokinumab	tralokinumab	NOUN
dpc-4315	92	16	in	in	ADP
dpc-4315	92	17	adults	adult	NOUN
dpc-4315	92	18	with	with	ADP
dpc-4315	92	19	moderate	moderate	ADJ
dpc-4315	92	20	-	-	PUNCT
dpc-4315	92	21	to	to	ADP
dpc-4315	92	22	-	-	PUNCT
dpc-4315	92	23	severe	severe	ADJ
dpc-4315	92	24	ad	ad	NOUN
dpc-4315	92	25	.	.	PUNCT
dpc-4315	92	26	  	  	SPACE
dpc-4315	93	1	this	this	DET
dpc-4315	93	2	phase	phase	NOUN
dpc-4315	93	3	2b	2b	NUM
dpc-4315	93	4	study	study	NOUN
dpc-4315	93	5	(	(	PUNCT
dpc-4315	93	6	nct02347176	nct02347176	NOUN
dpc-4315	93	7	)	)	PUNCT
dpc-4315	93	8	analyzed	analyze	VERB
dpc-4315	93	9	204	204	NUM
dpc-4315	93	10	adults	adult	NOUN
dpc-4315	93	11	who	who	PRON
dpc-4315	93	12	were	be	AUX
dpc-4315	93	13	randomized	randomize	VERB
dpc-4315	93	14	1:1:1:1	1:1:1:1	NUM
dpc-4315	93	15	to	to	PART
dpc-4315	93	16	receive	receive	VERB
dpc-4315	93	17	placebo	placebo	NOUN
dpc-4315	93	18	or	or	CCONJ
dpc-4315	93	19	45	45	NUM
dpc-4315	93	20	,	,	PUNCT
dpc-4315	93	21	150	150	NUM
dpc-4315	93	22	or	or	CCONJ
dpc-4315	93	23	300	300	NUM
dpc-4315	93	24	mg	mg	NOUN
dpc-4315	93	25	of	of	ADP
dpc-4315	93	26	subcutaneous	subcutaneous	ADJ
dpc-4315	93	27	tralokinumab	tralokinumab	NOUN
dpc-4315	93	28	with	with	ADP
dpc-4315	93	29	concomitant	concomitant	ADJ
dpc-4315	93	30	topical	topical	ADJ
dpc-4315	93	31	glucocorticoids	glucocorticoid	NOUN
dpc-4315	93	32	for	for	ADP
dpc-4315	93	33	a	a	DET
dpc-4315	93	34	total	total	NOUN
dpc-4315	93	35	of	of	ADP
dpc-4315	93	36	12	12	NUM
dpc-4315	93	37	weeks	week	NOUN
dpc-4315	93	38	in	in	ADP
dpc-4315	93	39	alternating	alternate	VERB
dpc-4315	93	40	weeks	week	NOUN
dpc-4315	94	1	[	[	X
dpc-4315	94	2	36	36	NUM
dpc-4315	94	3	]	]	PUNCT
dpc-4315	94	4	.	.	PUNCT
dpc-4315	95	1	at	at	ADP
dpc-4315	95	2	week	week	NOUN
dpc-4315	95	3	12	12	NUM
dpc-4315	95	4	,	,	PUNCT
dpc-4315	95	5	co	co	ADJ
dpc-4315	95	6	-	-	ADJ
dpc-4315	95	7	primary	primary	ADJ
dpc-4315	95	8	endpoints	endpoint	NOUN
dpc-4315	95	9	evaluated	evaluate	VERB
dpc-4315	95	10	the	the	DET
dpc-4315	95	11	percentage	percentage	NOUN
dpc-4315	95	12	of	of	ADP
dpc-4315	95	13	participants	participant	NOUN
dpc-4315	95	14	with	with	ADP
dpc-4315	95	15	an	an	DET
dpc-4315	95	16	investigator	investigator	NOUN
dpc-4315	95	17	global	global	ADJ
dpc-4315	95	18	assessment	assessment	NOUN
dpc-4315	95	19	response	response	NOUN
dpc-4315	95	20	and	and	CCONJ
dpc-4315	95	21	,	,	PUNCT
dpc-4315	95	22	above	above	ADP
dpc-4315	95	23	all	all	PRON
dpc-4315	95	24	,	,	PUNCT
dpc-4315	95	25	the	the	DET
dpc-4315	95	26	change	change	NOUN
dpc-4315	95	27	from	from	ADP
dpc-4315	95	28	baseline	baseline	NOUN
dpc-4315	95	29	in	in	ADP
dpc-4315	95	30	the	the	DET
dpc-4315	95	31	eczema	eczema	NOUN
dpc-4315	95	32	area	area	PROPN
dpc-4315	95	33	severity	severity	PROPN
dpc-4315	95	34	index	index	NOUN
dpc-4315	95	35	score	score	NOUN
dpc-4315	95	36	.	.	PUNCT
dpc-4315	96	1	a	a	DET
dpc-4315	96	2	significant	significant	ADJ
dpc-4315	96	3	change	change	NOUN
dpc-4315	96	4	from	from	ADP
dpc-4315	96	5	baseline	baseline	NOUN
dpc-4315	96	6	in	in	ADP
dpc-4315	96	7	the	the	DET
dpc-4315	96	8	eczema	eczema	NOUN
dpc-4315	96	9	area	area	NOUN
dpc-4315	96	10	severity	severity	PROPN
dpc-4315	96	11	index	index	NOUN
dpc-4315	96	12	score	score	NOUN
dpc-4315	96	13	was	be	AUX
dpc-4315	96	14	observed	observe	VERB
dpc-4315	96	15	with	with	ADP
dpc-4315	96	16	300	300	NUM
dpc-4315	96	17	mg	mg	NOUN
dpc-4315	96	18	of	of	ADP
dpc-4315	96	19	tralokinumab	tralokinumab	NOUN
dpc-4315	96	20	versus	versus	ADP
dpc-4315	96	21	placebo	placebo	NOUN
dpc-4315	96	22	.	.	PUNCT
dpc-4315	97	1	a	a	DET
dpc-4315	97	2	more	more	ADV
dpc-4315	97	3	considerable	considerable	ADJ
dpc-4315	97	4	percentage	percentage	NOUN
dpc-4315	97	5	of	of	ADP
dpc-4315	97	6	participants	participant	NOUN
dpc-4315	97	7	also	also	ADV
dpc-4315	97	8	achieved	achieve	VERB
dpc-4315	97	9	an	an	DET
dpc-4315	97	10	investigator	investigator	NOUN
dpc-4315	97	11	global	global	ADJ
dpc-4315	97	12	assessment	assessment	NOUN
dpc-4315	97	13	response	response	NOUN
dpc-4315	97	14	(	(	PUNCT
dpc-4315	97	15	26.7	26.7	NUM
dpc-4315	97	16	%	%	NOUN
dpc-4315	97	17	versus	versus	ADP
dpc-4315	97	18	11.8	11.8	NUM
dpc-4315	97	19	%	%	NOUN
dpc-4315	97	20	)	)	PUNCT
dpc-4315	97	21	.	.	PUNCT
dpc-4315	98	1	high	high	ADJ
dpc-4315	98	2	levels	level	NOUN
dpc-4315	98	3	of	of	ADP
dpc-4315	98	4	biomarkers	biomarker	NOUN
dpc-4315	98	5	of	of	ADP
dpc-4315	98	6	increased	increase	VERB
dpc-4315	98	7	il-13	il-13	ADP
dpc-4315	98	8	activity	activity	NOUN
dpc-4315	98	9	were	be	AUX
dpc-4315	98	10	observed	observe	VERB
dpc-4315	98	11	in	in	ADP
dpc-4315	98	12	participants	participant	NOUN
dpc-4315	98	13	with	with	ADP
dpc-4315	98	14	the	the	DET
dpc-4315	98	15	best	good	ADJ
dpc-4315	98	16	responses	response	NOUN
dpc-4315	98	17	.	.	PUNCT
dpc-4315	99	1	in	in	ADP
dpc-4315	99	2	addition	addition	NOUN
dpc-4315	99	3	,	,	PUNCT
dpc-4315	99	4	improvements	improvement	NOUN
dpc-4315	99	5	in	in	ADP
dpc-4315	99	6	table	table	NOUN
dpc-4315	99	7	1	1	NUM
dpc-4315	99	8	.	.	PUNCT
dpc-4315	99	9	relevant	relevant	ADJ
dpc-4315	99	10	clinical	clinical	ADJ
dpc-4315	99	11	studies	study	NOUN
dpc-4315	99	12	on	on	ADP
dpc-4315	99	13	the	the	DET
dpc-4315	99	14	role	role	NOUN
dpc-4315	99	15	of	of	ADP
dpc-4315	99	16	interleukin-13	interleukin-13	PROPN
dpc-4315	99	17	elevated	elevated	ADJ
dpc-4315	99	18	levels	level	NOUN
dpc-4315	99	19	of	of	ADP
dpc-4315	99	20	th2	th2	PROPN
dpc-4315	99	21	cytokines	cytokine	NOUN
dpc-4315	99	22	contribute	contribute	VERB
dpc-4315	99	23	significantly	significantly	ADV
dpc-4315	99	24	to	to	ADP
dpc-4315	99	25	the	the	DET
dpc-4315	99	26	etiopathogenesis	etiopathogenesis	NOUN
dpc-4315	99	27	of	of	ADP
dpc-4315	99	28	atopic	atopic	NOUN
dpc-4315	99	29	dermatitis	dermatitis	NOUN
dpc-4315	99	30	in	in	ADP
dpc-4315	99	31	terms	term	NOUN
dpc-4315	99	32	of	of	ADP
dpc-4315	99	33	skin	skin	NOUN
dpc-4315	99	34	barrier	barrier	NOUN
dpc-4315	99	35	disruption	disruption	NOUN
dpc-4315	99	36	.	.	PUNCT
dpc-4315	100	1	il-4	il-4	X
dpc-4315	101	1	and	and	CCONJ
dpc-4315	101	2	il-13	il-13	CCONJ
dpc-4315	101	3	represent	represent	VERB
dpc-4315	101	4	crucial	crucial	ADJ
dpc-4315	101	5	factors	factor	NOUN
dpc-4315	101	6	in	in	ADP
dpc-4315	101	7	the	the	DET
dpc-4315	101	8	atopic	atopic	NOUN
dpc-4315	101	9	patient	patient	ADJ
dpc-4315	101	10	immune	immune	ADJ
dpc-4315	101	11	response	response	NOUN
dpc-4315	102	1	[	[	X
dpc-4315	102	2	12	12	NUM
dpc-4315	102	3	]	]	PUNCT
dpc-4315	102	4	.	.	PUNCT
dpc-4315	103	1	cd8	cd8	PROPN
dpc-4315	103	2	+	+	PROPN
dpc-4315	103	3	t	t	PROPN
dpc-4315	103	4	lymphocytes	lymphocyte	NOUN
dpc-4315	103	5	produce	produce	VERB
dpc-4315	103	6	pro	pro	ADJ
dpc-4315	103	7	-	-	ADJ
dpc-4315	103	8	inflammatory	inflammatory	ADJ
dpc-4315	103	9	cytokines	cytokine	NOUN
dpc-4315	103	10	in	in	ADP
dpc-4315	103	11	the	the	DET
dpc-4315	103	12	patient	patient	NOUN
dpc-4315	103	13	with	with	ADP
dpc-4315	103	14	atopic	atopic	NOUN
dpc-4315	103	15	dermatitis	dermatitis	NOUN
dpc-4315	103	16	,	,	PUNCT
dpc-4315	103	17	such	such	ADJ
dpc-4315	103	18	as	as	ADP
dpc-4315	103	19	il-13	il-13	PRON
dpc-4315	103	20	,	,	PUNCT
dpc-4315	103	21	ifn	ifn	PROPN
dpc-4315	103	22	-	-	PUNCT
dpc-4315	103	23	γ	γ	NOUN
dpc-4315	103	24	,	,	PUNCT
dpc-4315	103	25	and	and	CCONJ
dpc-4315	103	26	il-22	il-22	NOUN
dpc-4315	103	27	.	.	PUNCT
dpc-4315	104	1	these	these	DET
dpc-4315	104	2	cytokines	cytokine	NOUN
dpc-4315	104	3	contribute	contribute	VERB
dpc-4315	104	4	to	to	ADP
dpc-4315	104	5	the	the	DET
dpc-4315	104	6	chronicity	chronicity	NOUN
dpc-4315	104	7	of	of	ADP
dpc-4315	104	8	the	the	DET
dpc-4315	104	9	disease	disease	NOUN
dpc-4315	104	10	[	[	X
dpc-4315	104	11	16	16	NUM
dpc-4315	104	12	]	]	PUNCT
dpc-4315	104	13	.	.	PUNCT
dpc-4315	104	14	il-4	il-4	PART
dpc-4315	105	1	and	and	CCONJ
dpc-4315	105	2	il-13	il-13	CCONJ
dpc-4315	105	3	reduce	reduce	VERB
dpc-4315	105	4	the	the	DET
dpc-4315	105	5	expression	expression	NOUN
dpc-4315	105	6	of	of	ADP
dpc-4315	105	7	loricrin	loricrin	NOUN
dpc-4315	105	8	,	,	PUNCT
dpc-4315	105	9	involucrin	involucrin	NOUN
dpc-4315	105	10	,	,	PUNCT
dpc-4315	105	11	keratin-1	keratin-1	PROPN
dpc-4315	105	12	,	,	PUNCT
dpc-4315	105	13	keratin-10	keratin-10	PROPN
dpc-4315	105	14	,	,	PUNCT
dpc-4315	105	15	hornerin	hornerin	NOUN
dpc-4315	105	16	,	,	PUNCT
dpc-4315	105	17	desmoglein	desmoglein	NOUN
dpc-4315	105	18	,	,	PUNCT
dpc-4315	105	19	and	and	CCONJ
dpc-4315	105	20	desmocollin-1	desmocollin-1	VERB
dpc-4315	105	21	in	in	ADP
dpc-4315	105	22	keratinocytes	keratinocyte	NOUN
dpc-4315	105	23	.	.	PUNCT
dpc-4315	106	1	they	they	PRON
dpc-4315	106	2	are	be	AUX
dpc-4315	106	3	also	also	ADV
dpc-4315	106	4	involved	involve	VERB
dpc-4315	106	5	in	in	ADP
dpc-4315	106	6	the	the	DET
dpc-4315	106	7	regulation	regulation	NOUN
dpc-4315	106	8	of	of	ADP
dpc-4315	106	9	lipid	lipid	ADJ
dpc-4315	106	10	composition	composition	NOUN
dpc-4315	106	11	,	,	PUNCT
dpc-4315	106	12	which	which	PRON
dpc-4315	106	13	is	be	AUX
dpc-4315	106	14	associated	associate	VERB
dpc-4315	106	15	with	with	ADP
dpc-4315	106	16	skin	skin	NOUN
dpc-4315	106	17	barrier	barrier	NOUN
dpc-4315	106	18	function	function	NOUN
dpc-4315	106	19	[	[	X
dpc-4315	106	20	22	22	NUM
dpc-4315	106	21	]	]	PUNCT
dpc-4315	106	22	.	.	PUNCT
dpc-4315	107	1	il-13	il-13	ADP
dpc-4315	107	2	,	,	PUNCT
dpc-4315	107	3	il-4	il-4	X
dpc-4315	107	4	,	,	PUNCT
dpc-4315	107	5	and	and	CCONJ
dpc-4315	107	6	il-31	il-31	PRON
dpc-4315	107	7	have	have	AUX
dpc-4315	107	8	been	be	AUX
dpc-4315	107	9	shown	show	VERB
dpc-4315	107	10	to	to	PART
dpc-4315	107	11	be	be	AUX
dpc-4315	107	12	pruritogenic	pruritogenic	ADJ
dpc-4315	107	13	,	,	PUNCT
dpc-4315	107	14	as	as	SCONJ
dpc-4315	107	15	they	they	PRON
dpc-4315	107	16	result	result	VERB
dpc-4315	107	17	in	in	ADP
dpc-4315	107	18	stimulation	stimulation	NOUN
dpc-4315	107	19	of	of	ADP
dpc-4315	107	20	sensory	sensory	ADJ
dpc-4315	107	21	neurons	neuron	NOUN
dpc-4315	107	22	with	with	ADP
dpc-4315	107	23	induction	induction	NOUN
dpc-4315	107	24	of	of	ADP
dpc-4315	107	25	peripheral	peripheral	ADJ
dpc-4315	107	26	itching	itching	NOUN
dpc-4315	108	1	[	[	X
dpc-4315	108	2	23	23	NUM
dpc-4315	108	3	]	]	PUNCT
dpc-4315	108	4	.	.	PUNCT
dpc-4315	109	1	il	il	PROPN
dpc-4315	109	2	=	=	NOUN
dpc-4315	109	3	interleukin	interleukin	NOUN
dpc-4315	109	4	.	.	PUNCT
dpc-4315	110	1	4	4	NUM
dpc-4315	110	2	review	review	NOUN
dpc-4315	110	3	|	|	ADV
dpc-4315	110	4	dermatol	dermatol	ADJ
dpc-4315	110	5	pract	pract	NOUN
dpc-4315	110	6	concept	concept	NOUN
dpc-4315	110	7	.	.	PUNCT
dpc-4315	111	1	2024;14(3):e2024204	2024;14(3):e2024204	NUM
dpc-4315	111	2	trials	trial	NOUN
dpc-4315	111	3	.	.	PUNCT
dpc-4315	112	1	adverse	adverse	ADJ
dpc-4315	112	2	events	event	NOUN
dpc-4315	112	3	were	be	AUX
dpc-4315	112	4	similar	similar	ADJ
dpc-4315	112	5	for	for	ADP
dpc-4315	112	6	anti	anti	ADJ
dpc-4315	112	7	-	-	ADJ
dpc-4315	112	8	il-13	il-13	PUNCT
dpc-4315	112	9	and	and	CCONJ
dpc-4315	112	10	placebo	placebo	NOUN
dpc-4315	112	11	up	up	ADV
dpc-4315	112	12	to	to	ADP
dpc-4315	112	13	52	52	NUM
dpc-4315	112	14	weeks	week	NOUN
dpc-4315	112	15	.	.	PUNCT
dpc-4315	113	1	in	in	ADP
dpc-4315	113	2	addition	addition	NOUN
dpc-4315	113	3	,	,	PUNCT
dpc-4315	113	4	ezctend	ezctend	VERB
dpc-4315	113	5	demonstrated	demonstrate	VERB
dpc-4315	113	6	efficacy	efficacy	NOUN
dpc-4315	113	7	of	of	ADP
dpc-4315	113	8	tralokinumab	tralokinumab	NOUN
dpc-4315	113	9	for	for	ADP
dpc-4315	113	10	more	more	ADJ
dpc-4315	113	11	than	than	ADP
dpc-4315	113	12	2	2	NUM
dpc-4315	113	13	years	year	NOUN
dpc-4315	113	14	of	of	ADP
dpc-4315	113	15	treatment	treatment	NOUN
dpc-4315	113	16	with	with	ADP
dpc-4315	113	17	a	a	DET
dpc-4315	113	18	significant	significant	ADJ
dpc-4315	113	19	reduction	reduction	NOUN
dpc-4315	113	20	of	of	ADP
dpc-4315	113	21	easi	easi	NOUN
dpc-4315	113	22	and	and	CCONJ
dpc-4315	113	23	dlqi	dlqi	VERB
dpc-4315	114	1	[	[	X
dpc-4315	114	2	38	38	NUM
dpc-4315	114	3	]	]	PUNCT
dpc-4315	114	4	.	.	PUNCT
dpc-4315	115	1	ewulu	ewulu	VERB
dpc-4315	115	2	et	et	PROPN
dpc-4315	115	3	al	al	PROPN
dpc-4315	115	4	performed	perform	VERB
dpc-4315	115	5	review	review	NOUN
dpc-4315	115	6	to	to	PART
dpc-4315	115	7	investigate	investigate	VERB
dpc-4315	115	8	the	the	DET
dpc-4315	115	9	efficacy	efficacy	NOUN
dpc-4315	115	10	and	and	CCONJ
dpc-4315	115	11	safety	safety	NOUN
dpc-4315	115	12	of	of	ADP
dpc-4315	115	13	tralokinumab	tralokinumab	NOUN
dpc-4315	115	14	also	also	ADV
dpc-4315	115	15	in	in	ADP
dpc-4315	115	16	adolescent	adolescent	ADJ
dpc-4315	115	17	population	population	NOUN
dpc-4315	115	18	with	with	ADP
dpc-4315	115	19	ad	ad	NOUN
dpc-4315	115	20	[	[	X
dpc-4315	115	21	39	39	NUM
dpc-4315	115	22	]	]	PUNCT
dpc-4315	115	23	.	.	PUNCT
dpc-4315	116	1	they	they	PRON
dpc-4315	116	2	concluded	conclude	VERB
dpc-4315	116	3	that	that	SCONJ
dpc-4315	116	4	the	the	DET
dpc-4315	116	5	use	use	NOUN
dpc-4315	116	6	of	of	ADP
dpc-4315	116	7	tralokinumab	tralokinumab	NOUN
dpc-4315	116	8	could	could	AUX
dpc-4315	116	9	also	also	ADV
dpc-4315	116	10	be	be	AUX
dpc-4315	116	11	extended	extend	VERB
dpc-4315	116	12	to	to	ADP
dpc-4315	116	13	adolescents	adolescent	NOUN
dpc-4315	116	14	suffering	suffer	VERB
dpc-4315	116	15	from	from	ADP
dpc-4315	116	16	moderate	moderate	ADJ
dpc-4315	116	17	-	-	PUNCT
dpc-4315	116	18	to	to	ADP
dpc-4315	116	19	-	-	PUNCT
dpc-4315	116	20	severe	severe	ADJ
dpc-4315	116	21	ad	ad	NOUN
dpc-4315	116	22	.	.	PUNCT
dpc-4315	117	1	a	a	PRON
dpc-4315	117	2	52	52	NUM
dpc-4315	117	3	-	-	PUNCT
dpc-4315	117	4	week	week	NOUN
dpc-4315	117	5	,	,	PUNCT
dpc-4315	117	6	randomized	randomize	VERB
dpc-4315	117	7	,	,	PUNCT
dpc-4315	117	8	double	double	ADJ
dpc-4315	117	9	-	-	PUNCT
dpc-4315	117	10	blind	blind	ADJ
dpc-4315	117	11	,	,	PUNCT
dpc-4315	117	12	placebo	placebo	NOUN
dpc-4315	117	13	-	-	PUNCT
dpc-4315	117	14	controlled	control	VERB
dpc-4315	117	15	phase	phase	NOUN
dpc-4315	117	16	3	3	NUM
dpc-4315	117	17	study	study	NOUN
dpc-4315	117	18	ecztra	ecztra	NOUN
dpc-4315	117	19	6	6	NUM
dpc-4315	117	20	was	be	AUX
dpc-4315	117	21	conducted	conduct	VERB
dpc-4315	117	22	involving	involve	VERB
dpc-4315	117	23	72	72	NUM
dpc-4315	117	24	centers	center	NOUN
dpc-4315	117	25	in	in	ADP
dpc-4315	117	26	10	10	NUM
dpc-4315	117	27	countries	country	NOUN
dpc-4315	117	28	that	that	PRON
dpc-4315	117	29	enrolled	enrol	VERB
dpc-4315	117	30	adolescent	adolescent	ADJ
dpc-4315	117	31	patients	patient	NOUN
dpc-4315	117	32	(	(	PUNCT
dpc-4315	117	33	12	12	NUM
dpc-4315	117	34	-	-	SYM
dpc-4315	117	35	17	17	NUM
dpc-4315	117	36	years	year	NOUN
dpc-4315	117	37	)	)	PUNCT
dpc-4315	117	38	with	with	ADP
dpc-4315	117	39	moderate	moderate	ADJ
dpc-4315	117	40	to	to	ADP
dpc-4315	117	41	severe	severe	ADJ
dpc-4315	117	42	form	form	NOUN
dpc-4315	117	43	of	of	ADP
dpc-4315	117	44	ad	ad	NOUN
dpc-4315	117	45	(	(	PUNCT
dpc-4315	117	46	iga	iga	PROPN
dpc-4315	117	47	score	score	NOUN
dpc-4315	117	48	≥3	≥3	PROPN
dpc-4315	117	49	;	;	PUNCT
dpc-4315	117	50	easi	easi	NOUN
dpc-4315	117	51	≥16	≥16	NOUN
dpc-4315	117	52	)	)	PUNCT
dpc-4315	117	53	,	,	PUNCT
dpc-4315	117	54	treated	treat	VERB
dpc-4315	117	55	with	with	ADP
dpc-4315	117	56	tralokinumab	tralokinumab	NOUN
dpc-4315	117	57	150	150	NUM
dpc-4315	117	58	mg	mg	NOUN
dpc-4315	117	59	,	,	PUNCT
dpc-4315	117	60	300	300	NUM
dpc-4315	117	61	mg	mg	NOUN
dpc-4315	117	62	and	and	CCONJ
dpc-4315	117	63	placebo	placebo	NOUN
dpc-4315	117	64	(	(	PUNCT
dpc-4315	117	65	initially	initially	ADV
dpc-4315	117	66	)	)	PUNCT
dpc-4315	117	67	.	.	PUNCT
dpc-4315	118	1	despite	despite	SCONJ
dpc-4315	118	2	some	some	DET
dpc-4315	118	3	limitations	limitation	NOUN
dpc-4315	118	4	such	such	ADJ
dpc-4315	118	5	as	as	ADP
dpc-4315	118	6	low	low	ADJ
dpc-4315	118	7	sample	sample	NOUN
dpc-4315	118	8	size	size	NOUN
dpc-4315	118	9	and	and	CCONJ
dpc-4315	118	10	lack	lack	NOUN
dpc-4315	118	11	of	of	ADP
dpc-4315	118	12	a	a	DET
dpc-4315	118	13	placebo	placebo	NOUN
dpc-4315	118	14	group	group	NOUN
dpc-4315	118	15	in	in	ADP
dpc-4315	118	16	the	the	DET
dpc-4315	118	17	maintenance	maintenance	NOUN
dpc-4315	118	18	phase	phase	NOUN
dpc-4315	118	19	,	,	PUNCT
dpc-4315	118	20	the	the	DET
dpc-4315	118	21	results	result	NOUN
dpc-4315	118	22	confirmed	confirm	VERB
dpc-4315	118	23	safety	safety	NOUN
dpc-4315	118	24	and	and	CCONJ
dpc-4315	118	25	efficacy	efficacy	NOUN
dpc-4315	118	26	of	of	ADP
dpc-4315	118	27	anti	anti	NOUN
dpc-4315	118	28	-	-	NOUN
dpc-4315	118	29	il-13	il-13	ADJ
dpc-4315	118	30	in	in	ADP
dpc-4315	118	31	the	the	DET
dpc-4315	118	32	treatment	treatment	NOUN
dpc-4315	118	33	of	of	ADP
dpc-4315	118	34	moderate	moderate	ADJ
dpc-4315	118	35	-	-	PUNCT
dpc-4315	118	36	to	to	ADP
dpc-4315	118	37	-	-	PUNCT
dpc-4315	118	38	severe	severe	ADJ
dpc-4315	118	39	forms	form	NOUN
dpc-4315	118	40	in	in	ADP
dpc-4315	118	41	the	the	DET
dpc-4315	118	42	adolescent	adolescent	ADJ
dpc-4315	118	43	population	population	NOUN
dpc-4315	119	1	[	[	X
dpc-4315	119	2	40	40	NUM
dpc-4315	119	3	]	]	PUNCT
dpc-4315	119	4	.	.	PUNCT
dpc-4315	120	1	merola	merola	PROPN
dpc-4315	120	2	et	et	PROPN
dpc-4315	120	3	al	al	PROPN
dpc-4315	120	4	conducted	conduct	VERB
dpc-4315	120	5	a	a	DET
dpc-4315	120	6	post	post	X
dpc-4315	120	7	hoc	hoc	X
dpc-4315	120	8	analysis	analysis	NOUN
dpc-4315	120	9	focused	focus	VERB
dpc-4315	120	10	on	on	ADP
dpc-4315	120	11	the	the	DET
dpc-4315	120	12	adult	adult	NOUN
dpc-4315	120	13	population	population	NOUN
dpc-4315	120	14	,	,	PUNCT
dpc-4315	120	15	aged	age	VERB
dpc-4315	120	16	65	65	NUM
dpc-4315	120	17	years	year	NOUN
dpc-4315	120	18	and	and	CCONJ
dpc-4315	120	19	older	old	ADJ
dpc-4315	120	20	,	,	PUNCT
dpc-4315	120	21	stratifying	stratify	VERB
dpc-4315	120	22	data	datum	NOUN
dpc-4315	120	23	from	from	ADP
dpc-4315	120	24	the	the	DET
dpc-4315	120	25	phase	phase	NOUN
dpc-4315	120	26	3	3	NUM
dpc-4315	120	27	studies	study	NOUN
dpc-4315	120	28	:	:	PUNCT
dpc-4315	120	29	ecztra	ecztra	NOUN
dpc-4315	120	30	1	1	NUM
dpc-4315	120	31	,	,	PUNCT
dpc-4315	120	32	2	2	NUM
dpc-4315	120	33	and	and	CCONJ
dpc-4315	120	34	ecztra	ecztra	NOUN
dpc-4315	120	35	3	3	X
dpc-4315	120	36	.	.	PUNCT
dpc-4315	121	1	the	the	DET
dpc-4315	121	2	results	result	NOUN
dpc-4315	121	3	suggest	suggest	VERB
dpc-4315	121	4	that	that	SCONJ
dpc-4315	121	5	tralokinumab	tralokinumab	NOUN
dpc-4315	121	6	is	be	AUX
dpc-4315	121	7	well	well	ADV
dpc-4315	121	8	tolerated	tolerate	VERB
dpc-4315	121	9	and	and	CCONJ
dpc-4315	121	10	effective	effective	ADJ
dpc-4315	121	11	in	in	ADP
dpc-4315	121	12	older	old	ADJ
dpc-4315	121	13	patients	patient	NOUN
dpc-4315	121	14	(	(	PUNCT
dpc-4315	121	15	65	65	NUM
dpc-4315	121	16	years	year	NOUN
dpc-4315	121	17	and	and	CCONJ
dpc-4315	121	18	older	old	ADJ
dpc-4315	121	19	)	)	PUNCT
dpc-4315	121	20	with	with	ADP
dpc-4315	121	21	moderate	moderate	ADJ
dpc-4315	121	22	-	-	PUNCT
dpc-4315	121	23	to	to	ADP
dpc-4315	121	24	-	-	PUNCT
dpc-4315	121	25	severe	severe	ADJ
dpc-4315	121	26	ad	ad	NOUN
dpc-4315	122	1	[	[	X
dpc-4315	122	2	41	41	NUM
dpc-4315	122	3	]	]	PUNCT
dpc-4315	122	4	.	.	PUNCT
dpc-4315	123	1	relevant	relevant	ADJ
dpc-4315	123	2	randomized	randomize	VERB
dpc-4315	123	3	clinical	clinical	ADJ
dpc-4315	123	4	trials	trial	NOUN
dpc-4315	123	5	on	on	ADP
dpc-4315	123	6	the	the	DET
dpc-4315	123	7	efficacy	efficacy	NOUN
dpc-4315	123	8	and	and	CCONJ
dpc-4315	123	9	safety	safety	NOUN
dpc-4315	123	10	of	of	ADP
dpc-4315	123	11	tralokinumab	tralokinumab	NOUN
dpc-4315	123	12	in	in	ADP
dpc-4315	123	13	adults	adult	NOUN
dpc-4315	123	14	and	and	CCONJ
dpc-4315	123	15	adolescents	adolescent	NOUN
dpc-4315	123	16	with	with	ADP
dpc-4315	123	17	ad	ad	NOUN
dpc-4315	123	18	are	be	AUX
dpc-4315	123	19	summarized	summarize	VERB
dpc-4315	123	20	in	in	ADP
dpc-4315	123	21	table	table	NOUN
dpc-4315	123	22	2	2	NUM
dpc-4315	123	23	.	.	PUNCT
dpc-4315	124	1	conclusions	conclusion	NOUN
dpc-4315	124	2	tralokinumab	tralokinumab	NOUN
dpc-4315	124	3	represents	represent	VERB
dpc-4315	124	4	an	an	DET
dpc-4315	124	5	innovative	innovative	ADJ
dpc-4315	124	6	therapeutic	therapeutic	ADJ
dpc-4315	124	7	agent	agent	NOUN
dpc-4315	124	8	with	with	ADP
dpc-4315	124	9	an	an	DET
dpc-4315	124	10	excellent	excellent	ADJ
dpc-4315	124	11	efficacy	efficacy	NOUN
dpc-4315	124	12	and	and	CCONJ
dpc-4315	124	13	safety	safety	NOUN
dpc-4315	124	14	profile	profile	NOUN
dpc-4315	124	15	,	,	PUNCT
dpc-4315	124	16	as	as	SCONJ
dpc-4315	124	17	demonstrated	demonstrate	VERB
dpc-4315	124	18	by	by	ADP
dpc-4315	124	19	phase	phase	NOUN
dpc-4315	124	20	2	2	NUM
dpc-4315	124	21	and	and	CCONJ
dpc-4315	124	22	3	3	NUM
dpc-4315	124	23	studies	study	NOUN
dpc-4315	124	24	and	and	CCONJ
dpc-4315	124	25	post	post	ADJ
dpc-4315	124	26	-	-	ADJ
dpc-4315	124	27	hoc	hoc	ADJ
dpc-4315	124	28	analysis	analysis	NOUN
dpc-4315	124	29	.	.	PUNCT
dpc-4315	125	1	this	this	DET
dpc-4315	125	2	humanized	humanize	VERB
dpc-4315	125	3	monoclonal	monoclonal	NOUN
dpc-4315	125	4	antibody	antibody	NOUN
dpc-4315	125	5	caused	cause	VERB
dpc-4315	125	6	an	an	DET
dpc-4315	125	7	early	early	ADJ
dpc-4315	125	8	and	and	CCONJ
dpc-4315	125	9	sustained	sustained	ADJ
dpc-4315	125	10	response	response	NOUN
dpc-4315	125	11	in	in	ADP
dpc-4315	125	12	ad	ad	NOUN
dpc-4315	125	13	patients	patient	NOUN
dpc-4315	125	14	,	,	PUNCT
dpc-4315	125	15	and	and	CCONJ
dpc-4315	125	16	it	it	PRON
dpc-4315	125	17	demonstrated	demonstrate	VERB
dpc-4315	125	18	to	to	PART
dpc-4315	125	19	be	be	AUX
dpc-4315	125	20	acceptably	acceptably	ADV
dpc-4315	125	21	safe	safe	ADJ
dpc-4315	125	22	and	and	CCONJ
dpc-4315	125	23	tolerable	tolerable	ADJ
dpc-4315	125	24	,	,	PUNCT
dpc-4315	125	25	giving	give	VERB
dpc-4315	125	26	significant	significant	ADJ
dpc-4315	125	27	proof	proof	NOUN
dpc-4315	125	28	for	for	ADP
dpc-4315	125	29	targeting	target	VERB
dpc-4315	125	30	il13	il13	PROPN
dpc-4315	125	31	in	in	ADP
dpc-4315	125	32	ad	ad	NOUN
dpc-4315	125	33	patients	patient	NOUN
dpc-4315	125	34	.	.	PUNCT
dpc-4315	125	35	 	 	SPACE
dpc-4315	126	1	several	several	ADJ
dpc-4315	126	2	drugs	drug	NOUN
dpc-4315	126	3	to	to	PART
dpc-4315	126	4	manage	manage	VERB
dpc-4315	126	5	ad	ad	NOUN
dpc-4315	126	6	 	 	SPACE
dpc-4315	126	7	are	be	AUX
dpc-4315	126	8	currently	currently	ADV
dpc-4315	126	9	approved	approve	VERB
dpc-4315	126	10	:	:	PUNCT
dpc-4315	126	11	dupilumab	dupilumab	NOUN
dpc-4315	126	12	,	,	PUNCT
dpc-4315	126	13	abrocitinib	abrocitinib	NOUN
dpc-4315	126	14	and	and	CCONJ
dpc-4315	126	15	upadacitinib	upadacitinib	NOUN
dpc-4315	126	16	.	.	PUNCT
dpc-4315	127	1	nevertheless	nevertheless	ADV
dpc-4315	127	2	,	,	PUNCT
dpc-4315	127	3	based	base	VERB
dpc-4315	127	4	on	on	ADP
dpc-4315	127	5	the	the	DET
dpc-4315	127	6	results	result	NOUN
dpc-4315	127	7	of	of	ADP
dpc-4315	127	8	trials	trial	NOUN
dpc-4315	127	9	,	,	PUNCT
dpc-4315	127	10	tralokinumab	tralokinumab	NOUN
dpc-4315	127	11	appears	appear	VERB
dpc-4315	127	12	to	to	PART
dpc-4315	127	13	be	be	AUX
dpc-4315	127	14	a	a	DET
dpc-4315	127	15	promising	promising	ADJ
dpc-4315	127	16	treatment	treatment	NOUN
dpc-4315	127	17	option	option	NOUN
dpc-4315	127	18	for	for	ADP
dpc-4315	127	19	patients	patient	NOUN
dpc-4315	127	20	with	with	ADP
dpc-4315	127	21	moderate	moderate	ADJ
dpc-4315	127	22	to	to	ADP
dpc-4315	127	23	severe	severe	ADJ
dpc-4315	127	24	ad	ad	NOUN
dpc-4315	127	25	.	.	PUNCT
dpc-4315	128	1	different	different	ADJ
dpc-4315	128	2	from	from	ADP
dpc-4315	128	3	dupilumab	dupilumab	NOUN
dpc-4315	128	4	,	,	PUNCT
dpc-4315	128	5	tralokinumab	tralokinumab	NOUN
dpc-4315	128	6	does	do	AUX
dpc-4315	128	7	not	not	PART
dpc-4315	128	8	currently	currently	ADV
dpc-4315	128	9	have	have	VERB
dpc-4315	128	10	an	an	DET
dpc-4315	128	11	indication	indication	NOUN
dpc-4315	128	12	for	for	ADP
dpc-4315	128	13	the	the	DET
dpc-4315	128	14	treatment	treatment	NOUN
dpc-4315	128	15	of	of	ADP
dpc-4315	128	16	ad	ad	NOUN
dpc-4315	128	17	in	in	ADP
dpc-4315	128	18	the	the	DET
dpc-4315	128	19	pediatric	pediatric	ADJ
dpc-4315	128	20	patients	patient	NOUN
dpc-4315	128	21	.	.	PUNCT
dpc-4315	129	1	nevertheless	nevertheless	ADV
dpc-4315	129	2	,	,	PUNCT
dpc-4315	129	3	efficacy	efficacy	NOUN
dpc-4315	129	4	and	and	CCONJ
dpc-4315	129	5	a	a	DET
dpc-4315	129	6	good	good	ADJ
dpc-4315	129	7	safety	safety	NOUN
dpc-4315	129	8	profile	profile	NOUN
dpc-4315	129	9	of	of	ADP
dpc-4315	129	10	tralokinumab	tralokinumab	NOUN
dpc-4315	129	11	has	have	AUX
dpc-4315	129	12	been	be	AUX
dpc-4315	129	13	demonstrated	demonstrate	VERB
dpc-4315	129	14	in	in	ADP
dpc-4315	129	15	adolescents	adolescent	NOUN
dpc-4315	129	16	and	and	CCONJ
dpc-4315	129	17	elderly	elderly	ADJ
dpc-4315	129	18	ad	ad	NOUN
dpc-4315	129	19	patients	patient	NOUN
dpc-4315	129	20	.	.	PUNCT
dpc-4315	130	1	our	our	PRON
dpc-4315	130	2	clinical	clinical	ADJ
dpc-4315	130	3	experience	experience	NOUN
dpc-4315	130	4	also	also	ADV
dpc-4315	130	5	proved	prove	VERB
dpc-4315	130	6	that	that	SCONJ
dpc-4315	130	7	anti	anti	ADJ
dpc-4315	130	8	il-13	il-13	ADP
dpc-4315	130	9	is	be	AUX
dpc-4315	130	10	an	an	DET
dpc-4315	130	11	effective	effective	ADJ
dpc-4315	130	12	drug	drug	NOUN
dpc-4315	130	13	for	for	ADP
dpc-4315	130	14	severe	severe	ADJ
dpc-4315	130	15	forms	form	NOUN
dpc-4315	130	16	of	of	ADP
dpc-4315	130	17	ad	ad	NOUN
dpc-4315	130	18	without	without	ADP
dpc-4315	130	19	significant	significant	ADJ
dpc-4315	130	20	side	side	NOUN
dpc-4315	130	21	effects	effect	NOUN
dpc-4315	130	22	.	.	PUNCT
dpc-4315	131	1	in	in	ADP
dpc-4315	131	2	particular	particular	ADJ
dpc-4315	131	3	,	,	PUNCT
dpc-4315	131	4	ophthalmic	ophthalmic	ADJ
dpc-4315	131	5	side	side	NOUN
dpc-4315	131	6	effects	effect	NOUN
dpc-4315	131	7	,	,	PUNCT
dpc-4315	131	8	primarily	primarily	ADV
dpc-4315	131	9	conjunctivitis	conjunctivitis	NOUN
dpc-4315	131	10	,	,	PUNCT
dpc-4315	131	11	were	be	AUX
dpc-4315	131	12	observed	observe	VERB
dpc-4315	131	13	less	less	ADV
dpc-4315	131	14	frequently	frequently	ADV
dpc-4315	131	15	than	than	ADP
dpc-4315	131	16	in	in	ADP
dpc-4315	131	17	patients	patient	NOUN
dpc-4315	131	18	treated	treat	VERB
dpc-4315	131	19	with	with	ADP
dpc-4315	131	20	dupilumab	dupilumab	NOUN
dpc-4315	131	21	.	.	PUNCT
dpc-4315	132	1	despite	despite	SCONJ
dpc-4315	132	2	its	its	PRON
dpc-4315	132	3	induction	induction	NOUN
dpc-4315	132	4	,	,	PUNCT
dpc-4315	132	5	tralokinumab	tralokinumab	NOUN
dpc-4315	132	6	dermatology	dermatology	NOUN
dpc-4315	132	7	life	life	NOUN
dpc-4315	132	8	quality	quality	PROPN
dpc-4315	132	9	index	index	NOUN
dpc-4315	132	10	,	,	PUNCT
dpc-4315	132	11	scorad	scorad	NOUN
dpc-4315	132	12	and	and	CCONJ
dpc-4315	132	13	numeric	numeric	ADJ
dpc-4315	132	14	rating	rating	NOUN
dpc-4315	132	15	scale	scale	NOUN
dpc-4315	132	16	pruritus	pruritus	NOUN
dpc-4315	132	17	(	(	PUNCT
dpc-4315	132	18	nrs	nrs	PROPN
dpc-4315	132	19	pruritus	pruritus	PROPN
dpc-4315	132	20	)	)	PUNCT
dpc-4315	132	21	were	be	AUX
dpc-4315	132	22	demonstrated	demonstrate	VERB
dpc-4315	132	23	in	in	ADP
dpc-4315	132	24	patients	patient	NOUN
dpc-4315	132	25	taking	take	VERB
dpc-4315	132	26	300	300	NUM
dpc-4315	132	27	mg	mg	NOUN
dpc-4315	132	28	tralokinumab	tralokinumab	NOUN
dpc-4315	132	29	compared	compare	VERB
dpc-4315	132	30	to	to	ADP
dpc-4315	132	31	placebo	placebo	NOUN
dpc-4315	132	32	.	.	PUNCT
dpc-4315	133	1	the	the	DET
dpc-4315	133	2	most	most	ADV
dpc-4315	133	3	frequent	frequent	ADJ
dpc-4315	133	4	treatment	treatment	NOUN
dpc-4315	133	5	-	-	PUNCT
dpc-4315	133	6	emergent	emergent	NOUN
dpc-4315	133	7	adverse	adverse	ADJ
dpc-4315	133	8	event	event	NOUN
dpc-4315	133	9	reported	report	VERB
dpc-4315	133	10	was	be	AUX
dpc-4315	133	11	upper	upper	ADJ
dpc-4315	133	12	respiratory	respiratory	ADJ
dpc-4315	133	13	tract	tract	NOUN
dpc-4315	133	14	infection	infection	NOUN
dpc-4315	133	15	,	,	PUNCT
dpc-4315	133	16	but	but	CCONJ
dpc-4315	133	17	in	in	ADP
dpc-4315	133	18	the	the	DET
dpc-4315	133	19	same	same	ADJ
dpc-4315	133	20	percentage	percentage	NOUN
dpc-4315	133	21	(	(	PUNCT
dpc-4315	133	22	3.9	3.9	NUM
dpc-4315	133	23	%	%	NOUN
dpc-4315	133	24	)	)	PUNCT
dpc-4315	133	25	in	in	ADP
dpc-4315	133	26	both	both	DET
dpc-4315	133	27	groups	group	NOUN
dpc-4315	133	28	[	[	X
dpc-4315	133	29	37	37	NUM
dpc-4315	133	30	]	]	PUNCT
dpc-4315	133	31	.	.	PUNCT
dpc-4315	134	1	a	a	DET
dpc-4315	134	2	new	new	ADJ
dpc-4315	134	3	ongoing	ongoing	ADJ
dpc-4315	134	4	trial	trial	NOUN
dpc-4315	134	5	,	,	PUNCT
dpc-4315	134	6	ecztend	ecztend	NOUN
dpc-4315	134	7	,	,	PUNCT
dpc-4315	134	8	assessed	assess	VERB
dpc-4315	134	9	long	long	ADJ
dpc-4315	134	10	-	-	PUNCT
dpc-4315	134	11	term	term	NOUN
dpc-4315	134	12	safety	safety	NOUN
dpc-4315	134	13	in	in	ADP
dpc-4315	134	14	patients	patient	NOUN
dpc-4315	134	15	who	who	PRON
dpc-4315	134	16	were	be	AUX
dpc-4315	134	17	enrolled	enrol	VERB
dpc-4315	134	18	in	in	ADP
dpc-4315	134	19	previous	previous	ADJ
dpc-4315	134	20	parent	parent	NOUN
dpc-4315	134	21	table	table	NOUN
dpc-4315	134	22	2	2	NUM
dpc-4315	134	23	.	.	PUNCT
dpc-4315	134	24	relevant	relevant	ADJ
dpc-4315	134	25	clinical	clinical	ADJ
dpc-4315	134	26	studies	study	NOUN
dpc-4315	134	27	on	on	ADP
dpc-4315	134	28	tralokinumab	tralokinumab	NOUN
dpc-4315	134	29	ecztra	ecztra	NOUN
dpc-4315	134	30	1	1	NUM
dpc-4315	134	31	and	and	CCONJ
dpc-4315	134	32	2	2	NUM
dpc-4315	134	33	were	be	AUX
dpc-4315	134	34	identical	identical	ADJ
dpc-4315	134	35	monotherapy	monotherapy	NOUN
dpc-4315	134	36	studies	study	NOUN
dpc-4315	134	37	of1596	of1596	NOUN
dpc-4315	134	38	adult	adult	NOUN
dpc-4315	134	39	patients	patient	NOUN
dpc-4315	134	40	with	with	ADP
dpc-4315	134	41	moderate	moderate	ADJ
dpc-4315	134	42	to	to	ADP
dpc-4315	134	43	severe	severe	ADJ
dpc-4315	134	44	ad	ad	NOUN
dpc-4315	134	45	.	.	PUNCT
dpc-4315	135	1	patients	patient	NOUN
dpc-4315	135	2	were	be	AUX
dpc-4315	135	3	randomized	randomize	VERB
dpc-4315	135	4	into	into	ADP
dpc-4315	135	5	three	three	NUM
dpc-4315	135	6	arms	arm	NOUN
dpc-4315	135	7	:	:	PUNCT
dpc-4315	135	8	to	to	PART
dpc-4315	135	9	tralokinumab	tralokinumab	VERB
dpc-4315	135	10	600	600	NUM
dpc-4315	135	11	mg	mg	NOUN
dpc-4315	135	12	and	and	CCONJ
dpc-4315	135	13	300	300	NUM
dpc-4315	135	14	mg	mg	NOUN
dpc-4315	135	15	or	or	CCONJ
dpc-4315	135	16	to	to	ADP
dpc-4315	135	17	placebo	placebo	NOUN
dpc-4315	135	18	.	.	PUNCT
dpc-4315	136	1	patients	patient	NOUN
dpc-4315	136	2	could	could	AUX
dpc-4315	136	3	n’t	not	PART
dpc-4315	136	4	use	use	VERB
dpc-4315	136	5	topical	topical	ADJ
dpc-4315	136	6	corticosteroids	corticosteroid	NOUN
dpc-4315	136	7	during	during	ADP
dpc-4315	136	8	the	the	DET
dpc-4315	136	9	study	study	NOUN
dpc-4315	136	10	.	.	PUNCT
dpc-4315	137	1	a	a	DET
dpc-4315	137	2	significantly	significantly	ADV
dpc-4315	137	3	higher	high	ADJ
dpc-4315	137	4	proportion	proportion	NOUN
dpc-4315	137	5	of	of	ADP
dpc-4315	137	6	patients	patient	NOUN
dpc-4315	137	7	received	receive	VERB
dpc-4315	137	8	tralokinumab	tralokinumab	NOUN
dpc-4315	137	9	.	.	PUNCT
dpc-4315	138	1	in	in	ADP
dpc-4315	138	2	both	both	DET
dpc-4315	138	3	studies	study	NOUN
dpc-4315	138	4	,	,	PUNCT
dpc-4315	138	5	tralokinumab	tralokinumab	NOUN
dpc-4315	138	6	led	lead	VERB
dpc-4315	138	7	to	to	ADP
dpc-4315	138	8	an	an	DET
dpc-4315	138	9	improvement	improvement	NOUN
dpc-4315	138	10	in	in	ADP
dpc-4315	138	11	iga	iga	PROPN
dpc-4315	138	12	in	in	ADV
dpc-4315	138	13	twice	twice	ADV
dpc-4315	138	14	as	as	ADV
dpc-4315	138	15	many	many	ADJ
dpc-4315	138	16	patients	patient	NOUN
dpc-4315	138	17	as	as	ADP
dpc-4315	138	18	in	in	ADP
dpc-4315	138	19	the	the	DET
dpc-4315	138	20	placebo	placebo	NOUN
dpc-4315	138	21	group	group	NOUN
dpc-4315	138	22	(	(	PUNCT
dpc-4315	138	23	ecztra	ecztra	NOUN
dpc-4315	138	24	1	1	NUM
dpc-4315	138	25	:	:	SYM
dpc-4315	138	26	15.8	15.8	NUM
dpc-4315	138	27	%	%	NOUN
dpc-4315	138	28	versus	versus	ADP
dpc-4315	138	29	7.1	7.1	NUM
dpc-4315	138	30	%	%	NOUN
dpc-4315	138	31	;	;	PUNCT
dpc-4315	138	32	ecztra	ecztra	NOUN
dpc-4315	138	33	2	2	NUM
dpc-4315	138	34	:	:	PUNCT
dpc-4315	138	35	22.2	22.2	NUM
dpc-4315	138	36	%	%	NOUN
dpc-4315	138	37	versus	versus	ADP
dpc-4315	138	38	10.9	10.9	NUM
dpc-4315	138	39	%	%	NOUN
dpc-4315	138	40	)	)	PUNCT
dpc-4315	138	41	.	.	PUNCT
dpc-4315	139	1	easi	easi	NOUN
dpc-4315	139	2	75	75	NUM
dpc-4315	139	3	was	be	AUX
dpc-4315	139	4	achieved	achieve	VERB
dpc-4315	139	5	more	more	ADV
dpc-4315	139	6	frequently	frequently	ADV
dpc-4315	139	7	in	in	ADP
dpc-4315	139	8	the	the	DET
dpc-4315	139	9	groups	group	NOUN
dpc-4315	139	10	with	with	ADP
dpc-4315	139	11	tralokinumab	tralokinumab	NOUN
dpc-4315	139	12	in	in	ADP
dpc-4315	139	13	ecztra	ecztra	NOUN
dpc-4315	139	14	1	1	NUM
dpc-4315	139	15	(	(	PUNCT
dpc-4315	139	16	25.0	25.0	NUM
dpc-4315	139	17	%	%	NOUN
dpc-4315	139	18	versus	versus	ADP
dpc-4315	139	19	12.7	12.7	NUM
dpc-4315	139	20	%	%	NOUN
dpc-4315	139	21	)	)	PUNCT
dpc-4315	139	22	and	and	CCONJ
dpc-4315	139	23	ecztra	ecztra	NOUN
dpc-4315	139	24	2	2	NUM
dpc-4315	139	25	(	(	PUNCT
dpc-4315	139	26	33.2	33.2	NUM
dpc-4315	139	27	%	%	NOUN
dpc-4315	139	28	versus	versus	ADP
dpc-4315	139	29	11.4	11.4	NUM
dpc-4315	139	30	%	%	NOUN
dpc-4315	139	31	)	)	PUNCT
dpc-4315	139	32	.	.	PUNCT
dpc-4315	140	1	in	in	ADP
dpc-4315	140	2	the	the	DET
dpc-4315	140	3	initial	initial	ADJ
dpc-4315	140	4	16	16	NUM
dpc-4315	140	5	-	-	PUNCT
dpc-4315	140	6	week	week	NOUN
dpc-4315	140	7	treatment	treatment	NOUN
dpc-4315	140	8	period	period	NOUN
dpc-4315	140	9	,	,	PUNCT
dpc-4315	140	10	the	the	DET
dpc-4315	140	11	frequency	frequency	NOUN
dpc-4315	140	12	of	of	ADP
dpc-4315	140	13	adverse	adverse	ADJ
dpc-4315	140	14	events	event	NOUN
dpc-4315	140	15	was	be	AUX
dpc-4315	140	16	similar	similar	ADJ
dpc-4315	140	17	between	between	ADP
dpc-4315	140	18	tralokinumab	tralokinumab	NOUN
dpc-4315	140	19	and	and	CCONJ
dpc-4315	140	20	placebo	placebo	NOUN
dpc-4315	140	21	[	[	X
dpc-4315	140	22	28	28	NUM
dpc-4315	140	23	]	]	PUNCT
dpc-4315	140	24	.	.	PUNCT
dpc-4315	141	1	the	the	DET
dpc-4315	141	2	ecztra	ecztra	ADJ
dpc-4315	141	3	3	3	NUM
dpc-4315	141	4	trial	trial	NOUN
dpc-4315	141	5	involved	involve	VERB
dpc-4315	141	6	369	369	NUM
dpc-4315	141	7	adult	adult	NOUN
dpc-4315	141	8	patients	patient	NOUN
dpc-4315	141	9	with	with	ADP
dpc-4315	141	10	ad	ad	NOUN
dpc-4315	141	11	who	who	PRON
dpc-4315	141	12	were	be	AUX
dpc-4315	141	13	randomized	randomize	VERB
dpc-4315	141	14	to	to	PART
dpc-4315	141	15	tralokinumab	tralokinumab	VERB
dpc-4315	141	16	sc	sc	PROPN
dpc-4315	141	17	300	300	NUM
dpc-4315	141	18	mg	mg	NOUN
dpc-4315	141	19	q2w	q2w	NOUN
dpc-4315	141	20	or	or	CCONJ
dpc-4315	141	21	placebo	placebo	NOUN
dpc-4315	141	22	.	.	PUNCT
dpc-4315	142	1	patients	patient	NOUN
dpc-4315	142	2	could	could	AUX
dpc-4315	142	3	use	use	VERB
dpc-4315	142	4	topical	topical	ADJ
dpc-4315	142	5	corticosteroids	corticosteroid	NOUN
dpc-4315	142	6	throughout	throughout	ADP
dpc-4315	142	7	the	the	DET
dpc-4315	142	8	study	study	NOUN
dpc-4315	142	9	.	.	PUNCT
dpc-4315	143	1	response	response	NOUN
dpc-4315	143	2	rates	rate	NOUN
dpc-4315	143	3	were	be	AUX
dpc-4315	143	4	higher	high	ADJ
dpc-4315	143	5	for	for	ADP
dpc-4315	143	6	tralokinumab	tralokinumab	NOUN
dpc-4315	143	7	than	than	ADP
dpc-4315	143	8	for	for	ADP
dpc-4315	143	9	placebo	placebo	NOUN
dpc-4315	143	10	(	(	PUNCT
dpc-4315	143	11	iga	iga	PROPN
dpc-4315	143	12	:	:	PUNCT
dpc-4315	143	13	38.9	38.9	NUM
dpc-4315	143	14	%	%	NOUN
dpc-4315	143	15	versus	versus	ADP
dpc-4315	143	16	26.2	26.2	NUM
dpc-4315	143	17	%	%	NOUN
dpc-4315	143	18	;	;	PUNCT
dpc-4315	143	19	easi	easi	NOUN
dpc-4315	143	20	75	75	NUM
dpc-4315	143	21	:	:	PUNCT
dpc-4315	143	22	56.0	56.0	NUM
dpc-4315	143	23	%	%	NOUN
dpc-4315	143	24	versus	versus	ADP
dpc-4315	143	25	35.7	35.7	NUM
dpc-4315	143	26	%	%	NOUN
dpc-4315	143	27	)	)	PUNCT
dpc-4315	143	28	.	.	PUNCT
dpc-4315	144	1	in	in	ADP
dpc-4315	144	2	the	the	DET
dpc-4315	144	3	initial	initial	ADJ
dpc-4315	144	4	16	16	NUM
dpc-4315	144	5	-	-	PUNCT
dpc-4315	144	6	week	week	NOUN
dpc-4315	144	7	treatment	treatment	NOUN
dpc-4315	144	8	period	period	NOUN
dpc-4315	144	9	,	,	PUNCT
dpc-4315	144	10	the	the	DET
dpc-4315	144	11	frequency	frequency	NOUN
dpc-4315	144	12	of	of	ADP
dpc-4315	144	13	adverse	adverse	ADJ
dpc-4315	144	14	events	event	NOUN
dpc-4315	144	15	was	be	AUX
dpc-4315	144	16	similar	similar	ADJ
dpc-4315	144	17	between	between	ADP
dpc-4315	144	18	tralokinumab	tralokinumab	NOUN
dpc-4315	144	19	and	and	CCONJ
dpc-4315	144	20	placebo	placebo	NOUN
dpc-4315	144	21	.	.	PUNCT
dpc-4315	145	1	[	[	X
dpc-4315	145	2	33,34	33,34	NUM
dpc-4315	145	3	]	]	PUNCT
dpc-4315	145	4	.	.	PUNCT
dpc-4315	146	1	ecztra	ecztra	PROPN
dpc-4315	146	2	7	7	NUM
dpc-4315	146	3	demonstrated	demonstrate	VERB
dpc-4315	146	4	the	the	DET
dpc-4315	146	5	efficacy	efficacy	NOUN
dpc-4315	146	6	and	and	CCONJ
dpc-4315	146	7	safety	safety	NOUN
dpc-4315	146	8	of	of	ADP
dpc-4315	146	9	tralokinumab	tralokinumab	NOUN
dpc-4315	146	10	and	and	CCONJ
dpc-4315	146	11	topical	topical	ADJ
dpc-4315	146	12	cs	cs	PROPN
dpc-4315	146	13	after	after	ADP
dpc-4315	146	14	16	16	NUM
dpc-4315	146	15	weeks	week	NOUN
dpc-4315	146	16	in	in	ADP
dpc-4315	146	17	patients	patient	NOUN
dpc-4315	146	18	with	with	ADP
dpc-4315	146	19	inadequate	inadequate	ADJ
dpc-4315	146	20	response	response	NOUN
dpc-4315	146	21	or	or	CCONJ
dpc-4315	146	22	with	with	ADP
dpc-4315	146	23	contraindications	contraindication	NOUN
dpc-4315	146	24	to	to	ADP
dpc-4315	146	25	oral	oral	ADJ
dpc-4315	146	26	cyclosporin	cyclosporin	NOUN
dpc-4315	146	27	.	.	PUNCT
dpc-4315	147	1	[	[	X
dpc-4315	147	2	36	36	NUM
dpc-4315	147	3	]	]	PUNCT
dpc-4315	147	4	.	.	PUNCT
dpc-4315	148	1	ecztend	ecztend	PROPN
dpc-4315	148	2	evaluated	evaluate	VERB
dpc-4315	148	3	long	long	ADJ
dpc-4315	148	4	-	-	PUNCT
dpc-4315	148	5	term	term	NOUN
dpc-4315	148	6	safety	safety	NOUN
dpc-4315	148	7	in	in	ADP
dpc-4315	148	8	patients	patient	NOUN
dpc-4315	148	9	previously	previously	ADV
dpc-4315	148	10	enrolled	enrol	VERB
dpc-4315	148	11	in	in	ADP
dpc-4315	148	12	other	other	ADJ
dpc-4315	148	13	studies	study	NOUN
dpc-4315	148	14	.	.	PUNCT
dpc-4315	149	1	adverse	adverse	ADJ
dpc-4315	149	2	events	event	NOUN
dpc-4315	149	3	were	be	AUX
dpc-4315	149	4	similar	similar	ADJ
dpc-4315	149	5	for	for	ADP
dpc-4315	149	6	anti	anti	ADJ
dpc-4315	149	7	-	-	ADJ
dpc-4315	149	8	il-13	il-13	PUNCT
dpc-4315	149	9	and	and	CCONJ
dpc-4315	149	10	placebo	placebo	NOUN
dpc-4315	149	11	up	up	ADV
dpc-4315	149	12	to	to	ADP
dpc-4315	149	13	52	52	NUM
dpc-4315	149	14	weeks	week	NOUN
dpc-4315	149	15	.	.	PUNCT
dpc-4315	150	1	it	it	PRON
dpc-4315	150	2	also	also	ADV
dpc-4315	150	3	demonstrated	demonstrate	VERB
dpc-4315	150	4	the	the	DET
dpc-4315	150	5	efficacy	efficacy	NOUN
dpc-4315	150	6	of	of	ADP
dpc-4315	150	7	tralokinumab	tralokinumab	NOUN
dpc-4315	150	8	over	over	ADP
dpc-4315	150	9	2	2	NUM
dpc-4315	150	10	years	year	NOUN
dpc-4315	150	11	of	of	ADP
dpc-4315	150	12	treatment	treatment	NOUN
dpc-4315	150	13	,	,	PUNCT
dpc-4315	150	14	with	with	ADP
dpc-4315	150	15	a	a	DET
dpc-4315	150	16	significant	significant	ADJ
dpc-4315	150	17	reduction	reduction	NOUN
dpc-4315	150	18	in	in	ADP
dpc-4315	150	19	easi	easi	NOUN
dpc-4315	150	20	and	and	CCONJ
dpc-4315	150	21	dlqi.[38	dlqi.[38	PROPN
dpc-4315	150	22	]	]	PUNCT
dpc-4315	150	23	ecztra	ecztra	NOUN
dpc-4315	150	24	6	6	NUM
dpc-4315	150	25	is	be	AUX
dpc-4315	150	26	a	a	DET
dpc-4315	150	27	phase	phase	NOUN
dpc-4315	150	28	3	3	NUM
dpc-4315	150	29	,	,	PUNCT
dpc-4315	150	30	randomized	randomize	VERB
dpc-4315	150	31	,	,	PUNCT
dpc-4315	150	32	double	double	ADJ
dpc-4315	150	33	-	-	PUNCT
dpc-4315	150	34	blind	blind	ADJ
dpc-4315	150	35	,	,	PUNCT
dpc-4315	150	36	placebo	placebo	NOUN
dpc-4315	150	37	-	-	PUNCT
dpc-4315	150	38	controlled	control	VERB
dpc-4315	150	39	,	,	PUNCT
dpc-4315	150	40	52	52	NUM
dpc-4315	150	41	-	-	PUNCT
dpc-4315	150	42	week	week	NOUN
dpc-4315	150	43	study	study	NOUN
dpc-4315	150	44	involving	involve	VERB
dpc-4315	150	45	72	72	NUM
dpc-4315	150	46	centers	center	NOUN
dpc-4315	150	47	in	in	ADP
dpc-4315	150	48	10	10	NUM
dpc-4315	150	49	 	 	SPACE
dpc-4315	150	50	countries	country	NOUN
dpc-4315	150	51	.	.	PUNCT
dpc-4315	151	1	adolescent	adolescent	ADJ
dpc-4315	151	2	patients	patient	NOUN
dpc-4315	151	3	(	(	PUNCT
dpc-4315	151	4	12	12	NUM
dpc-4315	151	5	-	-	SYM
dpc-4315	151	6	17	17	NUM
dpc-4315	151	7	years	year	NOUN
dpc-4315	151	8	)	)	PUNCT
dpc-4315	151	9	with	with	ADP
dpc-4315	151	10	moderate	moderate	ADJ
dpc-4315	151	11	-	-	PUNCT
dpc-4315	151	12	to	to	ADP
dpc-4315	151	13	-	-	PUNCT
dpc-4315	151	14	severe	severe	ADJ
dpc-4315	151	15	form	form	NOUN
dpc-4315	151	16	of	of	ADP
dpc-4315	151	17	ad	ad	NOUN
dpc-4315	151	18	(	(	PUNCT
dpc-4315	151	19	iga	iga	PROPN
dpc-4315	151	20	score	score	NOUN
dpc-4315	151	21	≥3	≥3	PROPN
dpc-4315	151	22	;	;	PUNCT
dpc-4315	151	23	easi	easi	PROPN
dpc-4315	151	24	≥16	≥16	NOUN
dpc-4315	151	25	)	)	PUNCT
dpc-4315	151	26	were	be	AUX
dpc-4315	151	27	enrolled	enrol	VERB
dpc-4315	151	28	,	,	PUNCT
dpc-4315	151	29	and	and	CCONJ
dpc-4315	151	30	were	be	AUX
dpc-4315	151	31	randomized	randomize	VERB
dpc-4315	151	32	to	to	ADP
dpc-4315	151	33	tralokinumab	tralokinumab	NOUN
dpc-4315	151	34	150	150	NUM
dpc-4315	151	35	mg	mg	NOUN
dpc-4315	151	36	,	,	PUNCT
dpc-4315	151	37	300	300	NUM
dpc-4315	151	38	mg	mg	NOUN
dpc-4315	151	39	,	,	PUNCT
dpc-4315	151	40	and	and	CCONJ
dpc-4315	151	41	placebo	placebo	NOUN
dpc-4315	151	42	(	(	PUNCT
dpc-4315	151	43	initially	initially	ADV
dpc-4315	151	44	)	)	PUNCT
dpc-4315	151	45	.	.	PUNCT
dpc-4315	152	1	the	the	DET
dpc-4315	152	2	results	result	NOUN
dpc-4315	152	3	confirmed	confirm	VERB
dpc-4315	152	4	the	the	DET
dpc-4315	152	5	safety	safety	NOUN
dpc-4315	152	6	and	and	CCONJ
dpc-4315	152	7	efficacy	efficacy	NOUN
dpc-4315	152	8	of	of	ADP
dpc-4315	152	9	anti	anti	NOUN
dpc-4315	152	10	-	-	NOUN
dpc-4315	152	11	il-13	il-13	ADJ
dpc-4315	152	12	in	in	ADP
dpc-4315	152	13	the	the	DET
dpc-4315	152	14	treatment	treatment	NOUN
dpc-4315	152	15	of	of	ADP
dpc-4315	152	16	moderate	moderate	ADJ
dpc-4315	152	17	-	-	PUNCT
dpc-4315	152	18	severe	severe	ADJ
dpc-4315	152	19	forms	form	NOUN
dpc-4315	152	20	in	in	ADP
dpc-4315	152	21	the	the	DET
dpc-4315	152	22	adolescent	adolescent	ADJ
dpc-4315	152	23	population	population	NOUN
dpc-4315	153	1	[	[	X
dpc-4315	153	2	40	40	NUM
dpc-4315	153	3	]	]	PUNCT
dpc-4315	153	4	.	.	PUNCT
dpc-4315	154	1	ad	ad	NOUN
dpc-4315	154	2	=	=	SYM
dpc-4315	154	3	atopic	atopic	NOUN
dpc-4315	154	4	dermatitis	dermatitis	NOUN
dpc-4315	154	5	;	;	PUNCT
dpc-4315	154	6	cs	cs	PROPN
dpc-4315	154	7	=	=	NOUN
dpc-4315	154	8	corticosteroids	corticosteroid	NOUN
dpc-4315	154	9	;	;	PUNCT
dpc-4315	154	10	dlqi	dlqi	ADJ
dpc-4315	154	11	=	=	PUNCT
dpc-4315	154	12	dermatology	dermatology	NOUN
dpc-4315	154	13	life	life	NOUN
dpc-4315	154	14	quality	quality	NOUN
dpc-4315	154	15	index	index	NOUN
dpc-4315	154	16	;	;	PUNCT
dpc-4315	154	17	easi	easi	NOUN
dpc-4315	154	18	=	=	SYM
dpc-4315	154	19	eczema	eczema	NOUN
dpc-4315	154	20	area	area	NOUN
dpc-4315	154	21	and	and	CCONJ
dpc-4315	154	22	severity	severity	NOUN
dpc-4315	154	23	index	index	NOUN
dpc-4315	154	24	;	;	PUNCT
dpc-4315	154	25	iga	iga	PROPN
dpc-4315	154	26	=	=	SYM
dpc-4315	154	27	investigator	investigator	NOUN
dpc-4315	154	28	global	global	ADJ
dpc-4315	154	29	assessment	assessment	NOUN
dpc-4315	154	30	;	;	PUNCT
dpc-4315	154	31	il	il	PROPN
dpc-4315	154	32	=	=	SYM
dpc-4315	154	33	interleukin	interleukin	NOUN
dpc-4315	154	34	;	;	PUNCT
dpc-4315	154	35	sc	sc	ADJ
dpc-4315	154	36	=	=	NOUN
dpc-4315	154	37	subcutaneous	subcutaneous	ADJ
dpc-4315	154	38	.	.	PUNCT
dpc-4315	155	1	review	review	NOUN
dpc-4315	155	2	|	|	ADV
dpc-4315	155	3	dermatol	dermatol	ADJ
dpc-4315	155	4	pract	pract	NOUN
dpc-4315	155	5	concept	concept	NOUN
dpc-4315	155	6	.	.	PUNCT
dpc-4315	156	1	2024;14(3):e2024204	2024;14(3):e2024204	NUM
dpc-4315	156	2	5	5	NUM
dpc-4315	156	3	13	13	NUM
dpc-4315	156	4	.	.	PUNCT
dpc-4315	157	1	tazawa	tazawa	PROPN
dpc-4315	157	2	t	t	PROPN
dpc-4315	157	3	,	,	PUNCT
dpc-4315	157	4	sugiura	sugiura	NOUN
dpc-4315	157	5	h	h	PROPN
dpc-4315	157	6	,	,	PUNCT
dpc-4315	157	7	sugiura	sugiura	NOUN
dpc-4315	157	8	y	y	PROPN
dpc-4315	157	9	,	,	PUNCT
dpc-4315	157	10	uehara	uehara	PROPN
dpc-4315	157	11	m.	m.	PROPN
dpc-4315	157	12	relative	relative	ADJ
dpc-4315	157	13	importance	importance	NOUN
dpc-4315	157	14	of	of	ADP
dpc-4315	157	15	il-4	il-4	NOUN
dpc-4315	157	16	and	and	CCONJ
dpc-4315	157	17	il-13	il-13	ADP
dpc-4315	157	18	in	in	ADP
dpc-4315	157	19	lesional	lesional	ADJ
dpc-4315	157	20	skin	skin	NOUN
dpc-4315	157	21	of	of	ADP
dpc-4315	157	22	atopic	atopic	NOUN
dpc-4315	157	23	dermatitis	dermatitis	NOUN
dpc-4315	157	24	.	.	PUNCT
dpc-4315	158	1	arch	arch	ADJ
dpc-4315	158	2	dermatol	dermatol	NOUN
dpc-4315	158	3	res	re	NOUN
dpc-4315	158	4	.	.	PUNCT
dpc-4315	158	5	2004	2004	NUM
dpc-4315	158	6	apr;295(11):459	apr;295(11):459	PROPN
dpc-4315	158	7	-	-	PUNCT
dpc-4315	158	8	64	64	NUM
dpc-4315	158	9	.	.	PUNCT
dpc-4315	159	1	doi	doi	NOUN
dpc-4315	159	2	:	:	PUNCT
dpc-4315	159	3	10.1007	10.1007	NUM
dpc-4315	159	4	/	/	SYM
dpc-4315	159	5	s00403	s00403	NOUN
dpc-4315	159	6	-	-	PUNCT
dpc-4315	159	7	004	004	NUM
dpc-4315	159	8	-0455	-0455	PROPN
dpc-4315	159	9	-	-	PUNCT
dpc-4315	159	10	6	6	NUM
dpc-4315	159	11	.	.	PUNCT
dpc-4315	160	1	epub	epub	PROPN
dpc-4315	160	2	2004	2004	NUM
dpc-4315	160	3	mar	mar	PROPN
dpc-4315	160	4	10	10	NUM
dpc-4315	160	5	.	.	PUNCT
dpc-4315	161	1	pmid	pmid	NOUN
dpc-4315	161	2	:	:	PUNCT
dpc-4315	161	3	15014952	15014952	NUM
dpc-4315	161	4	.	.	PUNCT
dpc-4315	162	1	14	14	NUM
dpc-4315	162	2	.	.	PUNCT
dpc-4315	163	1	hamid	hamid	PROPN
dpc-4315	163	2	q	q	PROPN
dpc-4315	163	3	,	,	PUNCT
dpc-4315	163	4	naseer	naseer	PROPN
dpc-4315	163	5	t	t	PROPN
dpc-4315	163	6	,	,	PUNCT
dpc-4315	163	7	minshall	minshall	PRON
dpc-4315	163	8	em	em	PRON
dpc-4315	163	9	,	,	PUNCT
dpc-4315	163	10	song	song	NOUN
dpc-4315	163	11	yl	yl	NOUN
dpc-4315	163	12	,	,	PUNCT
dpc-4315	163	13	boguniewicz	boguniewicz	PROPN
dpc-4315	163	14	m	m	PROPN
dpc-4315	163	15	,	,	PUNCT
dpc-4315	163	16	leung	leung	PROPN
dpc-4315	163	17	dy	dy	PROPN
dpc-4315	163	18	.	.	PUNCT
dpc-4315	164	1	in	in	ADP
dpc-4315	164	2	vivo	vivo	ADJ
dpc-4315	164	3	expression	expression	NOUN
dpc-4315	164	4	of	of	ADP
dpc-4315	164	5	il-12	il-12	NOUN
dpc-4315	164	6	and	and	CCONJ
dpc-4315	164	7	il-13	il-13	X
dpc-4315	164	8	in	in	ADP
dpc-4315	164	9	atopic	atopic	NOUN
dpc-4315	164	10	dermatitis	dermatitis	NOUN
dpc-4315	164	11	.	.	PUNCT
dpc-4315	165	1	j	j	PROPN
dpc-4315	165	2	allergy	allergy	PROPN
dpc-4315	165	3	clin	clin	PROPN
dpc-4315	165	4	immunol	immunol	PROPN
dpc-4315	165	5	.	.	PUNCT
dpc-4315	165	6	1996	1996	NUM
dpc-4315	165	7	jul;98(1):225	jul;98(1):225	PUNCT
dpc-4315	165	8	-	-	PUNCT
dpc-4315	165	9	31	31	NUM
dpc-4315	165	10	.	.	PUNCT
dpc-4315	166	1	doi	doi	NOUN
dpc-4315	166	2	:	:	PUNCT
dpc-4315	166	3	10.1016	10.1016	NUM
dpc-4315	166	4	/	/	SYM
dpc-4315	166	5	s0091	s0091	NOUN
dpc-4315	166	6	-	-	PUNCT
dpc-4315	166	7	6749(96)70246	6749(96)70246	NUM
dpc-4315	166	8	-	-	SYM
dpc-4315	166	9	4	4	NUM
dpc-4315	166	10	.	.	PUNCT
dpc-4315	167	1	pmid	pmid	NOUN
dpc-4315	167	2	:	:	PUNCT
dpc-4315	167	3	8765838	8765838	NUM
dpc-4315	167	4	.	.	PUNCT
dpc-4315	168	1	15	15	NUM
dpc-4315	168	2	.	.	PUNCT
dpc-4315	169	1	zheng	zheng	PROPN
dpc-4315	169	2	t	t	PROPN
dpc-4315	169	3	,	,	PUNCT
dpc-4315	169	4	oh	oh	INTJ
dpc-4315	169	5	mh	mh	PROPN
dpc-4315	169	6	,	,	PUNCT
dpc-4315	169	7	oh	oh	INTJ
dpc-4315	169	8	sy	sy	INTJ
dpc-4315	169	9	,	,	PUNCT
dpc-4315	169	10	schroeder	schroeder	PROPN
dpc-4315	169	11	jt	jt	PROPN
dpc-4315	169	12	,	,	PUNCT
dpc-4315	169	13	glick	glick	PROPN
dpc-4315	169	14	ab	ab	PROPN
dpc-4315	169	15	,	,	PUNCT
dpc-4315	169	16	zhu	zhu	PROPN
dpc-4315	169	17	z.	z.	NOUN
dpc-4315	169	18	transgenic	transgenic	NOUN
dpc-4315	169	19	expression	expression	NOUN
dpc-4315	169	20	of	of	ADP
dpc-4315	169	21	interleukin-13	interleukin-13	PROPN
dpc-4315	169	22	in	in	ADP
dpc-4315	169	23	the	the	DET
dpc-4315	169	24	skin	skin	NOUN
dpc-4315	169	25	induces	induce	VERB
dpc-4315	169	26	a	a	DET
dpc-4315	169	27	pruritic	pruritic	ADJ
dpc-4315	169	28	dermatitis	dermatitis	NOUN
dpc-4315	169	29	and	and	CCONJ
dpc-4315	169	30	skin	skin	NOUN
dpc-4315	169	31	remodeling	remodeling	NOUN
dpc-4315	169	32	.	.	PUNCT
dpc-4315	170	1	j	j	PROPN
dpc-4315	170	2	invest	invest	VERB
dpc-4315	170	3	dermatol	dermatol	NOUN
dpc-4315	170	4	.	.	PUNCT
dpc-4315	171	1	2009	2009	NUM
dpc-4315	171	2	mar;129(3):742	mar;129(3):742	NOUN
dpc-4315	171	3	-	-	SYM
dpc-4315	171	4	51	51	NUM
dpc-4315	171	5	.	.	PUNCT
dpc-4315	172	1	doi	doi	NOUN
dpc-4315	172	2	:	:	PUNCT
dpc-4315	172	3	10.1038	10.1038	NUM
dpc-4315	172	4	/	/	SYM
dpc-4315	172	5	jid.2008.295	jid.2008.295	PROPN
dpc-4315	172	6	.	.	PUNCT
dpc-4315	173	1	epub	epub	PROPN
dpc-4315	173	2	2008	2008	NUM
dpc-4315	173	3	oct	oct	PROPN
dpc-4315	173	4	2	2	NUM
dpc-4315	173	5	.	.	PUNCT
dpc-4315	174	1	pmid	pmid	NOUN
dpc-4315	174	2	:	:	PUNCT
dpc-4315	174	3	18830273	18830273	NUM
dpc-4315	174	4	;	;	PUNCT
dpc-4315	174	5	pmcid	pmcid	ADJ
dpc-4315	174	6	:	:	PUNCT
dpc-4315	174	7	pmc4356214	pmc4356214	ADJ
dpc-4315	174	8	.	.	PUNCT
dpc-4315	175	1	16	16	NUM
dpc-4315	175	2	.	.	PUNCT
dpc-4315	176	1	hijnen	hijnen	NOUN
dpc-4315	176	2	d	d	NOUN
dpc-4315	176	3	,	,	PUNCT
dpc-4315	176	4	knol	knol	PROPN
dpc-4315	176	5	ef	ef	PROPN
dpc-4315	176	6	,	,	PUNCT
dpc-4315	176	7	gent	gent	NOUN
dpc-4315	176	8	yy	yy	PROPN
dpc-4315	176	9	,	,	PUNCT
dpc-4315	176	10	et	et	PROPN
dpc-4315	176	11	al	al	PROPN
dpc-4315	176	12	.	.	PUNCT
dpc-4315	176	13	cd8(1	cd8(1	NOUN
dpc-4315	176	14	)	)	PUNCT
dpc-4315	176	15	t	t	NOUN
dpc-4315	176	16	cells	cell	NOUN
dpc-4315	176	17	in	in	ADP
dpc-4315	176	18	the	the	DET
dpc-4315	176	19	lesional	lesional	ADJ
dpc-4315	176	20	skin	skin	NOUN
dpc-4315	176	21	of	of	ADP
dpc-4315	176	22	atopic	atopic	NOUN
dpc-4315	176	23	dermatitis	dermatitis	NOUN
dpc-4315	176	24	and	and	CCONJ
dpc-4315	176	25	psoriasis	psoriasis	NOUN
dpc-4315	176	26	patients	patient	NOUN
dpc-4315	176	27	are	be	AUX
dpc-4315	176	28	an	an	DET
dpc-4315	176	29	important	important	ADJ
dpc-4315	176	30	source	source	NOUN
dpc-4315	176	31	of	of	ADP
dpc-4315	176	32	ifn	ifn	PROPN
dpc-4315	176	33	-	-	PUNCT
dpc-4315	176	34	gamma	gamma	NOUN
dpc-4315	176	35	,	,	PUNCT
dpc-4315	176	36	il-13	il-13	NUM
dpc-4315	176	37	,	,	PUNCT
dpc-4315	176	38	il-17	il-17	X
dpc-4315	176	39	,	,	PUNCT
dpc-4315	176	40	and	and	CCONJ
dpc-4315	176	41	il-22	il-22	NOUN
dpc-4315	176	42	.	.	PUNCT
dpc-4315	177	1	j	j	PROPN
dpc-4315	177	2	invest	invest	VERB
dpc-4315	177	3	dermatol	dermatol	NOUN
dpc-4315	177	4	.	.	PUNCT
dpc-4315	178	1	2013;133(4):973–9	2013;133(4):973–9	NUM
dpc-4315	178	2	.	.	PUNCT
dpc-4315	179	1	17	17	NUM
dpc-4315	179	2	.	.	PUNCT
dpc-4315	180	1	burd	burd	PROPN
dpc-4315	180	2	pr	pr	PROPN
dpc-4315	180	3	,	,	PUNCT
dpc-4315	180	4	thompson	thompson	PROPN
dpc-4315	180	5	wc	wc	PROPN
dpc-4315	180	6	,	,	PUNCT
dpc-4315	180	7	max	max	PROPN
dpc-4315	180	8	ee	ee	PROPN
dpc-4315	180	9	,	,	PUNCT
dpc-4315	180	10	mills	mills	PROPN
dpc-4315	180	11	fc	fc	PROPN
dpc-4315	180	12	.	.	PROPN
dpc-4315	180	13	activated	activate	VERB
dpc-4315	180	14	mast	mast	NOUN
dpc-4315	180	15	cells	cell	NOUN
dpc-4315	180	16	produce	produce	VERB
dpc-4315	180	17	interleukin	interleukin	NOUN
dpc-4315	180	18	13	13	NUM
dpc-4315	180	19	.	.	PUNCT
dpc-4315	181	1	j	j	PROPN
dpc-4315	181	2	exp	exp	NOUN
dpc-4315	181	3	med	med	PROPN
dpc-4315	181	4	.	.	PUNCT
dpc-4315	181	5	1995	1995	NUM
dpc-4315	181	6	apr	apr	PROPN
dpc-4315	181	7	1;181(4	1;181(4	NUM
dpc-4315	181	8	):	):	PUNCT
dpc-4315	181	9	1373	1373	NUM
dpc-4315	181	10	-	-	SYM
dpc-4315	181	11	80	80	NUM
dpc-4315	181	12	.	.	PUNCT
dpc-4315	182	1	doi	doi	NOUN
dpc-4315	182	2	:	:	PUNCT
dpc-4315	182	3	10.1084	10.1084	NUM
dpc-4315	182	4	/	/	SYM
dpc-4315	182	5	jem.181.4.1373	jem.181.4.1373	PROPN
dpc-4315	182	6	.	.	PUNCT
dpc-4315	183	1	pmid	pmid	NOUN
dpc-4315	183	2	:	:	PUNCT
dpc-4315	183	3	7535336	7535336	NUM
dpc-4315	183	4	;	;	PUNCT
dpc-4315	183	5	pmcid	pmcid	NOUN
dpc-4315	183	6	:	:	PUNCT
dpc-4315	183	7	pmc2191950	pmc2191950	NOUN
dpc-4315	183	8	.	.	PUNCT
dpc-4315	184	1	18	18	NUM
dpc-4315	184	2	.	.	PUNCT
dpc-4315	184	3	li	li	PROPN
dpc-4315	184	4	h	h	PROPN
dpc-4315	184	5	,	,	PUNCT
dpc-4315	184	6	sim	sim	ADJ
dpc-4315	184	7	tc	tc	NOUN
dpc-4315	184	8	,	,	PUNCT
dpc-4315	184	9	alam	alam	PROPN
dpc-4315	184	10	r.	r.	PROPN
dpc-4315	184	11	il-13	il-13	PUNCT
dpc-4315	184	12	released	release	VERB
dpc-4315	184	13	by	by	ADP
dpc-4315	184	14	and	and	CCONJ
dpc-4315	184	15	localized	localize	VERB
dpc-4315	184	16	in	in	ADP
dpc-4315	184	17	human	human	ADJ
dpc-4315	184	18	basophils	basophil	NOUN
dpc-4315	184	19	.	.	PUNCT
dpc-4315	185	1	j	j	PROPN
dpc-4315	185	2	immunol	immunol	NOUN
dpc-4315	185	3	.	.	PUNCT
dpc-4315	186	1	1996	1996	NUM
dpc-4315	186	2	jun	jun	PROPN
dpc-4315	186	3	15;156(12):4833	15;156(12):4833	NUM
dpc-4315	186	4	-	-	SYM
dpc-4315	186	5	8	8	NUM
dpc-4315	186	6	.	.	PUNCT
dpc-4315	187	1	pmid	pmid	NOUN
dpc-4315	187	2	:	:	PUNCT
dpc-4315	187	3	8648131.schmid	8648131.schmid	NUM
dpc-4315	187	4	-	-	NOUN
dpc-4315	187	5	grendelmeier	grendelmeier	NOUN
dpc-4315	187	6	p	p	NOUN
dpc-4315	187	7	,	,	PUNCT
dpc-4315	187	8	altznauer	altznauer	NOUN
dpc-4315	187	9	f	f	PROPN
dpc-4315	187	10	,	,	PUNCT
dpc-4315	187	11	fischer	fischer	PROPN
dpc-4315	187	12	b	b	PROPN
dpc-4315	187	13	,	,	PUNCT
dpc-4315	187	14	et	et	PROPN
dpc-4315	187	15	al	al	PROPN
dpc-4315	187	16	.	.	PROPN
dpc-4315	187	17	eosinophils	eosinophil	VERB
dpc-4315	187	18	express	express	VERB
dpc-4315	187	19	functional	functional	ADJ
dpc-4315	187	20	il-13	il-13	ADP
dpc-4315	187	21	in	in	ADP
dpc-4315	187	22	eosinophilic	eosinophilic	ADJ
dpc-4315	187	23	inflammatory	inflammatory	ADJ
dpc-4315	187	24	diseases	disease	NOUN
dpc-4315	187	25	.	.	PUNCT
dpc-4315	188	1	j	j	PROPN
dpc-4315	188	2	immunol	immunol	NOUN
dpc-4315	188	3	.	.	PUNCT
dpc-4315	189	1	2002	2002	NUM
dpc-4315	189	2	;	;	PUNCT
dpc-4315	189	3	169(2):1021	169(2):1021	NUM
dpc-4315	189	4	-	-	SYM
dpc-4315	189	5	7	7	NUM
dpc-4315	189	6	.	.	NOUN
dpc-4315	189	7	19	19	NUM
dpc-4315	189	8	.	.	PUNCT
dpc-4315	190	1	oh	oh	INTJ
dpc-4315	190	2	mh	mh	PROPN
dpc-4315	190	3	,	,	PUNCT
dpc-4315	190	4	oh	oh	INTJ
dpc-4315	190	5	sy	sy	PROPN
dpc-4315	190	6	,	,	PUNCT
dpc-4315	190	7	yu	yu	PROPN
dpc-4315	190	8	j	j	PROPN
dpc-4315	190	9	,	,	PUNCT
dpc-4315	190	10	et	et	PROPN
dpc-4315	190	11	al	al	PROPN
dpc-4315	190	12	.	.	PROPN
dpc-4315	191	1	il-13	il-13	PUNCT
dpc-4315	191	2	induces	induce	VERB
dpc-4315	191	3	skin	skin	NOUN
dpc-4315	191	4	fibrosis	fibrosis	NOUN
dpc-4315	191	5	in	in	ADP
dpc-4315	191	6	atopic	atopic	NOUN
dpc-4315	191	7	dermatitis	dermatitis	NOUN
dpc-4315	191	8	by	by	ADP
dpc-4315	191	9	thymic	thymic	ADJ
dpc-4315	191	10	stromal	stromal	ADJ
dpc-4315	191	11	lymphopoietin	lymphopoietin	NOUN
dpc-4315	191	12	.	.	PUNCT
dpc-4315	192	1	j	j	PROPN
dpc-4315	192	2	immunol	immunol	NOUN
dpc-4315	192	3	.	.	PUNCT
dpc-4315	193	1	2011;186(12):7232	2011;186(12):7232	NUM
dpc-4315	193	2	-	-	PUNCT
dpc-4315	193	3	7242	7242	NUM
dpc-4315	193	4	.	.	PUNCT
dpc-4315	194	1	doi:10.4049	doi:10.4049	PROPN
dpc-4315	194	2	/	/	SYM
dpc-4315	194	3	jimmunol.1100504	jimmunol.1100504	PROPN
dpc-4315	194	4	20	20	NUM
dpc-4315	194	5	.	.	PUNCT
dpc-4315	195	1	howell	howell	PROPN
dpc-4315	195	2	md	md	PROPN
dpc-4315	195	3	,	,	PUNCT
dpc-4315	195	4	kim	kim	PROPN
dpc-4315	195	5	be	be	PROPN
dpc-4315	195	6	,	,	PUNCT
dpc-4315	195	7	gao	gao	PROPN
dpc-4315	195	8	p	p	X
dpc-4315	195	9	,	,	PUNCT
dpc-4315	195	10	grant	grant	PROPN
dpc-4315	195	11	av	av	PROPN
dpc-4315	195	12	,	,	PUNCT
dpc-4315	195	13	boguniewicz	boguniewicz	PROPN
dpc-4315	195	14	m	m	PROPN
dpc-4315	195	15	,	,	PUNCT
dpc-4315	195	16	debenedetto	debenedetto	PROPN
dpc-4315	195	17	a	a	X
dpc-4315	195	18	,	,	PUNCT
dpc-4315	195	19	schneider	schneider	PROPN
dpc-4315	195	20	l	l	PROPN
dpc-4315	195	21	,	,	PUNCT
dpc-4315	195	22	beck	beck	PROPN
dpc-4315	195	23	la	la	PROPN
dpc-4315	195	24	,	,	PUNCT
dpc-4315	195	25	barnes	barnes	PROPN
dpc-4315	195	26	kc	kc	PROPN
dpc-4315	195	27	,	,	PUNCT
dpc-4315	195	28	leung	leung	PROPN
dpc-4315	195	29	dy	dy	PROPN
dpc-4315	195	30	.	.	PROPN
dpc-4315	195	31	cytokine	cytokine	ADJ
dpc-4315	195	32	modulation	modulation	NOUN
dpc-4315	195	33	of	of	ADP
dpc-4315	195	34	atopic	atopic	NOUN
dpc-4315	195	35	dermatitis	dermatitis	NOUN
dpc-4315	195	36	filaggrin	filaggrin	NOUN
dpc-4315	195	37	skin	skin	NOUN
dpc-4315	195	38	expression	expression	NOUN
dpc-4315	195	39	.	.	PUNCT
dpc-4315	196	1	j	j	PROPN
dpc-4315	196	2	allergy	allergy	PROPN
dpc-4315	196	3	clin	clin	PROPN
dpc-4315	196	4	immunol	immunol	PROPN
dpc-4315	196	5	.	.	PUNCT
dpc-4315	197	1	2009	2009	NUM
dpc-4315	197	2	sep;124(3	sep;124(3	NUM
dpc-4315	197	3	suppl	suppl	PROPN
dpc-4315	197	4	2):r7	2):r7	NUM
dpc-4315	197	5	-	-	PUNCT
dpc-4315	197	6	r12	r12	NOUN
dpc-4315	197	7	.	.	PUNCT
dpc-4315	198	1	doi	doi	NOUN
dpc-4315	198	2	:	:	PUNCT
dpc-4315	198	3	10.1016	10.1016	NUM
dpc-4315	198	4	/	/	SYM
dpc-4315	198	5	j.jaci.2009.07.012	j.jaci.2009.07.012	PROPN
dpc-4315	198	6	.	.	PUNCT
dpc-4315	199	1	pmid	pmid	NOUN
dpc-4315	199	2	:	:	PUNCT
dpc-4315	199	3	19720210	19720210	NUM
dpc-4315	199	4	.	.	PUNCT
dpc-4315	200	1	21	21	NUM
dpc-4315	200	2	.	.	X
dpc-4315	201	1	kim	kim	PROPN
dpc-4315	201	2	be	be	PROPN
dpc-4315	201	3	,	,	PUNCT
dpc-4315	201	4	leung	leung	PROPN
dpc-4315	201	5	dy	dy	PROPN
dpc-4315	201	6	,	,	PUNCT
dpc-4315	201	7	boguniewicz	boguniewicz	PROPN
dpc-4315	201	8	m	m	PROPN
dpc-4315	201	9	,	,	PUNCT
dpc-4315	201	10	howell	howell	PROPN
dpc-4315	201	11	md	md	PROPN
dpc-4315	201	12	.	.	PROPN
dpc-4315	201	13	loricrin	loricrin	PROPN
dpc-4315	201	14	and	and	CCONJ
dpc-4315	201	15	involucrin	involucrin	ADJ
dpc-4315	201	16	expression	expression	NOUN
dpc-4315	201	17	is	be	AUX
dpc-4315	201	18	down	down	ADV
dpc-4315	201	19	-	-	PUNCT
dpc-4315	201	20	regulated	regulate	VERB
dpc-4315	201	21	by	by	ADP
dpc-4315	201	22	th2	th2	PROPN
dpc-4315	201	23	cytokines	cytokine	NOUN
dpc-4315	201	24	through	through	ADP
dpc-4315	201	25	stat-6	stat-6	NUM
dpc-4315	201	26	.	.	PUNCT
dpc-4315	201	27	clin	clin	PROPN
dpc-4315	201	28	immunol	immunol	PROPN
dpc-4315	201	29	.	.	PUNCT
dpc-4315	202	1	2008	2008	NUM
dpc-4315	202	2	mar;126(3):332	mar;126(3):332	NOUN
dpc-4315	202	3	-	-	PUNCT
dpc-4315	202	4	7	7	NUM
dpc-4315	202	5	.	.	PUNCT
dpc-4315	202	6	doi	doi	NOUN
dpc-4315	202	7	:	:	PUNCT
dpc-4315	202	8	10.1016	10.1016	NUM
dpc-4315	202	9	/j.clim.2007.11.006	/j.clim.2007.11.006	NOUN
dpc-4315	202	10	.	.	PUNCT
dpc-4315	203	1	epub	epub	PROPN
dpc-4315	203	2	2007	2007	NUM
dpc-4315	203	3	dec	dec	PROPN
dpc-4315	203	4	31	31	NUM
dpc-4315	203	5	.	.	PUNCT
dpc-4315	204	1	pmid	pmid	NOUN
dpc-4315	204	2	:	:	PUNCT
dpc-4315	204	3	18166499	18166499	NUM
dpc-4315	204	4	;	;	PUNCT
dpc-4315	204	5	pmcid	pmcid	ADJ
dpc-4315	204	6	:	:	PUNCT
dpc-4315	204	7	pmc2275206	pmc2275206	NOUN
dpc-4315	204	8	.	.	PUNCT
dpc-4315	205	1	22	22	NUM
dpc-4315	205	2	.	.	PUNCT
dpc-4315	206	1	oetjen	oetjen	PROPN
dpc-4315	206	2	lk	lk	PROPN
dpc-4315	206	3	,	,	PUNCT
dpc-4315	206	4	mack	mack	PROPN
dpc-4315	206	5	mr	mr	PROPN
dpc-4315	206	6	,	,	PUNCT
dpc-4315	206	7	feng	feng	PROPN
dpc-4315	206	8	j	j	PROPN
dpc-4315	206	9	,	,	PUNCT
dpc-4315	206	10	et	et	PROPN
dpc-4315	206	11	al	al	PROPN
dpc-4315	206	12	.	.	PUNCT
dpc-4315	207	1	sensory	sensory	ADJ
dpc-4315	207	2	neurons	neuron	NOUN
dpc-4315	207	3	co	co	ADJ
dpc-4315	207	4	-	-	ADJ
dpc-4315	207	5	opt	opt	ADJ
dpc-4315	207	6	classical	classical	ADJ
dpc-4315	207	7	immune	immune	NOUN
dpc-4315	207	8	signaling	signal	VERB
dpc-4315	207	9	pathways	pathway	NOUN
dpc-4315	207	10	to	to	PART
dpc-4315	207	11	mediate	mediate	VERB
dpc-4315	207	12	chronic	chronic	ADJ
dpc-4315	207	13	itch	itch	NOUN
dpc-4315	207	14	.	.	PUNCT
dpc-4315	208	1	cell	cell	NOUN
dpc-4315	208	2	.	.	PUNCT
dpc-4315	209	1	2017;171(1):217	2017;171(1):217	X
dpc-4315	209	2	-	-	PUNCT
dpc-4315	209	3	228.e13	228.e13	NUM
dpc-4315	209	4	.	.	PUNCT
dpc-4315	209	5	doi:10.1016	doi:10.1016	PROPN
dpc-4315	209	6	/	/	SYM
dpc-4315	209	7	j.cell.2017.08.006	j.cell.2017.08.006	PROPN
dpc-4315	209	8	23	23	NUM
dpc-4315	209	9	.	.	PUNCT
dpc-4315	210	1	bieber	bieber	PROPN
dpc-4315	210	2	t.	t.	PROPN
dpc-4315	210	3	et	et	PROPN
dpc-4315	210	4	al	al	PROPN
dpc-4315	210	5	.	.	PUNCT
dpc-4315	211	1	interleukin-13	interleukin-13	PROPN
dpc-4315	211	2	:	:	PUNCT
dpc-4315	211	3	targeting	target	VERB
dpc-4315	211	4	an	an	DET
dpc-4315	211	5	underestimated	underestimated	ADJ
dpc-4315	211	6	cytokine	cytokine	NOUN
dpc-4315	211	7	in	in	ADP
dpc-4315	211	8	atopic	atopic	NOUN
dpc-4315	211	9	dermatitis	dermatitis	NOUN
dpc-4315	211	10	.	.	PUNCT
dpc-4315	212	1	allergy	allergy	NOUN
dpc-4315	212	2	.	.	PUNCT
dpc-4315	213	1	2020	2020	NUM
dpc-4315	214	1	jan;75(1):54	jan;75(1):54	PROPN
dpc-4315	214	2	-	-	PUNCT
dpc-4315	214	3	62	62	PROPN
dpc-4315	214	4	.	.	PUNCT
dpc-4315	215	1	doi	doi	NOUN
dpc-4315	215	2	:	:	PUNCT
dpc-4315	215	3	10.1111	10.1111	NUM
dpc-4315	215	4	/	/	SYM
dpc-4315	215	5	all.13954	all.13954	ADP
dpc-4315	215	6	.	.	PUNCT
dpc-4315	216	1	epub	epub	PROPN
dpc-4315	216	2	2019	2019	NUM
dpc-4315	216	3	jul	jul	PROPN
dpc-4315	216	4	15	15	NUM
dpc-4315	216	5	.	.	PUNCT
dpc-4315	217	1	pmid	pmid	NOUN
dpc-4315	217	2	:	:	PUNCT
dpc-4315	217	3	31230370	31230370	NUM
dpc-4315	217	4	.	.	PUNCT
dpc-4315	218	1	24	24	NUM
dpc-4315	218	2	.	.	PUNCT
dpc-4315	219	1	tollenaere	tollenaere	NUM
dpc-4315	219	2	max	max	PROPN
dpc-4315	219	3	,	,	PUNCT
dpc-4315	219	4	mølck	mølck	NOUN
dpc-4315	219	5	c	c	NOUN
dpc-4315	219	6	,	,	PUNCT
dpc-4315	219	7	henderson	henderson	PROPN
dpc-4315	219	8	i	i	PROPN
dpc-4315	219	9	,	,	PUNCT
dpc-4315	219	10	pollack	pollack	PROPN
dpc-4315	219	11	s	s	PROPN
dpc-4315	219	12	,	,	PUNCT
dpc-4315	219	13	addis	addis	PROPN
dpc-4315	219	14	p	p	PROPN
dpc-4315	219	15	,	,	PUNCT
dpc-4315	219	16	petersen	petersen	PROPN
dpc-4315	219	17	hh	hh	PROPN
dpc-4315	219	18	,	,	PUNCT
dpc-4315	219	19	norsgaard	norsgaard	PROPN
dpc-4315	219	20	h.	h.	PROPN
dpc-4315	219	21	et	et	PROPN
dpc-4315	219	22	al	al	PROPN
dpc-4315	219	23	.	.	PROPN
dpc-4315	219	24	tralokinumab	tralokinumab	NOUN
dpc-4315	219	25	effectively	effectively	ADV
dpc-4315	219	26	disrupts	disrupt	VERB
dpc-4315	219	27	the	the	DET
dpc-4315	219	28	il-13	il-13	PRON
dpc-4315	219	29	/	/	SYM
dpc-4315	219	30	il-13rα1	il-13rα1	PROPN
dpc-4315	219	31	/	/	SYM
dpc-4315	219	32	il-4rα	il-4rα	PROPN
dpc-4315	219	33	signaling	signal	VERB
dpc-4315	219	34	complex	complex	NOUN
dpc-4315	219	35	but	but	CCONJ
dpc-4315	219	36	not	not	PART
dpc-4315	219	37	the	the	DET
dpc-4315	219	38	il-13	il-13	PRON
dpc-4315	219	39	/	/	SYM
dpc-4315	219	40	il-13rα2	il-13rα2	PROPN
dpc-4315	219	41	complex	complex	NOUN
dpc-4315	219	42	.	.	PUNCT
dpc-4315	220	1	jid	jid	PROPN
dpc-4315	220	2	innov	innov	PROPN
dpc-4315	220	3	.	.	PUNCT
dpc-4315	221	1	2023	2023	NUM
dpc-4315	221	2	jul	jul	PROPN
dpc-4315	221	3	4;3(5):100214	4;3(5):100214	NUM
dpc-4315	221	4	.	.	PUNCT
dpc-4315	222	1	doi	doi	NOUN
dpc-4315	222	2	:	:	PUNCT
dpc-4315	222	3	10.1016	10.1016	NUM
dpc-4315	222	4	/	/	SYM
dpc-4315	222	5	j.xjidi.2023.100214	j.xjidi.2023.100214	PROPN
dpc-4315	222	6	.	.	PUNCT
dpc-4315	223	1	pmid	pmid	NOUN
dpc-4315	223	2	:	:	PUNCT
dpc-4315	223	3	37554517	37554517	NUM
dpc-4315	223	4	;	;	PUNCT
dpc-4315	223	5	pmcid	pmcid	NOUN
dpc-4315	223	6	:	:	PUNCT
dpc-4315	223	7	pmc10405097	pmc10405097	ADJ
dpc-4315	223	8	.	.	PUNCT
dpc-4315	224	1	25	25	NUM
dpc-4315	224	2	.	.	PUNCT
dpc-4315	225	1	li	li	PROPN
dpc-4315	225	2	y	y	PROPN
dpc-4315	225	3	,	,	PUNCT
dpc-4315	225	4	li	li	PROPN
dpc-4315	225	5	h	h	PROPN
dpc-4315	225	6	,	,	PUNCT
dpc-4315	225	7	yang	yang	PROPN
dpc-4315	225	8	f	f	PROPN
dpc-4315	225	9	,	,	PUNCT
dpc-4315	225	10	smith	smith	NOUN
dpc-4315	225	11	-	-	PUNCT
dpc-4315	225	12	gill	gill	PROPN
dpc-4315	225	13	s	s	PART
dpc-4315	225	14	,	,	PUNCT
dpc-4315	225	15	mariuzza	mariuzza	PROPN
dpc-4315	225	16	ra	ra	PROPN
dpc-4315	225	17	.	.	PROPN
dpc-4315	225	18	et	et	PROPN
dpc-4315	226	1	al	al	PROPN
dpc-4315	226	2	.	.	PUNCT
dpc-4315	227	1	x	x	X
dpc-4315	227	2	-	-	PUNCT
dpc-4315	227	3	ray	ray	NOUN
dpc-4315	227	4	snapshots	snapshot	NOUN
dpc-4315	227	5	of	of	ADP
dpc-4315	227	6	the	the	DET
dpc-4315	227	7	maturation	maturation	NOUN
dpc-4315	227	8	of	of	ADP
dpc-4315	227	9	an	an	DET
dpc-4315	227	10	antibody	antibody	NOUN
dpc-4315	227	11	response	response	NOUN
dpc-4315	227	12	to	to	ADP
dpc-4315	227	13	a	a	DET
dpc-4315	227	14	protein	protein	NOUN
dpc-4315	227	15	antigen	antigen	ADV
dpc-4315	227	16	.	.	PUNCT
dpc-4315	228	1	nat	nat	PROPN
dpc-4315	228	2	struct	struct	NOUN
dpc-4315	228	3	mol	mol	ADP
dpc-4315	228	4	biol	biol	NOUN
dpc-4315	228	5	.	.	PUNCT
dpc-4315	229	1	2003;10:482–488	2003;10:482–488	NUM
dpc-4315	229	2	.	.	PUNCT
dpc-4315	230	1	26	26	NUM
dpc-4315	230	2	.	.	PUNCT
dpc-4315	231	1	fransson	fransson	PROPN
dpc-4315	231	2	f	f	PROPN
dpc-4315	231	3	,	,	PUNCT
dpc-4315	231	4	teplyakov	teplyakov	X
dpc-4315	231	5	a	a	X
dpc-4315	231	6	,	,	PUNCT
dpc-4315	231	7	raghunathan	raghunathan	VERB
dpc-4315	231	8	g	g	NOUN
dpc-4315	231	9	,	,	PUNCT
dpc-4315	231	10	et	et	PROPN
dpc-4315	231	11	al	al	PROPN
dpc-4315	231	12	.	.	PUNCT
dpc-4315	232	1	human	human	ADJ
dpc-4315	232	2	framework	framework	NOUN
dpc-4315	232	3	adaptation	adaptation	NOUN
dpc-4315	232	4	of	of	ADP
dpc-4315	232	5	a	a	DET
dpc-4315	232	6	mouse	mouse	NOUN
dpc-4315	232	7	anti	anti	ADJ
dpc-4315	232	8	-	-	ADJ
dpc-4315	232	9	human	human	ADJ
dpc-4315	232	10	il-13	il-13	VERB
dpc-4315	232	11	antibody	antibody	NOUN
dpc-4315	232	12	.	.	PUNCT
dpc-4315	233	1	j	j	PROPN
dpc-4315	233	2	mol	mol	PROPN
dpc-4315	233	3	biol	biol	PROPN
dpc-4315	233	4	.	.	PUNCT
dpc-4315	234	1	2010;398	2010;398	NUM
dpc-4315	234	2	:	:	PUNCT
dpc-4315	235	1	214–231	214–231	NUM
dpc-4315	235	2	.	.	PUNCT
dpc-4315	236	1	27	27	NUM
dpc-4315	236	2	.	.	PUNCT
dpc-4315	237	1	wollenberg	wollenberg	PROPN
dpc-4315	237	2	a	a	PROPN
dpc-4315	237	3	,	,	PUNCT
dpc-4315	237	4	blauvelt	blauvelt	PROPN
dpc-4315	237	5	a	a	DET
dpc-4315	237	6	,	,	PUNCT
dpc-4315	237	7	guttman	guttman	ADJ
dpc-4315	237	8	-	-	PUNCT
dpc-4315	237	9	yassky	yassky	NOUN
dpc-4315	237	10	e	e	NOUN
dpc-4315	237	11	,	,	PUNCT
dpc-4315	237	12	et	et	PROPN
dpc-4315	237	13	al	al	PROPN
dpc-4315	237	14	.	.	PROPN
dpc-4315	237	15	tralokinumab	tralokinumab	NOUN
dpc-4315	237	16	for	for	ADP
dpc-4315	237	17	moderate	moderate	ADJ
dpc-4315	237	18	-	-	PUNCT
dpc-4315	237	19	to	to	ADP
dpc-4315	237	20	-	-	PUNCT
dpc-4315	237	21	severe	severe	ADJ
dpc-4315	237	22	atopic	atopic	NOUN
dpc-4315	237	23	dermatitis	dermatitis	NOUN
dpc-4315	237	24	:	:	PUNCT
dpc-4315	237	25	results	result	VERB
dpc-4315	237	26	from	from	ADP
dpc-4315	237	27	two	two	NUM
dpc-4315	237	28	52	52	NUM
dpc-4315	237	29	-	-	PUNCT
dpc-4315	237	30	week	week	NOUN
dpc-4315	237	31	,	,	PUNCT
dpc-4315	237	32	randomized	randomize	VERB
dpc-4315	237	33	,	,	PUNCT
dpc-4315	237	34	double	double	ADJ
dpc-4315	237	35	-	-	PUNCT
dpc-4315	237	36	blind	blind	ADJ
dpc-4315	237	37	,	,	PUNCT
dpc-4315	237	38	multicentre	multicentre	NOUN
dpc-4315	237	39	,	,	PUNCT
dpc-4315	237	40	offers	offer	VERB
dpc-4315	237	41	long	long	ADJ
dpc-4315	237	42	-	-	PUNCT
dpc-4315	237	43	term	term	NOUN
dpc-4315	237	44	superiority	superiority	NOUN
dpc-4315	237	45	over	over	ADP
dpc-4315	237	46	other	other	ADJ
dpc-4315	237	47	therapies	therapy	NOUN
dpc-4315	237	48	,	,	PUNCT
dpc-4315	237	49	based	base	VERB
dpc-4315	237	50	on	on	ADP
dpc-4315	237	51	excellent	excellent	ADJ
dpc-4315	237	52	safety	safety	NOUN
dpc-4315	237	53	and	and	CCONJ
dpc-4315	237	54	efficacy	efficacy	NOUN
dpc-4315	237	55	profile	profile	NOUN
dpc-4315	237	56	.	.	PUNCT
dpc-4315	238	1	data	datum	NOUN
dpc-4315	238	2	availability	availability	NOUN
dpc-4315	238	3	statement	statement	NOUN
dpc-4315	238	4	data	datum	NOUN
dpc-4315	238	5	sharing	sharing	NOUN
dpc-4315	238	6	is	be	AUX
dpc-4315	238	7	not	not	PART
dpc-4315	238	8	applicable	applicable	ADJ
dpc-4315	238	9	to	to	ADP
dpc-4315	238	10	this	this	DET
dpc-4315	238	11	article	article	NOUN
dpc-4315	238	12	as	as	SCONJ
dpc-4315	238	13	no	no	DET
dpc-4315	238	14	new	new	ADJ
dpc-4315	238	15	data	datum	NOUN
dpc-4315	238	16	were	be	AUX
dpc-4315	238	17	created	create	VERB
dpc-4315	238	18	or	or	CCONJ
dpc-4315	238	19	analyzed	analyze	VERB
dpc-4315	238	20	in	in	ADP
dpc-4315	238	21	this	this	DET
dpc-4315	238	22	study	study	NOUN
dpc-4315	238	23	.	.	PUNCT
dpc-4315	239	1	references	reference	NOUN
dpc-4315	239	2	1	1	NUM
dpc-4315	239	3	.	.	PUNCT
dpc-4315	240	1	gargiulo	gargiulo	PROPN
dpc-4315	240	2	l	l	NOUN
dpc-4315	240	3	,	,	PUNCT
dpc-4315	240	4	ibba	ibba	ADJ
dpc-4315	240	5	l	l	NOUN
dpc-4315	240	6	,	,	PUNCT
dpc-4315	240	7	vignoli	vignoli	PROPN
dpc-4315	240	8	ca	ca	PROPN
dpc-4315	240	9	,	,	PUNCT
dpc-4315	240	10	et	et	PROPN
dpc-4315	240	11	al	al	PROPN
dpc-4315	240	12	.	.	PROPN
dpc-4315	240	13	tralokinumab	tralokinumab	NOUN
dpc-4315	240	14	rapidly	rapidly	ADV
dpc-4315	240	15	improves	improve	VERB
dpc-4315	240	16	subjective	subjective	ADJ
dpc-4315	240	17	symptoms	symptom	NOUN
dpc-4315	240	18	and	and	CCONJ
dpc-4315	240	19	quality	quality	NOUN
dpc-4315	240	20	of	of	ADP
dpc-4315	240	21	life	life	NOUN
dpc-4315	240	22	in	in	ADP
dpc-4315	240	23	patients	patient	NOUN
dpc-4315	240	24	with	with	ADP
dpc-4315	240	25	moderate	moderate	ADJ
dpc-4315	240	26	-	-	PUNCT
dpc-4315	240	27	to	to	ADP
dpc-4315	240	28	-	-	PUNCT
dpc-4315	240	29	severe	severe	ADJ
dpc-4315	240	30	atopic	atopic	NOUN
dpc-4315	240	31	dermatitis	dermatitis	NOUN
dpc-4315	240	32	:	:	PUNCT
dpc-4315	240	33	a	a	DET
dpc-4315	240	34	real	real	ADJ
dpc-4315	240	35	-	-	PUNCT
dpc-4315	240	36	life	life	NOUN
dpc-4315	240	37	16	16	NUM
dpc-4315	240	38	-	-	PUNCT
dpc-4315	240	39	week	week	NOUN
dpc-4315	240	40	experience	experience	NOUN
dpc-4315	240	41	.	.	PUNCT
dpc-4315	241	1	j	j	PROPN
dpc-4315	241	2	dermatolog	dermatolog	PROPN
dpc-4315	241	3	treat	treat	NOUN
dpc-4315	241	4	.	.	PUNCT
dpc-4315	242	1	2023	2023	NUM
dpc-4315	242	2	dec;34(1):2216815	dec;34(1):2216815	PROPN
dpc-4315	242	3	.	.	PROPN
dpc-4315	242	4	doi	doi	PROPN
dpc-4315	242	5	:	:	PUNCT
dpc-4315	242	6	10.1080/09546634.2023.2216815	10.1080/09546634.2023.2216815	NUM
dpc-4315	242	7	.	.	PUNCT
dpc-4315	243	1	pmid	pmid	NOUN
dpc-4315	243	2	:	:	PUNCT
dpc-4315	243	3	37246920	37246920	NUM
dpc-4315	243	4	.	.	PUNCT
dpc-4315	244	1	2	2	X
dpc-4315	244	2	.	.	X
dpc-4315	244	3	spergel	spergel	NOUN
dpc-4315	244	4	,	,	PUNCT
dpc-4315	244	5	jonathan	jonathan	PROPN
dpc-4315	244	6	m	m	PROPN
dpc-4315	244	7	,	,	PUNCT
dpc-4315	244	8	and	and	CCONJ
dpc-4315	244	9	amy	amy	PROPN
dpc-4315	244	10	s	s	PROPN
dpc-4315	244	11	paller	paller	NOUN
dpc-4315	244	12	.	.	PUNCT
dpc-4315	245	1	“	"	PUNCT
dpc-4315	245	2	atopic	atopic	NOUN
dpc-4315	245	3	dermatitis	dermatitis	NOUN
dpc-4315	245	4	and	and	CCONJ
dpc-4315	245	5	the	the	DET
dpc-4315	245	6	atopic	atopic	NOUN
dpc-4315	245	7	march	march	NOUN
dpc-4315	245	8	.	.	PUNCT
dpc-4315	245	9	”	"	PUNCT
dpc-4315	246	1	the	the	DET
dpc-4315	246	2	journal	journal	NOUN
dpc-4315	246	3	of	of	ADP
dpc-4315	246	4	allergy	allergy	NOUN
dpc-4315	246	5	and	and	CCONJ
dpc-4315	246	6	clinical	clinical	ADJ
dpc-4315	246	7	immunology	immunology	NOUN
dpc-4315	246	8	vol	vol	NOUN
dpc-4315	246	9	.	.	PUNCT
dpc-4315	247	1	112,6	112,6	NUM
dpc-4315	247	2	suppl	suppl	ADJ
dpc-4315	247	3	(	(	PUNCT
dpc-4315	247	4	2003	2003	NUM
dpc-4315	247	5	):	):	PUNCT
dpc-4315	247	6	s118	s118	PROPN
dpc-4315	247	7	-	-	SYM
dpc-4315	247	8	27	27	NUM
dpc-4315	247	9	.	.	PUNCT
dpc-4315	248	1	doi:10.1016	doi:10.1016	PROPN
dpc-4315	248	2	/	/	SYM
dpc-4315	248	3	j.jaci.2003	j.jaci.2003	PROPN
dpc-4315	248	4	.09.033	.09.033	PROPN
dpc-4315	248	5	3	3	X
dpc-4315	248	6	.	.	X
dpc-4315	248	7	tanei	tanei	PROPN
dpc-4315	248	8	r.	r.	PROPN
dpc-4315	248	9	atopic	atopic	PROPN
dpc-4315	248	10	dermatitis	dermatitis	PROPN
dpc-4315	248	11	in	in	ADP
dpc-4315	248	12	the	the	DET
dpc-4315	248	13	elderly	elderly	ADJ
dpc-4315	248	14	.	.	PUNCT
dpc-4315	249	1	inflamm	inflamm	PROPN
dpc-4315	249	2	allergy	allergy	PROPN
dpc-4315	249	3	drug	drug	NOUN
dpc-4315	249	4	targets	target	NOUN
dpc-4315	249	5	.	.	PUNCT
dpc-4315	250	1	2009	2009	NUM
dpc-4315	250	2	dec;8(5):398	dec;8(5):398	PROPN
dpc-4315	250	3	-	-	PUNCT
dpc-4315	250	4	404	404	PROPN
dpc-4315	250	5	.	.	PUNCT
dpc-4315	251	1	doi	doi	NOUN
dpc-4315	251	2	:	:	PUNCT
dpc-4315	251	3	10.2174/1871528	10.2174/1871528	NUM
dpc-4315	251	4	110908050398	110908050398	NUM
dpc-4315	251	5	.	.	PUNCT
dpc-4315	252	1	pmid	pmid	NOUN
dpc-4315	252	2	:	:	PUNCT
dpc-4315	252	3	20025588	20025588	NUM
dpc-4315	252	4	.	.	PUNCT
dpc-4315	253	1	4	4	X
dpc-4315	253	2	.	.	X
dpc-4315	253	3	nettis	nettis	NOUN
dpc-4315	253	4	,	,	PUNCT
dpc-4315	253	5	e	e	X
dpc-4315	253	6	et	et	PROPN
dpc-4315	253	7	al	al	PROPN
dpc-4315	253	8	.	.	PUNCT
dpc-4315	254	1	“	"	PUNCT
dpc-4315	254	2	a	a	DET
dpc-4315	254	3	multicenter	multicenter	ADJ
dpc-4315	254	4	study	study	NOUN
dpc-4315	254	5	on	on	ADP
dpc-4315	254	6	the	the	DET
dpc-4315	254	7	prevalence	prevalence	NOUN
dpc-4315	254	8	of	of	ADP
dpc-4315	254	9	clinical	clinical	ADJ
dpc-4315	254	10	patterns	pattern	NOUN
dpc-4315	254	11	and	and	CCONJ
dpc-4315	254	12	clinical	clinical	ADJ
dpc-4315	254	13	phenotypes	phenotype	NOUN
dpc-4315	254	14	in	in	ADP
dpc-4315	254	15	adult	adult	NOUN
dpc-4315	254	16	atopic	atopic	NOUN
dpc-4315	254	17	dermatitis	dermatitis	NOUN
dpc-4315	254	18	.	.	PUNCT
dpc-4315	254	19	”	"	PUNCT
dpc-4315	255	1	journal	journal	NOUN
dpc-4315	255	2	of	of	ADP
dpc-4315	255	3	investigational	investigational	ADJ
dpc-4315	255	4	allergology	allergology	NOUN
dpc-4315	255	5	&	&	CCONJ
dpc-4315	255	6	clinical	clinical	ADJ
dpc-4315	255	7	immunology	immunology	NOUN
dpc-4315	255	8	vol	vol	NOUN
dpc-4315	255	9	.	.	PUNCT
dpc-4315	256	1	30,6	30,6	NUM
dpc-4315	256	2	(	(	PUNCT
dpc-4315	256	3	2020	2020	NUM
dpc-4315	256	4	):	):	PUNCT
dpc-4315	256	5	448	448	NUM
dpc-4315	256	6	-	-	SYM
dpc-4315	256	7	450	450	NUM
dpc-4315	256	8	.	.	PUNCT
dpc-4315	256	9	doi:10.18176	doi:10.18176	NOUN
dpc-4315	256	10	/	/	SYM
dpc-4315	256	11	jiaci.0519	jiaci.0519	PROPN
dpc-4315	256	12	5	5	NUM
dpc-4315	256	13	.	.	PUNCT
dpc-4315	257	1	morelli	morelli	PROPN
dpc-4315	257	2	p	p	PROPN
dpc-4315	257	3	,	,	PUNCT
dpc-4315	257	4	gaspari	gaspari	PROPN
dpc-4315	257	5	m	m	PROPN
dpc-4315	257	6	,	,	PUNCT
dpc-4315	257	7	gabriele	gabriele	PROPN
dpc-4315	257	8	c	c	PROPN
dpc-4315	257	9	et	et	PROPN
dpc-4315	257	10	al	al	PROPN
dpc-4315	257	11	.	.	PROPN
dpc-4315	258	1	proteomic	proteomic	ADJ
dpc-4315	258	2	analysis	analysis	NOUN
dpc-4315	258	3	from	from	ADP
dpc-4315	258	4	skin	skin	NOUN
dpc-4315	258	5	swabs	swab	NOUN
dpc-4315	258	6	reveals	reveal	VERB
dpc-4315	258	7	a	a	DET
dpc-4315	258	8	new	new	ADJ
dpc-4315	258	9	set	set	NOUN
dpc-4315	258	10	of	of	ADP
dpc-4315	258	11	proteins	protein	NOUN
dpc-4315	258	12	identifying	identify	VERB
dpc-4315	258	13	skin	skin	NOUN
dpc-4315	258	14	impairment	impairment	NOUN
dpc-4315	258	15	in	in	ADP
dpc-4315	258	16	atopic	atopic	NOUN
dpc-4315	258	17	dermatitis	dermatitis	NOUN
dpc-4315	258	18	.	.	PUNCT
dpc-4315	259	1	exp	exp	NOUN
dpc-4315	259	2	dermatol	dermatol	NOUN
dpc-4315	259	3	.	.	PUNCT
dpc-4315	260	1	2021	2021	NUM
dpc-4315	260	2	jun;30(6	jun;30(6	NOUN
dpc-4315	260	3	):	):	PUNCT
dpc-4315	260	4	811	811	NUM
dpc-4315	260	5	-	-	SYM
dpc-4315	260	6	819	819	NUM
dpc-4315	260	7	.	.	NOUN
dpc-4315	260	8	6	6	NUM
dpc-4315	260	9	.	.	X
dpc-4315	260	10	bonnart	bonnart	PROPN
dpc-4315	260	11	c	c	PROPN
dpc-4315	260	12	,	,	PUNCT
dpc-4315	260	13	deraison	deraison	NOUN
dpc-4315	260	14	c	c	NOUN
dpc-4315	260	15	,	,	PUNCT
dpc-4315	260	16	lacroix	lacroix	PROPN
dpc-4315	260	17	m	m	PROPN
dpc-4315	260	18	,	,	PUNCT
dpc-4315	260	19	et	et	PROPN
dpc-4315	260	20	al	al	PROPN
dpc-4315	260	21	.	.	PROPN
dpc-4315	260	22	elastase	elastase	PROPN
dpc-4315	260	23	2	2	NUM
dpc-4315	260	24	is	be	AUX
dpc-4315	260	25	expressed	express	VERB
dpc-4315	260	26	in	in	ADP
dpc-4315	260	27	human	human	ADJ
dpc-4315	260	28	and	and	CCONJ
dpc-4315	260	29	mouse	mouse	NOUN
dpc-4315	260	30	epidermis	epidermis	NOUN
dpc-4315	260	31	and	and	CCONJ
dpc-4315	260	32	impairs	impair	VERB
dpc-4315	260	33	skin	skin	NOUN
dpc-4315	260	34	barrier	barrier	NOUN
dpc-4315	260	35	function	function	NOUN
dpc-4315	260	36	in	in	ADP
dpc-4315	260	37	netherton	netherton	PROPN
dpc-4315	260	38	syndrome	syndrome	NOUN
dpc-4315	260	39	through	through	ADP
dpc-4315	260	40	filaggrin	filaggrin	NOUN
dpc-4315	260	41	and	and	CCONJ
dpc-4315	260	42	lipid	lipid	NOUN
dpc-4315	260	43	misprocessing	misprocesse	VERB
dpc-4315	260	44	.	.	PUNCT
dpc-4315	261	1	j	j	PROPN
dpc-4315	261	2	clin	clin	PROPN
dpc-4315	261	3	invest	invest	VERB
dpc-4315	261	4	.	.	PUNCT
dpc-4315	262	1	2010;120:871–82	2010;120:871–82	X
dpc-4315	262	2	.	.	X
dpc-4315	263	1	7	7	X
dpc-4315	263	2	.	.	X
dpc-4315	263	3	dattola	dattola	PROPN
dpc-4315	263	4	a	a	PRON
dpc-4315	263	5	,	,	PUNCT
dpc-4315	263	6	bennardo	bennardo	PROPN
dpc-4315	263	7	l	l	NOUN
dpc-4315	263	8	,	,	PUNCT
dpc-4315	263	9	silvestri	silvestri	PROPN
dpc-4315	263	10	m	m	PROPN
dpc-4315	263	11	,	,	PUNCT
dpc-4315	263	12	nisticò	nisticò	PROPN
dpc-4315	263	13	sp	sp	PROPN
dpc-4315	263	14	.	.	PUNCT
dpc-4315	264	1	what	what	PRON
dpc-4315	264	2	’s	’	VERB
dpc-4315	264	3	new	new	ADJ
dpc-4315	264	4	in	in	ADP
dpc-4315	264	5	the	the	DET
dpc-4315	264	6	treatment	treatment	NOUN
dpc-4315	264	7	of	of	ADP
dpc-4315	264	8	atopic	atopic	NOUN
dpc-4315	264	9	dermatitis	dermatitis	NOUN
dpc-4315	264	10	?	?	PUNCT
dpc-4315	265	1	dermatol	dermatol	NOUN
dpc-4315	265	2	ther	ther	ADV
dpc-4315	265	3	.	.	PUNCT
dpc-4315	266	1	2019	2019	NUM
dpc-4315	266	2	mar;32(2):e12787	mar;32(2):e12787	X
dpc-4315	266	3	.	.	PUNCT
dpc-4315	267	1	doi	doi	NOUN
dpc-4315	267	2	:	:	PUNCT
dpc-4315	267	3	10.1111	10.1111	NUM
dpc-4315	267	4	/	/	SYM
dpc-4315	267	5	dth.12787	dth.12787	X
dpc-4315	267	6	.	.	PUNCT
dpc-4315	268	1	epub	epub	PROPN
dpc-4315	268	2	2018	2018	NUM
dpc-4315	268	3	dec	dec	PROPN
dpc-4315	268	4	12	12	NUM
dpc-4315	268	5	.	.	PUNCT
dpc-4315	269	1	pmid	pmid	NOUN
dpc-4315	269	2	:	:	PUNCT
dpc-4315	269	3	30548724	30548724	NUM
dpc-4315	269	4	.	.	PUNCT
dpc-4315	270	1	8	8	X
dpc-4315	270	2	.	.	X
dpc-4315	270	3	may	may	AUX
dpc-4315	270	4	rd	rd	PROPN
dpc-4315	270	5	,	,	PUNCT
dpc-4315	270	6	monk	monk	PROPN
dpc-4315	270	7	pd	pd	PROPN
dpc-4315	270	8	,	,	PUNCT
dpc-4315	270	9	cohen	cohen	PROPN
dpc-4315	270	10	es	es	PROPN
dpc-4315	270	11	,	,	PUNCT
dpc-4315	270	12	manuel	manuel	PROPN
dpc-4315	270	13	d	d	PROPN
dpc-4315	270	14	,	,	PUNCT
dpc-4315	270	15	dempsey	dempsey	PROPN
dpc-4315	270	16	f	f	PROPN
dpc-4315	270	17	,	,	PUNCT
dpc-4315	270	18	davis	davis	PROPN
dpc-4315	270	19	nh	nh	PROPN
dpc-4315	270	20	,	,	PUNCT
dpc-4315	270	21	dodd	dodd	PROPN
dpc-4315	270	22	aj	aj	PROPN
dpc-4315	270	23	,	,	PUNCT
dpc-4315	270	24	corkill	corkill	NOUN
dpc-4315	270	25	dj	dj	PROPN
dpc-4315	270	26	,	,	PUNCT
dpc-4315	270	27	woods	woods	PROPN
dpc-4315	270	28	j	j	PROPN
dpc-4315	270	29	,	,	PUNCT
dpc-4315	270	30	joberty	joberty	NOUN
dpc-4315	270	31	-	-	PUNCT
dpc-4315	270	32	candotti	candotti	NOUN
dpc-4315	270	33	c	c	PROPN
dpc-4315	270	34	,	,	PUNCT
dpc-4315	270	35	conroy	conroy	PROPN
dpc-4315	270	36	la	la	PROPN
dpc-4315	270	37	,	,	PUNCT
dpc-4315	270	38	koentgen	koentgen	PROPN
dpc-4315	270	39	f	f	PROPN
dpc-4315	270	40	,	,	PUNCT
dpc-4315	270	41	martin	martin	PROPN
dpc-4315	270	42	ec	ec	PROPN
dpc-4315	270	43	,	,	PUNCT
dpc-4315	270	44	wilson	wilson	PROPN
dpc-4315	270	45	r	r	PROPN
dpc-4315	270	46	,	,	PUNCT
dpc-4315	270	47	brennan	brennan	PROPN
dpc-4315	270	48	n	n	CCONJ
dpc-4315	270	49	,	,	PUNCT
dpc-4315	270	50	powell	powell	PROPN
dpc-4315	270	51	j	j	PROPN
dpc-4315	270	52	,	,	PUNCT
dpc-4315	270	53	anderson	anderson	PROPN
dpc-4315	270	54	ik	ik	PROPN
dpc-4315	270	55	.	.	PROPN
dpc-4315	270	56	preclinical	preclinical	ADJ
dpc-4315	270	57	development	development	NOUN
dpc-4315	270	58	of	of	ADP
dpc-4315	270	59	cat-354	cat-354	PROPN
dpc-4315	270	60	,	,	PUNCT
dpc-4315	270	61	an	an	DET
dpc-4315	270	62	il-13	il-13	ADV
dpc-4315	270	63	neutralizing	neutralize	VERB
dpc-4315	270	64	antibody	antibody	NOUN
dpc-4315	270	65	,	,	PUNCT
dpc-4315	270	66	for	for	ADP
dpc-4315	270	67	the	the	DET
dpc-4315	270	68	treatment	treatment	NOUN
dpc-4315	270	69	of	of	ADP
dpc-4315	270	70	severe	severe	ADJ
dpc-4315	270	71	uncontrolled	uncontrolled	ADJ
dpc-4315	270	72	asthma	asthma	NOUN
dpc-4315	270	73	.	.	PUNCT
dpc-4315	271	1	br	br	PROPN
dpc-4315	271	2	j	j	PROPN
dpc-4315	271	3	pharmacol	pharmacol	PROPN
dpc-4315	271	4	.	.	PUNCT
dpc-4315	272	1	2012	2012	NUM
dpc-4315	272	2	may;166(1):177	may;166(1):177	X
dpc-4315	272	3	-	-	PROPN
dpc-4315	272	4	93	93	NUM
dpc-4315	272	5	.	.	PUNCT
dpc-4315	273	1	doi	doi	NOUN
dpc-4315	273	2	:	:	PUNCT
dpc-4315	273	3	10.1111	10.1111	NUM
dpc-4315	273	4	/	/	SYM
dpc-4315	273	5	j.14765381.2011.01659.x	j.14765381.2011.01659.x	PROPN
dpc-4315	273	6	.	.	PUNCT
dpc-4315	274	1	pmid	pmid	NOUN
dpc-4315	274	2	:	:	PUNCT
dpc-4315	274	3	21895629	21895629	NUM
dpc-4315	274	4	;	;	PUNCT
dpc-4315	274	5	pmcid	pmcid	NOUN
dpc-4315	274	6	:	:	PUNCT
dpc-4315	274	7	pmc3415647	pmc3415647	ADJ
dpc-4315	274	8	.	.	PUNCT
dpc-4315	275	1	9	9	X
dpc-4315	275	2	.	.	X
dpc-4315	276	1	silverberg	silverberg	PROPN
dpc-4315	276	2	ji	ji	PROPN
dpc-4315	276	3	,	,	PUNCT
dpc-4315	276	4	kantor	kantor	PROPN
dpc-4315	276	5	r.	r.	PROPN
dpc-4315	276	6	et	et	PROPN
dpc-4315	276	7	al	al	PROPN
dpc-4315	276	8	.	.	PUNCT
dpc-4315	277	1	the	the	DET
dpc-4315	277	2	role	role	NOUN
dpc-4315	277	3	of	of	ADP
dpc-4315	277	4	interleukins	interleukin	NOUN
dpc-4315	277	5	4	4	NUM
dpc-4315	277	6	and	and	CCONJ
dpc-4315	277	7	/or	/or	PROPN
dpc-4315	277	8	13	13	NUM
dpc-4315	277	9	in	in	ADP
dpc-4315	277	10	the	the	DET
dpc-4315	277	11	pathophysiology	pathophysiology	NOUN
dpc-4315	277	12	and	and	CCONJ
dpc-4315	277	13	treatment	treatment	NOUN
dpc-4315	277	14	of	of	ADP
dpc-4315	277	15	atopic	atopic	NOUN
dpc-4315	277	16	dermatitis	dermatitis	NOUN
dpc-4315	277	17	.	.	PUNCT
dpc-4315	278	1	dermatol	dermatol	NOUN
dpc-4315	278	2	clin	clin	PROPN
dpc-4315	278	3	.	.	PUNCT
dpc-4315	279	1	2017	2017	NUM
dpc-4315	279	2	jul;35(3):327	jul;35(3):327	NOUN
dpc-4315	279	3	-	-	PUNCT
dpc-4315	279	4	334	334	PROPN
dpc-4315	279	5	.	.	PUNCT
dpc-4315	280	1	doi	doi	NOUN
dpc-4315	280	2	:	:	PUNCT
dpc-4315	280	3	10.1016	10.1016	NUM
dpc-4315	280	4	/j.det.2017.02.005	/j.det.2017.02.005	PUNCT
dpc-4315	280	5	.	.	PUNCT
dpc-4315	281	1	epub	epub	PROPN
dpc-4315	281	2	2017	2017	NUM
dpc-4315	281	3	apr	apr	NOUN
dpc-4315	281	4	22	22	NUM
dpc-4315	281	5	.	.	PUNCT
dpc-4315	282	1	pmid	pmid	NOUN
dpc-4315	282	2	:	:	PUNCT
dpc-4315	282	3	28577802	28577802	NUM
dpc-4315	282	4	.	.	PUNCT
dpc-4315	283	1	10	10	NUM
dpc-4315	283	2	.	.	PUNCT
dpc-4315	284	1	hamid	hamid	PROPN
dpc-4315	284	2	q	q	PROPN
dpc-4315	284	3	,	,	PUNCT
dpc-4315	284	4	boguniewicz	boguniewicz	PROPN
dpc-4315	284	5	m	m	PROPN
dpc-4315	284	6	,	,	PUNCT
dpc-4315	284	7	leung	leung	PROPN
dpc-4315	284	8	dy	dy	PROPN
dpc-4315	284	9	.	.	PROPN
dpc-4315	284	10	differential	differential	PROPN
dpc-4315	284	11	in	in	ADP
dpc-4315	284	12	situ	situ	ADJ
dpc-4315	284	13	cytokine	cytokine	NOUN
dpc-4315	284	14	gene	gene	NOUN
dpc-4315	284	15	expression	expression	NOUN
dpc-4315	284	16	in	in	ADP
dpc-4315	284	17	acute	acute	ADJ
dpc-4315	284	18	versus	versus	ADP
dpc-4315	284	19	chronic	chronic	ADJ
dpc-4315	284	20	atopic	atopic	NOUN
dpc-4315	284	21	dermatitis	dermatitis	NOUN
dpc-4315	284	22	.	.	PUNCT
dpc-4315	285	1	j	j	PROPN
dpc-4315	285	2	clin	clin	PROPN
dpc-4315	285	3	invest	invest	PROPN
dpc-4315	285	4	.	.	PUNCT
dpc-4315	286	1	1994;94(2):870	1994;94(2):870	NUM
dpc-4315	286	2	-	-	PUNCT
dpc-4315	286	3	876	876	NUM
dpc-4315	286	4	.	.	PUNCT
dpc-4315	287	1	doi:10.1172	doi:10.1172	PROPN
dpc-4315	287	2	/	/	SYM
dpc-4315	287	3	jci117408	jci117408	PROPN
dpc-4315	287	4	11	11	NUM
dpc-4315	287	5	.	.	PUNCT
dpc-4315	288	1	chan	chan	PROPN
dpc-4315	288	2	ls	ls	PROPN
dpc-4315	288	3	,	,	PUNCT
dpc-4315	288	4	robinson	robinson	PROPN
dpc-4315	288	5	n	n	CCONJ
dpc-4315	288	6	,	,	PUNCT
dpc-4315	288	7	xu	xu	PROPN
dpc-4315	288	8	l.	l.	PROPN
dpc-4315	288	9	expression	expression	NOUN
dpc-4315	288	10	of	of	ADP
dpc-4315	288	11	interleukin-4	interleukin-4	PROPN
dpc-4315	288	12	in	in	ADP
dpc-4315	288	13	the	the	DET
dpc-4315	288	14	epidermis	epidermis	NOUN
dpc-4315	288	15	of	of	ADP
dpc-4315	288	16	transgenic	transgenic	NOUN
dpc-4315	288	17	mice	mouse	NOUN
dpc-4315	288	18	results	result	NOUN
dpc-4315	288	19	in	in	ADP
dpc-4315	288	20	a	a	DET
dpc-4315	288	21	pruritic	pruritic	ADJ
dpc-4315	288	22	inflammatory	inflammatory	ADJ
dpc-4315	288	23	skin	skin	NOUN
dpc-4315	288	24	disease	disease	NOUN
dpc-4315	288	25	:	:	PUNCT
dpc-4315	288	26	an	an	DET
dpc-4315	288	27	experimental	experimental	ADJ
dpc-4315	288	28	animal	animal	NOUN
dpc-4315	288	29	model	model	NOUN
dpc-4315	288	30	to	to	PART
dpc-4315	288	31	study	study	VERB
dpc-4315	288	32	atopic	atopic	NOUN
dpc-4315	288	33	dermatitis	dermatitis	NOUN
dpc-4315	288	34	.	.	PUNCT
dpc-4315	289	1	j	j	PROPN
dpc-4315	289	2	invest	invest	VERB
dpc-4315	289	3	dermatol	dermatol	NOUN
dpc-4315	289	4	.	.	PUNCT
dpc-4315	290	1	2001	2001	NUM
dpc-4315	290	2	oct;117(4):977	oct;117(4):977	NUM
dpc-4315	290	3	-	-	PUNCT
dpc-4315	290	4	83	83	NUM
dpc-4315	290	5	.	.	PUNCT
dpc-4315	291	1	doi	doi	NOUN
dpc-4315	291	2	:	:	PUNCT
dpc-4315	291	3	10.1046	10.1046	NUM
dpc-4315	291	4	/j.0022	/j.0022	SYM
dpc-4315	291	5	-	-	PUNCT
dpc-4315	291	6	202x.2001.01484.x	202x.2001.01484.x	PROPN
dpc-4315	291	7	.	.	PUNCT
dpc-4315	292	1	pmid	pmid	NOUN
dpc-4315	292	2	:	:	PUNCT
dpc-4315	292	3	11676841	11676841	NUM
dpc-4315	292	4	.	.	PUNCT
dpc-4315	293	1	12	12	NUM
dpc-4315	293	2	.	.	PUNCT
dpc-4315	293	3	brandt	brandt	PROPN
dpc-4315	293	4	eb	eb	PROPN
dpc-4315	293	5	,	,	PUNCT
dpc-4315	293	6	sivaprasad	sivaprasad	PROPN
dpc-4315	293	7	u.	u.	PROPN
dpc-4315	293	8	th2	th2	PROPN
dpc-4315	293	9	cytokines	cytokine	VERB
dpc-4315	293	10	and	and	CCONJ
dpc-4315	293	11	atopic	atopic	NOUN
dpc-4315	293	12	dermatitis	dermatitis	NOUN
dpc-4315	293	13	.	.	PUNCT
dpc-4315	294	1	j	j	PROPN
dpc-4315	294	2	clin	clin	PROPN
dpc-4315	294	3	cell	cell	PROPN
dpc-4315	294	4	immunol	immunol	NOUN
dpc-4315	294	5	.	.	PUNCT
dpc-4315	295	1	2011;2(3):110	2011;2(3):110	NUM
dpc-4315	295	2	.	.	PUNCT
dpc-4315	296	1	doi:10.4172/2155	doi:10.4172/2155	ADJ
dpc-4315	296	2	-	-	NOUN
dpc-4315	296	3	9899.1000110	9899.1000110	NOUN
dpc-4315	296	4	.	.	PUNCT
dpc-4315	297	1	6	6	NUM
dpc-4315	297	2	review	review	NOUN
dpc-4315	297	3	|	|	ADV
dpc-4315	297	4	dermatol	dermatol	ADJ
dpc-4315	297	5	pract	pract	NOUN
dpc-4315	297	6	concept	concept	NOUN
dpc-4315	297	7	.	.	PUNCT
dpc-4315	298	1	2024;14(3):e2024204	2024;14(3):e2024204	NUM
dpc-4315	298	2	2023	2023	NUM
dpc-4315	298	3	oct	oct	NOUN
dpc-4315	298	4	23	23	NUM
dpc-4315	298	5	.	.	PUNCT
dpc-4315	298	6	doi	doi	NOUN
dpc-4315	298	7	:	:	PUNCT
dpc-4315	298	8	10.1111/1346	10.1111/1346	NUM
dpc-4315	298	9	-	-	SYM
dpc-4315	298	10	8138.17009	8138.17009	NUM
dpc-4315	298	11	.	.	PUNCT
dpc-4315	299	1	epub	epub	NOUN
dpc-4315	299	2	ahead	ahead	ADV
dpc-4315	299	3	of	of	ADP
dpc-4315	299	4	print	print	NOUN
dpc-4315	299	5	.	.	PUNCT
dpc-4315	300	1	pmid	pmid	NOUN
dpc-4315	300	2	:	:	PUNCT
dpc-4315	300	3	37870261	37870261	NUM
dpc-4315	300	4	.	.	X
dpc-4315	301	1	35	35	NUM
dpc-4315	301	2	.	.	PUNCT
dpc-4315	302	1	gutermuth	gutermuth	PROPN
dpc-4315	302	2	j	j	PROPN
dpc-4315	302	3	,	,	PUNCT
dpc-4315	302	4	pink	pink	ADJ
dpc-4315	302	5	ae	ae	PROPN
dpc-4315	302	6	,	,	PUNCT
dpc-4315	302	7	worm	worm	NOUN
dpc-4315	302	8	m	m	PROPN
dpc-4315	302	9	,	,	PUNCT
dpc-4315	302	10	soldbro	soldbro	PROPN
dpc-4315	302	11	l	l	NOUN
dpc-4315	302	12	,	,	PUNCT
dpc-4315	302	13	bjerregård	bjerregård	PROPN
dpc-4315	302	14	øland	øland	PROPN
dpc-4315	302	15	c	c	NOUN
dpc-4315	302	16	,	,	PUNCT
dpc-4315	302	17	weidinger	weidinger	NOUN
dpc-4315	302	18	s.	s.	PROPN
dpc-4315	302	19	et	et	PROPN
dpc-4315	302	20	al	al	PROPN
dpc-4315	302	21	.	.	PROPN
dpc-4315	302	22	tralokinumab	tralokinumab	NOUN
dpc-4315	302	23	plus	plus	CCONJ
dpc-4315	302	24	topical	topical	ADJ
dpc-4315	302	25	corticosteroids	corticosteroid	NOUN
dpc-4315	302	26	in	in	ADP
dpc-4315	302	27	adults	adult	NOUN
dpc-4315	302	28	with	with	ADP
dpc-4315	302	29	severe	severe	ADJ
dpc-4315	302	30	atopic	atopic	NOUN
dpc-4315	302	31	dermatitis	dermatitis	NOUN
dpc-4315	302	32	and	and	CCONJ
dpc-4315	302	33	inadequate	inadequate	ADJ
dpc-4315	302	34	response	response	NOUN
dpc-4315	302	35	to	to	ADP
dpc-4315	302	36	or	or	CCONJ
dpc-4315	302	37	intolerance	intolerance	NOUN
dpc-4315	302	38	of	of	ADP
dpc-4315	302	39	ciclosporin	ciclosporin	NOUN
dpc-4315	302	40	a	a	X
dpc-4315	302	41	:	:	PUNCT
dpc-4315	302	42	a	a	PRON
dpc-4315	302	43	placebo	placebo	NOUN
dpc-4315	302	44	-	-	PUNCT
dpc-4315	302	45	controlled	control	VERB
dpc-4315	302	46	,	,	PUNCT
dpc-4315	302	47	randomized	randomize	VERB
dpc-4315	302	48	,	,	PUNCT
dpc-4315	302	49	phase	phase	NOUN
dpc-4315	302	50	iii	iii	NUM
dpc-4315	302	51	clinical	clinical	ADJ
dpc-4315	302	52	trial	trial	NOUN
dpc-4315	302	53	(	(	PUNCT
dpc-4315	302	54	ecztra	ecztra	NOUN
dpc-4315	302	55	7	7	NUM
dpc-4315	302	56	)	)	PUNCT
dpc-4315	302	57	.	.	PUNCT
dpc-4315	303	1	br	br	PROPN
dpc-4315	303	2	j	j	PROPN
dpc-4315	303	3	dermatol	dermatol	NOUN
dpc-4315	303	4	.	.	PUNCT
dpc-4315	304	1	2022	2022	NUM
dpc-4315	304	2	mar;186(3):440	mar;186(3):440	NOUN
dpc-4315	304	3	-	-	PUNCT
dpc-4315	304	4	452	452	NUM
dpc-4315	304	5	.	.	PUNCT
dpc-4315	305	1	doi	doi	NOUN
dpc-4315	305	2	:	:	PUNCT
dpc-4315	305	3	10.1111	10.1111	NUM
dpc-4315	305	4	/	/	SYM
dpc-4315	305	5	bjd.20832	bjd.20832	NOUN
dpc-4315	305	6	.	.	PUNCT
dpc-4315	306	1	epub	epub	PROPN
dpc-4315	306	2	2021	2021	NUM
dpc-4315	306	3	dec	dec	PROPN
dpc-4315	306	4	22	22	NUM
dpc-4315	306	5	.	.	PUNCT
dpc-4315	307	1	pmid	pmid	NOUN
dpc-4315	307	2	:	:	PUNCT
dpc-4315	307	3	34698371	34698371	NUM
dpc-4315	307	4	.	.	PUNCT
dpc-4315	308	1	36	36	NUM
dpc-4315	308	2	.	.	PUNCT
dpc-4315	309	1	wollenberg	wollenberg	PROPN
dpc-4315	309	2	a	a	PROPN
dpc-4315	309	3	,	,	PUNCT
dpc-4315	309	4	howell	howell	PROPN
dpc-4315	309	5	md	md	PROPN
dpc-4315	309	6	,	,	PUNCT
dpc-4315	309	7	guttman	guttman	ADJ
dpc-4315	309	8	-	-	PUNCT
dpc-4315	309	9	yassky	yassky	NOUN
dpc-4315	309	10	e	e	NOUN
dpc-4315	309	11	,	,	PUNCT
dpc-4315	309	12	et	et	PROPN
dpc-4315	309	13	al	al	PROPN
dpc-4315	309	14	.	.	PUNCT
dpc-4315	310	1	treatment	treatment	NOUN
dpc-4315	310	2	of	of	ADP
dpc-4315	310	3	atopic	atopic	NOUN
dpc-4315	310	4	dermatitis	dermatitis	NOUN
dpc-4315	310	5	with	with	ADP
dpc-4315	310	6	tralokinumab	tralokinumab	NOUN
dpc-4315	310	7	,	,	PUNCT
dpc-4315	310	8	an	an	DET
dpc-4315	310	9	anti	anti	ADJ
dpc-4315	310	10	-	-	ADJ
dpc-4315	310	11	il-13	il-13	ADJ
dpc-4315	310	12	mab	mab	NOUN
dpc-4315	310	13	.	.	PUNCT
dpc-4315	311	1	j	j	PROPN
dpc-4315	311	2	allergy	allergy	PROPN
dpc-4315	311	3	clin	clin	PROPN
dpc-4315	311	4	immunol	immunol	PROPN
dpc-4315	311	5	.	.	PUNCT
dpc-4315	312	1	2019	2019	NUM
dpc-4315	312	2	jan;143(1):135	jan;143(1):135	NOUN
dpc-4315	312	3	-	-	PUNCT
dpc-4315	312	4	141	141	NUM
dpc-4315	312	5	.	.	PUNCT
dpc-4315	313	1	doi	doi	NOUN
dpc-4315	313	2	:	:	PUNCT
dpc-4315	313	3	10.1016	10.1016	NUM
dpc-4315	313	4	/j.jaci.2018.05.029	/j.jaci.2018.05.029	PUNCT
dpc-4315	313	5	.	.	PUNCT
dpc-4315	314	1	37	37	NUM
dpc-4315	314	2	.	.	PUNCT
dpc-4315	315	1	blauvelt	blauvelt	VERB
dpc-4315	315	2	a	a	PRON
dpc-4315	315	3	,	,	PUNCT
dpc-4315	315	4	langley	langley	PROPN
dpc-4315	315	5	rg	rg	PROPN
dpc-4315	315	6	,	,	PUNCT
dpc-4315	315	7	lacour	lacour	PROPN
dpc-4315	315	8	jp	jp	PROPN
dpc-4315	315	9	,	,	PUNCT
dpc-4315	315	10	et	et	PROPN
dpc-4315	315	11	al	al	PROPN
dpc-4315	315	12	.	.	PUNCT
dpc-4315	316	1	long	long	ADJ
dpc-4315	316	2	-	-	PUNCT
dpc-4315	316	3	term	term	NOUN
dpc-4315	316	4	2	2	NUM
dpc-4315	316	5	-	-	PUNCT
dpc-4315	316	6	year	year	NOUN
dpc-4315	316	7	safety	safety	NOUN
dpc-4315	316	8	and	and	CCONJ
dpc-4315	316	9	efficacy	efficacy	NOUN
dpc-4315	316	10	of	of	ADP
dpc-4315	316	11	tralokinumab	tralokinumab	NOUN
dpc-4315	316	12	in	in	ADP
dpc-4315	316	13	adults	adult	NOUN
dpc-4315	316	14	with	with	ADP
dpc-4315	316	15	moderate	moderate	ADJ
dpc-4315	316	16	-	-	PUNCT
dpc-4315	316	17	to	to	ADP
dpc-4315	316	18	-	-	PUNCT
dpc-4315	316	19	severe	severe	ADJ
dpc-4315	316	20	atopic	atopic	NOUN
dpc-4315	316	21	dermatitis	dermatitis	NOUN
dpc-4315	316	22	:	:	PUNCT
dpc-4315	316	23	interim	interim	ADJ
dpc-4315	316	24	analysis	analysis	NOUN
dpc-4315	316	25	of	of	ADP
dpc-4315	316	26	the	the	DET
dpc-4315	316	27	ecztend	ecztend	NOUN
dpc-4315	316	28	open	open	ADJ
dpc-4315	316	29	-	-	PUNCT
dpc-4315	316	30	label	label	NOUN
dpc-4315	316	31	extension	extension	NOUN
dpc-4315	316	32	trial	trial	NOUN
dpc-4315	316	33	.	.	PUNCT
dpc-4315	317	1	j	j	PROPN
dpc-4315	317	2	am	be	AUX
dpc-4315	317	3	acad	acad	ADJ
dpc-4315	317	4	dermatol	dermatol	NOUN
dpc-4315	317	5	.	.	PUNCT
dpc-4315	318	1	2022	2022	NUM
dpc-4315	318	2	oct;87(4):815	oct;87(4):815	NOUN
dpc-4315	318	3	-	-	PUNCT
dpc-4315	318	4	824	824	NUM
dpc-4315	318	5	.	.	PUNCT
dpc-4315	319	1	doi	doi	NOUN
dpc-4315	319	2	:	:	PUNCT
dpc-4315	319	3	10.1016	10.1016	NUM
dpc-4315	319	4	/	/	SYM
dpc-4315	319	5	j.jaad.2022.07.019	j.jaad.2022.07.019	X
dpc-4315	319	6	.	.	PUNCT
dpc-4315	320	1	epub	epub	NOUN
dpc-4315	320	2	2022	2022	NUM
dpc-4315	320	3	jul	jul	PROPN
dpc-4315	320	4	19	19	NUM
dpc-4315	320	5	.	.	PUNCT
dpc-4315	321	1	pmid	pmid	NOUN
dpc-4315	321	2	:	:	PUNCT
dpc-4315	321	3	35863467	35863467	NUM
dpc-4315	321	4	.	.	PUNCT
dpc-4315	322	1	38	38	NUM
dpc-4315	322	2	.	.	PUNCT
dpc-4315	322	3	ewulu	ewulu	PROPN
dpc-4315	322	4	ar	ar	PROPN
dpc-4315	322	5	,	,	PUNCT
dpc-4315	322	6	prajapati	prajapati	PROPN
dpc-4315	322	7	s	s	PART
dpc-4315	322	8	,	,	PUNCT
dpc-4315	322	9	feldman	feldman	PROPN
dpc-4315	322	10	sr	sr	PROPN
dpc-4315	322	11	.	.	PUNCT
dpc-4315	323	1	et	et	PROPN
dpc-4315	323	2	al	al	PROPN
dpc-4315	323	3	.	.	PUNCT
dpc-4315	324	1	the	the	DET
dpc-4315	324	2	role	role	NOUN
dpc-4315	324	3	of	of	ADP
dpc-4315	324	4	tralokinumab	tralokinumab	NOUN
dpc-4315	324	5	in	in	ADP
dpc-4315	324	6	the	the	DET
dpc-4315	324	7	treatment	treatment	NOUN
dpc-4315	324	8	of	of	ADP
dpc-4315	324	9	atopic	atopic	NOUN
dpc-4315	324	10	dermatitis	dermatitis	NOUN
dpc-4315	324	11	and	and	CCONJ
dpc-4315	324	12	future	future	ADJ
dpc-4315	324	13	perspectives	perspective	NOUN
dpc-4315	324	14	for	for	ADP
dpc-4315	324	15	adolescents	adolescent	NOUN
dpc-4315	324	16	.	.	PUNCT
dpc-4315	325	1	immunotherapy	immunotherapy	NOUN
dpc-4315	325	2	.	.	PUNCT
dpc-4315	326	1	2023	2023	NUM
dpc-4315	326	2	nov;15(16):1341	nov;15(16):1341	ADV
dpc-4315	326	3	-	-	PUNCT
dpc-4315	326	4	1349	1349	NUM
dpc-4315	326	5	.	.	PUNCT
dpc-4315	327	1	doi	doi	NOUN
dpc-4315	327	2	:	:	PUNCT
dpc-4315	327	3	10.2217	10.2217	NUM
dpc-4315	327	4	/	/	SYM
dpc-4315	327	5	imt-2022	imt-2022	NOUN
dpc-4315	327	6	-	-	PUNCT
dpc-4315	327	7	0307	0307	NUM
dpc-4315	327	8	.	.	PUNCT
dpc-4315	328	1	epub	epub	PROPN
dpc-4315	328	2	2023	2023	NUM
dpc-4315	328	3	aug	aug	PROPN
dpc-4315	328	4	29	29	NUM
dpc-4315	328	5	.	.	PUNCT
dpc-4315	329	1	pmid	pmid	NOUN
dpc-4315	329	2	:	:	PUNCT
dpc-4315	329	3	37641871	37641871	NUM
dpc-4315	329	4	.	.	PUNCT
dpc-4315	330	1	39	39	NUM
dpc-4315	330	2	.	.	PUNCT
dpc-4315	330	3	paller	paller	NOUN
dpc-4315	330	4	as	as	ADP
dpc-4315	330	5	,	,	PUNCT
dpc-4315	330	6	flohr	flohr	PROPN
dpc-4315	330	7	c	c	NOUN
dpc-4315	330	8	,	,	PUNCT
dpc-4315	330	9	cork	cork	NOUN
dpc-4315	330	10	m	m	PRON
dpc-4315	330	11	,	,	PUNCT
dpc-4315	330	12	et	et	PROPN
dpc-4315	330	13	al	al	PROPN
dpc-4315	330	14	.	.	PROPN
dpc-4315	330	15	efficacy	efficacy	NOUN
dpc-4315	330	16	and	and	CCONJ
dpc-4315	330	17	safety	safety	NOUN
dpc-4315	330	18	of	of	ADP
dpc-4315	330	19	tralokinumab	tralokinumab	NOUN
dpc-4315	330	20	in	in	ADP
dpc-4315	330	21	adolescents	adolescent	NOUN
dpc-4315	330	22	with	with	ADP
dpc-4315	330	23	moderate	moderate	ADJ
dpc-4315	330	24	to	to	ADP
dpc-4315	330	25	severe	severe	ADJ
dpc-4315	330	26	atopic	atopic	NOUN
dpc-4315	330	27	dermatitis	dermatitis	NOUN
dpc-4315	330	28	:	:	PUNCT
dpc-4315	330	29	the	the	DET
dpc-4315	330	30	phase	phase	NOUN
dpc-4315	330	31	3	3	NUM
dpc-4315	330	32	ecztra	ecztra	NOUN
dpc-4315	330	33	6	6	NUM
dpc-4315	330	34	randomized	randomize	VERB
dpc-4315	330	35	clinical	clinical	ADJ
dpc-4315	330	36	trial	trial	NOUN
dpc-4315	330	37	.	.	PUNCT
dpc-4315	331	1	jama	jama	PROPN
dpc-4315	331	2	dermatol	dermatol	NOUN
dpc-4315	331	3	.	.	PUNCT
dpc-4315	332	1	2023	2023	NUM
dpc-4315	332	2	jun	jun	PROPN
dpc-4315	332	3	1;159(6):596	1;159(6):596	NUM
dpc-4315	332	4	-	-	SYM
dpc-4315	332	5	605	605	NUM
dpc-4315	332	6	.	.	PUNCT
dpc-4315	333	1	doi	doi	NOUN
dpc-4315	333	2	:	:	PUNCT
dpc-4315	333	3	10.1001	10.1001	NUM
dpc-4315	333	4	/jamadermatol.2023.0627	/jamadermatol.2023.0627	NOUN
dpc-4315	333	5	.	.	PUNCT
dpc-4315	334	1	erratum	erratum	PROPN
dpc-4315	334	2	in	in	ADP
dpc-4315	334	3	:	:	PUNCT
dpc-4315	334	4	jama	jama	X
dpc-4315	334	5	dermatol	dermatol	NOUN
dpc-4315	334	6	.	.	PUNCT
dpc-4315	335	1	2023	2023	NUM
dpc-4315	335	2	jun	jun	PROPN
dpc-4315	335	3	1;159(6):673	1;159(6):673	NUM
dpc-4315	335	4	.	.	PUNCT
dpc-4315	336	1	pmid	pmid	NOUN
dpc-4315	336	2	:	:	PUNCT
dpc-4315	336	3	37074705	37074705	NUM
dpc-4315	336	4	;	;	PUNCT
dpc-4315	336	5	pmcid	pmcid	NOUN
dpc-4315	336	6	:	:	PUNCT
dpc-4315	336	7	pmc10116386	pmc10116386	ADV
dpc-4315	336	8	.	.	PUNCT
dpc-4315	337	1	40	40	NUM
dpc-4315	337	2	.	.	PUNCT
dpc-4315	338	1	merola	merola	PROPN
dpc-4315	338	2	jf	jf	PROPN
dpc-4315	338	3	,	,	PUNCT
dpc-4315	338	4	butler	butler	PROPN
dpc-4315	338	5	dc	dc	PROPN
dpc-4315	338	6	,	,	PUNCT
dpc-4315	338	7	mark	mark	PROPN
dpc-4315	338	8	t	t	PROPN
dpc-4315	338	9	,	,	PUNCT
dpc-4315	338	10	schneider	schneider	PROPN
dpc-4315	338	11	s	s	PROPN
dpc-4315	338	12	,	,	PUNCT
dpc-4315	338	13	kim	kim	PROPN
dpc-4315	338	14	y	y	PROPN
dpc-4315	338	15	,	,	PUNCT
dpc-4315	338	16	abuabara	abuabara	PROPN
dpc-4315	338	17	k.	k.	PROPN
dpc-4315	338	18	et	et	PROPN
dpc-4315	338	19	al	al	PROPN
dpc-4315	338	20	.	.	PROPN
dpc-4315	338	21	safety	safety	NOUN
dpc-4315	338	22	and	and	CCONJ
dpc-4315	338	23	efficacy	efficacy	NOUN
dpc-4315	338	24	of	of	ADP
dpc-4315	338	25	tralokinumab	tralokinumab	NOUN
dpc-4315	338	26	in	in	ADP
dpc-4315	338	27	older	old	ADJ
dpc-4315	338	28	adults	adult	NOUN
dpc-4315	338	29	with	with	ADP
dpc-4315	338	30	moderate	moderate	ADJ
dpc-4315	338	31	-	-	PUNCT
dpc-4315	338	32	to	to	ADP
dpc-4315	338	33	-	-	PUNCT
dpc-4315	338	34	severe	severe	ADJ
dpc-4315	338	35	atopic	atopic	NOUN
dpc-4315	338	36	dermatitis	dermatitis	NOUN
dpc-4315	338	37	:	:	PUNCT
dpc-4315	338	38	a	a	DET
dpc-4315	338	39	secondary	secondary	ADJ
dpc-4315	338	40	analysis	analysis	NOUN
dpc-4315	338	41	.	.	PUNCT
dpc-4315	339	1	jama	jama	PROPN
dpc-4315	339	2	dermatol	dermatol	NOUN
dpc-4315	339	3	.	.	PUNCT
dpc-4315	340	1	2023	2023	NUM
dpc-4315	340	2	oct	oct	NOUN
dpc-4315	340	3	1;159(10):1119	1;159(10):1119	PROPN
dpc-4315	340	4	-	-	PUNCT
dpc-4315	340	5	1123	1123	NUM
dpc-4315	340	6	.	.	PUNCT
dpc-4315	341	1	doi	doi	NOUN
dpc-4315	341	2	:	:	PUNCT
dpc-4315	341	3	10.1001	10.1001	NUM
dpc-4315	341	4	/	/	SYM
dpc-4315	341	5	jamadermatol.2023.2626	jamadermatol.2023.2626	PROPN
dpc-4315	341	6	.	.	PUNCT
dpc-4315	342	1	pmid	pmid	NOUN
dpc-4315	342	2	:	:	PUNCT
dpc-4315	342	3	37610789	37610789	NUM
dpc-4315	342	4	;	;	PUNCT
dpc-4315	342	5	pmcid	pmcid	NOUN
dpc-4315	342	6	:	:	PUNCT
dpc-4315	342	7	pmc10448370	pmc10448370	ADJ
dpc-4315	342	8	.	.	PUNCT
dpc-4315	343	1	placebo	placebo	NOUN
dpc-4315	343	2	-	-	PUNCT
dpc-4315	343	3	controlled	control	VERB
dpc-4315	343	4	phase	phase	NOUN
dpc-4315	343	5	iii	iii	NUM
dpc-4315	343	6	trials	trial	NOUN
dpc-4315	343	7	(	(	PUNCT
dpc-4315	343	8	ecztra	ecztra	NOUN
dpc-4315	343	9	1	1	NUM
dpc-4315	343	10	and	and	CCONJ
dpc-4315	343	11	ecztra	ecztra	NOUN
dpc-4315	343	12	2	2	NUM
dpc-4315	343	13	)	)	PUNCT
dpc-4315	343	14	.	.	PUNCT
dpc-4315	344	1	br	br	PROPN
dpc-4315	344	2	j	j	PROPN
dpc-4315	344	3	dermatol	dermatol	NOUN
dpc-4315	344	4	.	.	PUNCT
dpc-4315	345	1	2021;184(3):437	2021;184(3):437	NUM
dpc-4315	345	2	-	-	SYM
dpc-4315	345	3	449	449	NUM
dpc-4315	345	4	.	.	NOUN
dpc-4315	345	5	28	28	NUM
dpc-4315	345	6	.	.	PUNCT
dpc-4315	346	1	torres	torres	PROPN
dpc-4315	346	2	t	t	PROPN
dpc-4315	346	3	,	,	PUNCT
dpc-4315	346	4	sohrt	sohrt	PROPN
dpc-4315	346	5	petersen	petersen	PROPN
dpc-4315	346	6	a	a	PROPN
dpc-4315	346	7	,	,	PUNCT
dpc-4315	346	8	ivens	iven	VERB
dpc-4315	346	9	u	u	NOUN
dpc-4315	346	10	,	,	PUNCT
dpc-4315	346	11	bosch	bosch	PROPN
dpc-4315	346	12	vilaro	vilaro	PROPN
dpc-4315	346	13	a	a	PRON
dpc-4315	346	14	,	,	PUNCT
dpc-4315	346	15	stinson	stinson	PROPN
dpc-4315	346	16	j	j	PROPN
dpc-4315	346	17	,	,	PUNCT
dpc-4315	346	18	carrascosa	carrascosa	PROPN
dpc-4315	347	1	jm	jm	PROPN
dpc-4315	347	2	.	.	PROPN
dpc-4315	347	3	et	et	PROPN
dpc-4315	348	1	al	al	PROPN
dpc-4315	348	2	.	.	PUNCT
dpc-4315	348	3	matching	matching	NOUN
dpc-4315	348	4	-	-	PUNCT
dpc-4315	348	5	adjusted	adjust	VERB
dpc-4315	348	6	indirect	indirect	ADJ
dpc-4315	348	7	comparison	comparison	NOUN
dpc-4315	348	8	of	of	ADP
dpc-4315	348	9	the	the	DET
dpc-4315	348	10	efficacy	efficacy	NOUN
dpc-4315	348	11	at	at	ADP
dpc-4315	348	12	week	week	NOUN
dpc-4315	348	13	32	32	NUM
dpc-4315	348	14	of	of	ADP
dpc-4315	348	15	tralokinumab	tralokinumab	NOUN
dpc-4315	348	16	and	and	CCONJ
dpc-4315	348	17	dupilumab	dupilumab	NOUN
dpc-4315	348	18	in	in	ADP
dpc-4315	348	19	the	the	DET
dpc-4315	348	20	treatment	treatment	NOUN
dpc-4315	348	21	of	of	ADP
dpc-4315	348	22	moderate	moderate	ADJ
dpc-4315	348	23	-	-	PUNCT
dpc-4315	348	24	to	to	ADP
dpc-4315	348	25	-	-	PUNCT
dpc-4315	348	26	severe	severe	ADJ
dpc-4315	348	27	atopic	atopic	NOUN
dpc-4315	348	28	dermatitis	dermatitis	NOUN
dpc-4315	348	29	.	.	PUNCT
dpc-4315	349	1	dermatol	dermatol	NOUN
dpc-4315	349	2	ther	ther	ADV
dpc-4315	349	3	(	(	PUNCT
dpc-4315	349	4	heidelb	heidelb	NOUN
dpc-4315	349	5	)	)	PUNCT
dpc-4315	349	6	.	.	PUNCT
dpc-4315	350	1	doi:10.1007	doi:10.1007	PROPN
dpc-4315	350	2	/	/	SYM
dpc-4315	350	3	s13555	s13555	PROPN
dpc-4315	350	4	-	-	PUNCT
dpc-4315	350	5	024	024	NUM
dpc-4315	350	6	-	-	PUNCT
dpc-4315	350	7	01143	01143	NUM
dpc-4315	350	8	-	-	PUNCT
dpc-4315	350	9	x	x	SYM
dpc-4315	350	10	29	29	NUM
dpc-4315	350	11	.	.	PUNCT
dpc-4315	351	1	guttman	guttman	ADJ
dpc-4315	351	2	-	-	PUNCT
dpc-4315	351	3	yassky	yassky	NOUN
dpc-4315	351	4	e	e	NOUN
dpc-4315	351	5	,	,	PUNCT
dpc-4315	351	6	kabashima	kabashima	PROPN
dpc-4315	351	7	k	k	PROPN
dpc-4315	351	8	,	,	PUNCT
dpc-4315	351	9	staumont	staumont	NOUN
dpc-4315	351	10	-	-	PUNCT
dpc-4315	351	11	salle	salle	PROPN
dpc-4315	351	12	d	d	PROPN
dpc-4315	351	13	,	,	PUNCT
dpc-4315	351	14	et	et	PROPN
dpc-4315	351	15	al	al	PROPN
dpc-4315	351	16	.	.	PUNCT
dpc-4315	352	1	targeting	target	VERB
dpc-4315	352	2	il-13	il-13	VERB
dpc-4315	352	3	with	with	ADP
dpc-4315	352	4	tralokinumab	tralokinumab	NOUN
dpc-4315	352	5	normalizes	normalize	VERB
dpc-4315	352	6	type	type	NOUN
dpc-4315	352	7	2	2	NUM
dpc-4315	352	8	inflammation	inflammation	NOUN
dpc-4315	352	9	in	in	ADP
dpc-4315	352	10	atopic	atopic	NOUN
dpc-4315	352	11	dermatitis	dermatitis	NOUN
dpc-4315	352	12	both	both	CCONJ
dpc-4315	352	13	early	early	ADJ
dpc-4315	352	14	and	and	CCONJ
dpc-4315	352	15	at	at	ADP
dpc-4315	352	16	2	2	NUM
dpc-4315	352	17	years	year	NOUN
dpc-4315	352	18	.	.	PUNCT
dpc-4315	353	1	allergy	allergy	NOUN
dpc-4315	353	2	.	.	PUNCT
dpc-4315	354	1	doi:10.1111	doi:10.1111	NOUN
dpc-4315	354	2	/	/	SYM
dpc-4315	354	3	all.16108	all.16108	NUM
dpc-4315	354	4	30	30	NUM
dpc-4315	354	5	.	.	PUNCT
dpc-4315	355	1	simpson	simpson	PROPN
dpc-4315	355	2	el	el	PROPN
dpc-4315	355	3	,	,	PUNCT
dpc-4315	355	4	blauvelt	blauvelt	VERB
dpc-4315	355	5	a	a	PRON
dpc-4315	355	6	,	,	PUNCT
dpc-4315	355	7	silverberg	silverberg	PROPN
dpc-4315	355	8	ji	ji	PROPN
dpc-4315	355	9	,	,	PUNCT
dpc-4315	355	10	et	et	PROPN
dpc-4315	355	11	al	al	PROPN
dpc-4315	355	12	.	.	PROPN
dpc-4315	355	13	tralokinumab	tralokinumab	NOUN
dpc-4315	355	14	provides	provide	VERB
dpc-4315	355	15	clinically	clinically	ADV
dpc-4315	355	16	meaningful	meaningful	ADJ
dpc-4315	355	17	responses	response	NOUN
dpc-4315	355	18	at	at	ADP
dpc-4315	355	19	week	week	NOUN
dpc-4315	355	20	16	16	NUM
dpc-4315	355	21	in	in	ADP
dpc-4315	355	22	adults	adult	NOUN
dpc-4315	355	23	with	with	ADP
dpc-4315	355	24	moderate	moderate	ADJ
dpc-4315	355	25	-	-	PUNCT
dpc-4315	355	26	to	to	ADP
dpc-4315	355	27	-	-	PUNCT
dpc-4315	355	28	severe	severe	ADJ
dpc-4315	355	29	atopic	atopic	NOUN
dpc-4315	355	30	dermatitis	dermatitis	NOUN
dpc-4315	355	31	who	who	PRON
dpc-4315	355	32	do	do	AUX
dpc-4315	355	33	not	not	PART
dpc-4315	355	34	achieve	achieve	VERB
dpc-4315	355	35	iga	iga	PROPN
dpc-4315	355	36	0/1	0/1	PROPN
dpc-4315	355	37	.	.	PUNCT
dpc-4315	356	1	am	be	AUX
dpc-4315	356	2	j	j	PROPN
dpc-4315	356	3	clin	clin	PROPN
dpc-4315	356	4	dermatol	dermatol	NOUN
dpc-4315	356	5	.	.	PUNCT
dpc-4315	357	1	2024;25(1):139	2024;25(1):139	NUM
dpc-4315	357	2	-	-	PUNCT
dpc-4315	357	3	148	148	NUM
dpc-4315	357	4	.	.	PUNCT
dpc-4315	358	1	doi:10.1007	doi:10.1007	PROPN
dpc-4315	358	2	/s40257	/s40257	PROPN
dpc-4315	358	3	-	-	PUNCT
dpc-4315	358	4	023	023	NUM
dpc-4315	358	5	-	-	PUNCT
dpc-4315	358	6	00817	00817	NUM
dpc-4315	358	7	-	-	SYM
dpc-4315	358	8	0	0	NUM
dpc-4315	358	9	31	31	NUM
dpc-4315	358	10	.	.	PUNCT
dpc-4315	359	1	cozzani	cozzani	PROPN
dpc-4315	359	2	e	e	X
dpc-4315	359	3	,	,	PUNCT
dpc-4315	359	4	marzano	marzano	PROPN
dpc-4315	359	5	av	av	PROPN
dpc-4315	359	6	,	,	PUNCT
dpc-4315	359	7	caproni	caproni	PROPN
dpc-4315	359	8	m	m	PROPN
dpc-4315	359	9	,	,	PUNCT
dpc-4315	359	10	feliciani	feliciani	PROPN
dpc-4315	359	11	c	c	X
dpc-4315	359	12	,	,	PUNCT
dpc-4315	359	13	calzavarapinton	calzavarapinton	PROPN
dpc-4315	359	14	p.	p.	NOUN
dpc-4315	359	15	cutaneous	cutaneous	ADJ
dpc-4315	359	16	immunology	immunology	NOUN
dpc-4315	359	17	group	group	NOUN
dpc-4315	359	18	of	of	ADP
dpc-4315	359	19	sidemast	sidemast	NOUN
dpc-4315	359	20	.	.	PUNCT
dpc-4315	360	1	bullous	bullous	ADJ
dpc-4315	360	2	pemphigoid	pemphigoid	ADV
dpc-4315	360	3	:	:	PUNCT
dpc-4315	360	4	italian	italian	ADJ
dpc-4315	360	5	guidelines	guideline	NOUN
dpc-4315	360	6	adapted	adapt	VERB
dpc-4315	360	7	from	from	ADP
dpc-4315	360	8	the	the	DET
dpc-4315	360	9	edf	edf	PROPN
dpc-4315	360	10	/	/	SYM
dpc-4315	360	11	eadv	eadv	ADJ
dpc-4315	360	12	guidelines	guideline	NOUN
dpc-4315	360	13	.	.	PUNCT
dpc-4315	361	1	g	g	ADP
dpc-4315	361	2	ital	ital	ADJ
dpc-4315	361	3	dermatol	dermatol	NOUN
dpc-4315	361	4	venereol	venereol	NOUN
dpc-4315	361	5	.	.	PUNCT
dpc-4315	362	1	2018	2018	NUM
dpc-4315	362	2	jun;153(3):305	jun;153(3):305	NOUN
dpc-4315	362	3	-	-	PUNCT
dpc-4315	362	4	315	315	NUM
dpc-4315	362	5	.	.	PUNCT
dpc-4315	363	1	doi	doi	NOUN
dpc-4315	363	2	:	:	PUNCT
dpc-4315	363	3	10.23736/	10.23736/	NUM
dpc-4315	363	4	s0392	s0392	NOUN
dpc-4315	363	5	-	-	PUNCT
dpc-4315	363	6	0488.18.06006	0488.18.06006	NUM
dpc-4315	363	7	-	-	PUNCT
dpc-4315	363	8	6	6	NUM
dpc-4315	363	9	.	.	PUNCT
dpc-4315	364	1	epub	epub	NOUN
dpc-4315	364	2	2018	2018	NUM
dpc-4315	364	3	mar	mar	PROPN
dpc-4315	364	4	30	30	NUM
dpc-4315	364	5	.	.	PUNCT
dpc-4315	365	1	pmid	pmid	NOUN
dpc-4315	365	2	:	:	PUNCT
dpc-4315	365	3	29600832	29600832	NUM
dpc-4315	365	4	.	.	PUNCT
dpc-4315	366	1	32	32	NUM
dpc-4315	366	2	.	.	PUNCT
dpc-4315	367	1	silverberg	silverberg	PROPN
dpc-4315	367	2	ji	ji	PROPN
dpc-4315	367	3	,	,	PUNCT
dpc-4315	367	4	toth	toth	PROPN
dpc-4315	367	5	d	d	PROPN
dpc-4315	367	6	,	,	PUNCT
dpc-4315	367	7	bieber	bieber	PROPN
dpc-4315	367	8	t	t	PROPN
dpc-4315	367	9	,	,	PUNCT
dpc-4315	367	10	et	et	PROPN
dpc-4315	367	11	al	al	PROPN
dpc-4315	367	12	.	.	PROPN
dpc-4315	367	13	tralokinumab	tralokinumab	NOUN
dpc-4315	367	14	plus	plus	CCONJ
dpc-4315	367	15	topical	topical	ADJ
dpc-4315	367	16	corticosteroids	corticosteroid	NOUN
dpc-4315	367	17	for	for	ADP
dpc-4315	367	18	the	the	DET
dpc-4315	367	19	treatment	treatment	NOUN
dpc-4315	367	20	of	of	ADP
dpc-4315	367	21	moderate	moderate	ADJ
dpc-4315	367	22	-	-	PUNCT
dpc-4315	367	23	to	to	ADP
dpc-4315	367	24	-	-	PUNCT
dpc-4315	367	25	severe	severe	ADJ
dpc-4315	367	26	atopic	atopic	NOUN
dpc-4315	367	27	dermatitis	dermatitis	NOUN
dpc-4315	367	28	:	:	PUNCT
dpc-4315	367	29	results	result	NOUN
dpc-4315	367	30	from	from	ADP
dpc-4315	367	31	the	the	DET
dpc-4315	367	32	double	double	ADJ
dpc-4315	367	33	-	-	PUNCT
dpc-4315	367	34	blind	blind	ADJ
dpc-4315	367	35	,	,	PUNCT
dpc-4315	367	36	randomized	randomize	VERB
dpc-4315	367	37	,	,	PUNCT
dpc-4315	367	38	multicentre	multicentre	NOUN
dpc-4315	367	39	,	,	PUNCT
dpc-4315	367	40	placebo	placebo	NOUN
dpc-4315	367	41	-	-	PUNCT
dpc-4315	367	42	controlled	control	VERB
dpc-4315	367	43	phase	phase	NOUN
dpc-4315	367	44	iii	iii	NUM
dpc-4315	367	45	ecztra	ecztra	ADJ
dpc-4315	367	46	3	3	NUM
dpc-4315	367	47	trial	trial	NOUN
dpc-4315	367	48	.	.	PUNCT
dpc-4315	368	1	br	br	PROPN
dpc-4315	368	2	j	j	PROPN
dpc-4315	368	3	dermatol	dermatol	NOUN
dpc-4315	368	4	.	.	PUNCT
dpc-4315	369	1	2020	2020	NUM
dpc-4315	369	2	;	;	PUNCT
dpc-4315	369	3	https://doi	https://doi	PROPN
dpc-4315	369	4	.	.	PUNCT
dpc-4315	369	5	org/10.1111	org/10.1111	PROPN
dpc-4315	369	6	/	/	SYM
dpc-4315	369	7	bjd.19573	bjd.19573	NOUN
dpc-4315	369	8	.	.	NOUN
dpc-4315	370	1	33	33	NUM
dpc-4315	370	2	.	.	PUNCT
dpc-4315	371	1	silverberg	silverberg	PROPN
dpc-4315	371	2	ji	ji	PROPN
dpc-4315	371	3	,	,	PUNCT
dpc-4315	371	4	adam	adam	PROPN
dpc-4315	371	5	dn	dn	PROPN
dpc-4315	371	6	,	,	PUNCT
dpc-4315	371	7	zirwas	zirwas	PROPN
dpc-4315	371	8	m	m	PROPN
dpc-4315	371	9	,	,	PUNCT
dpc-4315	371	10	et	et	PROPN
dpc-4315	371	11	al	al	PROPN
dpc-4315	371	12	.	.	PROPN
dpc-4315	371	13	tralokinumab	tralokinumab	NOUN
dpc-4315	371	14	plus	plus	CCONJ
dpc-4315	371	15	topical	topical	ADJ
dpc-4315	371	16	corticosteroids	corticosteroid	NOUN
dpc-4315	371	17	as	as	SCONJ
dpc-4315	371	18	needed	need	VERB
dpc-4315	371	19	provides	provide	VERB
dpc-4315	371	20	progressive	progressive	ADJ
dpc-4315	371	21	and	and	CCONJ
dpc-4315	371	22	sustained	sustain	VERB
dpc-4315	371	23	efficacy	efficacy	NOUN
dpc-4315	371	24	in	in	ADP
dpc-4315	371	25	adults	adult	NOUN
dpc-4315	371	26	with	with	ADP
dpc-4315	371	27	moderate	moderate	ADJ
dpc-4315	371	28	-	-	PUNCT
dpc-4315	371	29	to	to	ADP
dpc-4315	371	30	-	-	PUNCT
dpc-4315	371	31	severe	severe	ADJ
dpc-4315	371	32	atopic	atopic	NOUN
dpc-4315	371	33	dermatitis	dermatitis	NOUN
dpc-4315	371	34	over	over	ADP
dpc-4315	371	35	a	a	DET
dpc-4315	371	36	32	32	NUM
dpc-4315	371	37	-	-	PUNCT
dpc-4315	371	38	week	week	NOUN
dpc-4315	371	39	period	period	NOUN
dpc-4315	371	40	:	:	PUNCT
dpc-4315	371	41	an	an	DET
dpc-4315	371	42	ecztra	ecztra	ADJ
dpc-4315	371	43	3	3	NUM
dpc-4315	371	44	post	post	X
dpc-4315	371	45	hoc	hoc	X
dpc-4315	371	46	analysis	analysis	NOUN
dpc-4315	371	47	.	.	PUNCT
dpc-4315	372	1	am	be	AUX
dpc-4315	372	2	j	j	PROPN
dpc-4315	372	3	clin	clin	PROPN
dpc-4315	372	4	dermatol	dermatol	NOUN
dpc-4315	372	5	.	.	PUNCT
dpc-4315	373	1	2022	2022	NUM
dpc-4315	373	2	jul;23(4):547	jul;23(4):547	PROPN
dpc-4315	373	3	-	-	PUNCT
dpc-4315	373	4	559	559	NUM
dpc-4315	373	5	.	.	PUNCT
dpc-4315	374	1	doi	doi	NOUN
dpc-4315	374	2	:	:	PUNCT
dpc-4315	374	3	10.1007	10.1007	NUM
dpc-4315	374	4	/	/	SYM
dpc-4315	374	5	s40257	s40257	NOUN
dpc-4315	374	6	-	-	PUNCT
dpc-4315	374	7	022	022	NUM
dpc-4315	374	8	-	-	PUNCT
dpc-4315	374	9	007022	007022	NUM
dpc-4315	374	10	.	.	PUNCT
dpc-4315	375	1	epub	epub	NOUN
dpc-4315	375	2	2022	2022	NUM
dpc-4315	375	3	jul	jul	PROPN
dpc-4315	375	4	20	20	NUM
dpc-4315	375	5	.	.	PUNCT
dpc-4315	376	1	pmid	pmid	NOUN
dpc-4315	376	2	:	:	PUNCT
dpc-4315	376	3	35857179	35857179	NUM
dpc-4315	376	4	;	;	PUNCT
dpc-4315	376	5	pmcid	pmcid	ADJ
dpc-4315	376	6	:	:	PUNCT
dpc-4315	376	7	pmc9334431	pmc9334431	NOUN
dpc-4315	376	8	.	.	PUNCT
dpc-4315	377	1	34	34	NUM
dpc-4315	377	2	.	.	X
dpc-4315	377	3	alegre	alegre	VERB
dpc-4315	377	4	-	-	PUNCT
dpc-4315	377	5	bailo	bailo	NOUN
dpc-4315	377	6	a	a	DET
dpc-4315	377	7	,	,	PUNCT
dpc-4315	377	8	sánchez	sánchez	NOUN
dpc-4315	377	9	-	-	PUNCT
dpc-4315	377	10	gilo	gilo	PROPN
dpc-4315	377	11	a	a	PROPN
dpc-4315	377	12	,	,	PUNCT
dpc-4315	377	13	marlene	marlene	PROPN
dpc-4315	377	14	-	-	PUNCT
dpc-4315	377	15	mendoza	mendoza	PROPN
dpc-4315	377	16	nm	nm	PROPN
dpc-4315	377	17	,	,	PUNCT
dpc-4315	377	18	mateos	mateos	PROPN
dpc-4315	377	19	-	-	PUNCT
dpc-4315	377	20	rico	rico	PROPN
dpc-4315	377	21	jj	jj	PROPN
dpc-4315	377	22	,	,	PUNCT
dpc-4315	377	23	vicente	vicente	PROPN
dpc-4315	377	24	-	-	PUNCT
dpc-4315	377	25	martín	martín	PROPN
dpc-4315	377	26	fj	fj	PROPN
dpc-4315	377	27	.	.	PUNCT
dpc-4315	377	28	et	et	PROPN
dpc-4315	378	1	al	al	PROPN
dpc-4315	378	2	.	.	PROPN
dpc-4315	378	3	tralokinumab	tralokinumab	NOUN
dpc-4315	378	4	treatment	treatment	NOUN
dpc-4315	378	5	in	in	ADP
dpc-4315	378	6	atopic	atopic	NOUN
dpc-4315	378	7	dermatitis	dermatitis	NOUN
dpc-4315	378	8	:	:	PUNCT
dpc-4315	378	9	depicting	depict	VERB
dpc-4315	378	10	super	super	NOUN
dpc-4315	378	11	-	-	NOUN
dpc-4315	378	12	responders	responder	NOUN
dpc-4315	378	13	.	.	PUNCT
dpc-4315	379	1	j	j	PROPN
dpc-4315	379	2	dermatol	dermatol	NOUN
dpc-4315	379	3	.	.	PUNCT